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Hypertension and arterial stiffness are associated with structural and functional changes in 
cerebral circulation and cognitive function, but based on existing evidence the effects are 
potentially reversible by spironolactone (Spiro) reducing blood pressure (BP) and arterial 
stiffness. This thesis consisted of a double-blind, controlled trial with older hypertensive adults 
(OA) who were receiving stable treatment with centrally acting angiotensin converting enzyme 
inhibitors randomly assigned to Spiro or placebo to test the hypothesis that reductions in BP 
and arterial stiffness would be associated with improved anterior cerebral blood flow (aCBF) 
and cognitive function. Secondary objectives were to investigate how Spiro would affect 
cerebrovascular autoregulation and to conduct a supplementary experimental study in younger 
adults (YA) comparing blood pressure and arterial stiffness to OA; and to determine how 
induced acute small changes in BP could impact interpretation of the chronic changes in BP and 
arterial stiffness associated with Spiro therapy.  
 
The pooled data from the randomized, controlled trial (RCT) in OA (n=18) showed that age, 
mean arterial pressure (MAP), systolic (SBP), diastolic (DBP) and pulse pressure (PP) were 65±3 
years, 97±9 mmHg, 142±16 mmHg, 75±8 mmHg, and 66±13 mmHg respectively. There was a 
significant association between age and carotid distensibility coefficient (r= - 0.51, P<0.05). Six 
months of Spiro significantly reduced SBP and PP by 14±14 mmHg and 12±14 mmHg 
respectively. However arterial stiffness estimated by regional indicator carotid-femoral pulse 
wave velocity (cfPWV), or local indicators carotid distensibility coefficient and β-stiffness index, 
remained unchanged.   Spiro did not significantly improve aCBF or cognitive function scores. 
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Cerebrovascular autoregulation response to standing upright remained unchanged after Spiro 
compared to placebo.   Mean adherence to study-drug was at least 95% for both groups. The 
calculated Cohen’s d effect size for Spiro was 0.3 from this thesis RCT data; much smaller than 
the desired Cohen’s d effect size of 1.0 that was derived from observational data used to 
calculate sample size for the RCT. The supplementary experimental study in YA (n=14) 
demonstrated that OA in the RCT had greater MAP (97±9 mmHg vs 86±9 mmHg, P<0.01), SBP 
(142±16 mmHg vs 124±12 mmHg, P<0.01), DBP (75±8 mmHg vs 67±9 mmHg, P<0.05), PP 
(66±13 mmHg vs 57±7 mmHg, P<0.05), and arterial stiffness was greater as indicated by faster 
cfPWV (7.22±1.09 m/s vs 5.43±1.13 m/s, P<0.001), smaller carotid distensibility coefficient 
(0.0014±0.0006 mmHg-1 vs 0.0031±0.0008, P<0.001), and greater β-stiffness index (8.78±3.53 
a.u. vs 3.74±0.91, P<0.001). Application of lower body negative pressure to induce acute 
hemodynamic changes in these YA reduced stroke volume (P<0.001) and cardiac output 
(P<0.001); and increased total peripheral resistance (P<0.001) while MAP remained unchanged. 
There were also small acute decreases in both SBP (P<0.05) and PP (P<0.001) in these YA that 
were concurrent with a non-significant increase in arterial stiffness (cfPWV increase, carotid 
distensibility coefficient decrease, β-stiffness index increase). Transit times from R-peak of QRS 
complex to foot of aortic velocity pulse, carotid artery, or finger artery significantly increased 
with progressively increasing LBNP as a consequence of longer pre-ejection period (P<0.001). 
 
In conclusion for the main thesis objective, Spiro safely and effectively reduced BP while arterial 
stiffness, aCBF, cognitive function, and cerebrovascular autoregulation remained unchanged. 
OA, compared to YA, had greater blood pressure and arterial stiffness for all measures. In YA, 
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acute reductions in systolic and pulse pressure affected stiffness indicators, in contrast to 
unchanged stiffness indicators observed in OA. These limited data should be interpreted with 
caution given the small sample size in the RCT, small effect size of Spiro and that acute 
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CHAPTER 1 Effect of Spironolactone on Cerebral Blood Flow and Cognition  
 
The purpose of this chapter is to provide supportive background information on arterial aging, 
hypertension, arterial stiffness, cerebral blood flow and cognitive function for subsequent 
thesis chapters examining the effect of spironolactone on blood pressure, arterial stiffness, 
cerebral blood flow and cognition. Another important purpose is to outline thesis objectives, 
research questions, and hypotheses.  
 
1.1 An Aging Canada 
 
Canadians are aging. The median age of the Canadian population in 2011 was 39.9 years, up 
from 26.2 years in 1971 (Milan, 2010). The fastest growing age group is 65 years and older, 
likely reflecting an increase in life expectancy and the aging of the baby boomer generation. 
Five million Canadians were at least 65 years old in 2011, and this number is expected to double 
by 2035, so that by 2051 about a quarter of Canadians is expected to be over 65 
(StatisticsCanada, 2011). 
 
1.1.1 Age is an Important Risk Factor for Hypertension  
 
Hypertension, defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 
90 mmHg, affects about 1 in 5 of the Canadian adult population (Daskalopoulou et al., 2015; 
Robitaille et al., 2012). Age is an important risk factor for developing hypertension due to 
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changes in artery wall structure, endothelial dysfunction, up-regulation of renin-angiotensin-
aldosterone system (RAAS) activity and rise in pulse pressure. The structural changes that occur 
within large elastic arteries include intimal wall thickening with increased matrix proteins such 
as collagen, fragmentation of elastic lamellae possibly due to repetitive strain injury, and 
consequently dilatation that is accompanied by a reduction in compliance and increase in 
vascular stiffness (Fukutomi & Kario, 2010; Nilsson, 2008). Other key features of early vascular 
aging include chronic vascular inflammation, capillary rarefaction and dysfunctional regulation, 
oxidative stress, impairment of nitric oxide pathway, and arterial calcification (Nilsson, 2008). 
These age-related pathophysiological changes contribute to the development of hypertension 
by increasing central pulse pressure from increased arterial stiffness, exacerbating systolic 
hypertension, and arterial pressure wave reflection from an increase in pulse wave velocity, 
and narrowing of resistance arteries through inward eutrophic remodeling raising peripheral 
resistance (Buus et al., 2013; Mitchell, 2008). 
 
1.1.2 Aldosterone is Associated with Reversible Vascular Changes  
 
Angiotensin II (AT II) is an integral part of the RAAS designed to regulate blood pressure. Briefly, 
the proteolytic enzyme renin converts angiotensinogen to angiotensin I, which is converted to 
AT II by the angiotensin converting enzyme (ACE) in the vascular endothelium. AT II stimulates 
aldosterone secretion from the adrenal cortex leading to salt and water retention maintaining 
plasma volume, acts as a direct vasoconstrictor and stimulates sympathetic activity raising 
peripheral resistance, and  plays an integral role in the development of vascular disease partly 
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through activation of matrix metalloproteinase (MMP) (M. Wang, Kim, Monticone, & Lakatta, 
2015). MMPs are enzymes involved in arterial wall extracellular matrix degradation and 
remodelling. Independent of the effects of AT II on activation of MMPs, aldosterone induces 
reversible functional and structural vascular changes that increase systemic vascular resistance 
and arterial stiffness (Davies, Gavin, Band, Morris, & Struthers, 2005; Farquharson & Struthers, 
2000, 2002; Kithas & Supiano, 2010; Mahmud & Feely, 2005). Functional changes related to 
aldosterone include endothelial dysfunction, increased sympathetic tone, sodium retention, 
vascular inflammation and oxidative stress leading to reduced nitric oxide and endothelial-
derived hyperpolarizing factor bioavailability (Barrett, McCurley, & Jaffe, 2013; Bellien et al., 
2010; Duprez, 2007; Farquharson & Struthers, 2002; Zieman, Melenovsky, & Kass, 2005). 
Structural changes include elevated deposition of collagen, up-regulation of angiotensin II 
receptors, smooth muscle hypertrophy, and elevated vasoconstrictive and fibrotic effects linked 
with endothelin-1 (Bernini et al., 2008; Zieman et al., 2005). These detrimental, yet potentially 
reversible, changes have led to key findings that high plasma aldosterone is also associated with 
reduced aortic compliance and mild cognitive impairment (Scuteri, Brancati, Gianni, Assisi, & 
Volpe, 2005; Yagi et al., 2011). From the existing literature, it appears that aldosterone 
activates pathways responsible for functional and structural changes in cerebral blood vessels 
that could affect cerebral blood flow; consequently the aldosterone antagonist spironolactone 
was chosen for this thesis research.  
 




Stiffness is the resistance offered by an elastic body to deformation. All measures of stiffness 
ultimately represent relations between forces applied (e.g., blood pressure) to an elastic body 
(e.g., arterial wall) which result in mechanical stress and deformation (strain). This 
circumferential wall stress in arteries can be estimated by the direct relationship with the vessel 
radius and transluminal pressure, and inverse relationship to wall thickness. For arteries, the 
pressure-strain relationship is not  linear: at higher applied forces vessels become stiffer due to 
the curvilinear nature of arterial compliance. Acute changes in blood pressure shift the 
operational point of the arterial compliance curve to the steeper, flatter portion, resulting in 
functionally stiffer arteries on the same arterial compliance curve (Chirinos, 2012; Shibata & 
Levine, 2011). Therefore, assessment of arterial stiffness will depend on the ambient blood 
pressure, and introduces an important confounding variable by changing operational point on 
the same compliance curve, versus mechanically stiffer arteries that operate on a different 
compliance curve. CHAPTER 7 explores how these indicators of arterial stiffness are affected by 
acute small changes in blood pressure. The mechanical properties of arteries can be expressed 
using indicators that relate local changes in pressure and changes in volume, diameter, or area. 
Pressure-volume relations are influenced by stiffness of the arterial wall. Examples of indicators 
of local arterial stiffness include the carotid distensibility coefficient and β-stiffness index. 
Distensibility (arterial compliance) is the fractional change in arterial volume relative to the 
change in arterial pressure. The β-stiffness index is the natural logarithm of the ratio of 
maximum-to-minimum pressure relative to a fractional change in diameter. Due to the 
mathematical correction of the logarithm of maximum-to-minimum pressure, values within 
individuals may be less sensitive to distending blood pressure (Chirinos, 2012; Shibata & Levine, 
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2011). These arterial stiffness indicators are derived from local pressure-volume 
measurements. There are, however, regional indicators of arterial stiffness not derived from 
pressure-volume or pressure-diameter relationships; such as transit time (TT) and pulse wave 
velocity (PWV).  
 
TT is a useful and robust index of arterial stiffness that represents a functional parameter 
directly affected by arterial wall stiffness. TT is calculated as the time delay between the R-peak 
of the QRS complex and the time at which the pulse wave arrives at the arterial site within the 
same cardiac cycle. There are two distinct components of TT: Pre-ejection period (PEP), which is 
the time from the start of ventricular depolarization to the onset of ventricular ejection, and 
the time delay for the arterial pulse wave to travel from the aortic valve to a point in the 
peripheral arteries. PWV is simply speed the pulse wave travels between two arterial sites (such 
as the carotid and femoral arteries) that is calculated as the ratio of transit distance to TT.  
 
Carotid-femoral PWV (cfPWV) is the gold standard index of arterial stiffness due to the relative 
ease in determination and growing evidence demonstrating its association with incident 
cardiovascular disease and all-cause mortality (Laurent et al., 2001; Laurent et al., 2006; 
Meaume et al., 2001; Mitchell et al., 2010; O'Rourke, Staessen, Vlachopoulos, Duprez, & Plante, 
2002; Sutton-Tyrrell et al., 2005).  Normal aging, which may be amplified byhypertension, is 
accompanied by increased arterial stiffness, pulse pressure, and PWV, leading to a decrease in 
pulse wave transit time (Franklin et al., 1997; Hasegawa, Nagao, Kinoshita, Rodbard, & Asahina, 
1997; Koivistoinen et al., 2007; Mitchell et al., 2004; Schiffrin, 2004). PWV is directly related to 
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arterial distensibility (Young’s elastic modulus expressed as the ratio of tensile stress to tensile 
strain), wall thickness, interior diameter and density of blood that is estimated with the Moens-
Korteweg equation for wave propagation within a vessel of uniform geometry and properties: 
PWV2 = Eh/2Rρ. Where PWV denotes the speed at which the pressure wave propagates, E is 
the Young’s modulus of elasticity (material stiffness), h is the vessel wall thickness, R is the 
internal vessel radius, and ρ is the density of blood (Hughes, Babbs, Geddes, & Bourland, 1979; 
Nichols, 2011).  With Eh the structural stiffness, this equation shows that increases in either 
material stiffness or wall thickness can impact hemodynamics equally. The actual arterial 
system is obviously not a simple cylindrical vessel but branches, tapers, and terminates as 
microcirculation. These geometric changes along the arterial system path toward the 
microcirculation are sites of changing resistance to flow (impedance) that cause pressure wave 
reflections back towards the heart (Mitchell, 2009). Therefore arterial pressure is the sum of 
forward and backward travelling waves at that site. When wave reflection occurs at the 
microcirculation, there is minimal time delay between forward and backward waves leading to 
optimal overlap with wave reflection. Consequently, pressure pulse waves are amplified with 
increasing distance from the heart (Nichols, 2011).   
 
Existing studies have shown a significant correlation between cerebral blood flow (total 
cerebral blood flow measured using MRI) and cfPWV (Tarumi et al., 2014; Xing et al., 2017). 
There is also evidence of higher cfPWV being independently associated with manifestations of 
brain small-vessel disease (i.e., greater volume of white matter hyperintensities) in 
hypertensive patients (Henskens et al., 2008). Cerebral circulation is a high flow, low impedance, 
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system particularly susceptible to hemodynamic pulsatility in the rigid structure of the skull. Loss of 
stiffness gradient between aorta and muscular arteries leading to impedance matching may enhance 
transmission of pulsatile hemodynamic energy into fine penetrating cerebral circulation. Deleterious 
hemodynamic pulsatility may contribute to damage of deep microcirculation manifesting as white 
matter hyperintensities and cognitive dysfunction. Cerebrovascular structure and function are 
reviewed in the following section 1.3 to provide background to the subsequent thesis chapters 
on cerebral blood flow. 
 
1.3 Cerebral Blood Flow   
 
The brain is one of the most highly perfused organs in the body receiving 14% of resting cardiac 
output and accounts for nearly 20% of resting oxygen consumption. The special arterial 
adaption in the brain called the Circle of Willis (Figure 1) helps safeguard this high demand of 
oxygen-rich blood by forming collateral circulation from vascular networks that allows for 
redistribution of blood flow when extracranial or large intracranial vessels are occluded. The 
arterial blood supply to the brain reaches the Circle of Willis through two pairs of large arteries, 
the right and left internal carotid and the right and left vertebral arteries which branch off of 
the subclavian arteries (A. A. Phillips, Chan, Zheng, Krassioukov, & Ainslie, 2016).   The internal 
carotid arteries transmit approximately 70% of total brain blood flow, while the remainder is 
provided by the vertebral arteries. The two vertebral arteries join to form the basilar artery that 
anastomoses with internal carotid arteries at the Circle of Willis that gives rise to three pairs of 
main arteries, the anterior, middle, and posterior cerebral arteries. The vertebral arteries 
























Figure 1 Circle of Willis 
(Cipolla, 2009) 
 
The anterior, middle, and posterior arteries divide into progressively smaller vasoactive pial 
arteries that run on the surface of the brain within the pia-arachnoid space, then branch into 
deep penetrating arterioles that become parenchymal arterioles within the brain. Pial arteries 
on the brain surface have perivascular nerves and as penetrating arterioles become 
parenchymal arterioles with the brain, they become associated with neurons and astrocytes 
(Cipolla, 2009). Extracranial arteries (internal carotid and vertebral arteries), large arteries of 
the brain (e.g., middle cerebral artery) and pial arteries are all innervated by sympathetic and 
parasympathetic neurons. Unlike parenchymal arterioles which are regulated by neuronal 
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activation and astrocytic modulation (A. A. Phillips et al., 2016). All arteries of the brain are 
lined with specialized endothelial cells that tightly regulate exchange between the blood supply 
and the brain, called the blood-brain barrier. Importantly, certain drugs like ACE inhibitors can 
cross the blood-brain barrier, thus affecting arterial structure and function.  
 
1.3.1 Cerebrovascular Autoregulation is Critical to Maintain Cerebral Blood Flow 
 
Derived from Ohm’s law, cerebral blood flow (CBF) is directly proportional to cerebral perfusion 
pressure (CPP = MAP minus intra-cranial pressure) and inversely proportional to 
cerebrovascular vascular resistance (Willie, Tzeng, Fisher, & Ainslie, 2014). Under steady-state 
conditions, MAP is determined by cardiac output and total vascular resistance. Importantly, 
cerebrovascular resistance can have a significant effect on CBF by even small changes in lumen 
diameter (Ainslie & Tzeng, 2010). Autoregulation of CBF is the automated ability of the brain to 
maintain relatively constant blood flow despite changes in CPP (Aaslid, Markwalder, & Nornes, 
1982). This special task to maintain O2 supply (seemingly at all costs) with changing CPP has 
likely evolved to ensure the brain of 2% body mass, continues to get about 14% of resting 
cardiac output, representing 20% of resting O2 consumption (Levick, 2010). In normotensive 
adults, CBF is maintained at ~50ml per 100g whole brain tissue, provided CPP is between 60-
160 mmHg (S. J. Phillips & Whisnant, 1992). Above and below this wide CPP range, 
autoregulation is lost and CBF becomes dependent on MAP (van Beek, Claassen, Rikkert, & 
Jansen, 2008). To maintain stable CBF in response to changes in CPP, cerebral arteries adapt 
cerebrovascular resistance (CVR) by means of arterial blood gases (CO2 and O2), myogenic, 
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neurogenic, or metabolic mechanisms (Ainslie & Tzeng, 2010; A. M. Brown & Ransom, 2007; 
Willie et al., 2014).  
 
Cerebrovascular reactivity reflects the compensatory dilatory capacity of cerebral arterioles to a 
dilatory stimulus and is an important mechanism for maintaining CBF by adapting CVR. Carbon 
dioxide (CO2) has a profound and reversible effect on CBF, such that hypercapnia causes 
dilation of cerebral arteries and arterioles and increase blood flow, whereas hypocapnia causes 
vascular constriction and decreased blood flow (Battisti-Charbonney, Fisher, & Duffin, 2011; 
Skow et al., 2013; Willie et al., 2012). This sensitivity to CO2 appears to be more uniform across 
hypercapnic range compared to responses during hypocapnia (Willie et al., 2012). Since 
alteration in alveolar gas exchange (either in alveolar ventilation or metabolic generation of 
CO2) produces concomitant changes in both partial pressure of CO2 and pH, it is likely that both 
are responsible for changes in CBF. Vasodilation is partly mediated through endothelial nitric 
oxide and partly by diffusion of non-polar CO2 molecules across the blood-brain barrier that can 
induce a corresponding pH change in the extracellular space surrounding pial arteries, and thus 
alter smooth muscle tone (Willie et al., 2012). A normal cerebrovascular reactivity to CO2 is very 
important for a physiologic blood supply to the brain and an impaired cerebrovascular reactivity 
to CO2 has been associated with higher risk of stroke, vascular complications such as 
microalbuminuria and retinopathy in diabetes mellitus, described in non-controlled 
hypertension, and even under the condition of acute major depression (Fulesdi et al., 1997; 
Neu, Schlattmann, Schilling, & Hartmann, 2004; Settakis et al., 2003; Silvestrini, Troisi, Matteis, 
Cupini, & Bernardi, 1996; Yonas, Smith, Durham, Pentheny, & Johnson, 1993). Despite the drive 
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to maintain O2 supply to the brain at all costs, vascular tone is less responsive to O2 until a 
threshold of ~80% arterial saturation, or hypoxia reduces partial pressure of O2 lower than ~50 
mmHg, below which CBF increases substantially (Ainslie & Subudhi, 2014; Masamoto & 
Tanishita, 2009). This increase in CBF is accompanied by improved O2 extraction from 
hemoglobin represented by a ~100% saturation at partial pressure of O2 > 70 mmHg to about 
half saturation at partial pressure of O2 < 50 mmHg (Johnston, Steiner, Gupta, & Menon, 2003). 
Hypoxia reduces cerebrovascular smooth muscle tone through a complex interplay of 
neurovascular coupling involving potassium and calcium channels, release of adenosine and 
production of nitric oxide (Ainslie & Tzeng, 2010).  
 
Neurovascular coupling describes the tight relationship between local cerebral metabolism and 
local brain perfusion. Local metabolism can evoke functional hyperemia from vasoactive 
substances that include interstitial potassium ion, hydrogen ion, O2 or adenosine from neural 
activity (Levick 2010). This coupling of an anatomic and metabolic relationship is between 
neurons, astrocyte glial cells and vascular smooth muscle cells of deep penetrating 
neurovascular unit (A. A. Phillips et al., 2016). Briefly, excitatory and inhibitory neurons synapse 
on both astrocytes and interneurons, where their interneurons are in close association with 
astrocytes which terminate and envelope cortex-penetrating arterioles (Iadecola & Nedergaard, 
2007). Glutamate release by the synapse activates the release of nitric oxide from the 
interneuron and simultaneously activates epoxyeicosatrienoic acid and prostaglandin E2, which 
all serve to dilate cerebral arteries (A. A. Phillips et al., 2016). Autoregulation of CBF when 
pressure fluctuates at the high end of the autoregulatory curve is most likely due to the 
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myogenic behaviour of cerebral smooth muscle that constrict in response to elevated CPP and 
dilate in response to decrease pressure (Mellander, 1989; Osol, Brekke, McElroy-Yaggy, & 
Gokina, 2002).   
 
Both extracranial and pial arteries are innervated by sympathetic neurons originating from the 
superior cervical ganglion which may serve to support cerebral blood flow through release of 
norepinephrine and neuropeptide Y (Hamel, 2006; Hamner, Tan, Lee, Cohen, & Taylor, 2010). 
Parasympathetic neurons from cranial nerves modulate cerebrovascular tone by releasing 
acetylcholine, vasoactive intestinal peptide, and nitric oxide although human data are lacking. 
 
The response to a variation in CPP as an adaptation in CVR will adjust cerebral blood flow back 
to steady-state baseline. This hemodynamic process is called static cerebrovascular 
autoregulation (sCVA) when CPP changes gradually and dynamic CVA (dCVA) with more abrupt 
changes in CPP (Aaslid et al., 1982; Panerai, 1998; van Beek et al., 2008). However, the 
availability of transcranial Doppler (TCD) ultrasound and finger-cuff beat-to-beat monitoring of 
blood pressure have provided the opportunity to investigate the dynamic pressure-flow 
relationship with rapid changes in mean arterial pressure and cerebral blood flow velocity 
(Aaslid, Lindegaard, Sorteberg, & Nornes, 1989; Sorond, Serrador, Jones, Shaffer, & Lipsitz, 
2009; van Beek et al., 2008). These non-invasive tools will be used in this thesis to allow the 
high temporal resolution assessment of dynamic dCVA from changing posture from sitting to 
standing expressed as absolute and percent changes in CVR for the middle cerebral artery 
(MCA) blood velocity (BFV) and MAP: CVR = MAP/BFV(Lipsitz, Mukai, Hamner, Gagnon, & 
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Babikian, 2000; Sorond et al., 2009). This sit-to-stand posture change results in a transient fall in 
MAP resulting from several potential mechanisms that are associated with active rising: The 
rate of blood volume leaving the heart (cardiac output) into the arterial vasculature is 
temporarily less than the rate blood volume is leaving the arterial vasculature (vascular 
resistance) back to the heart; such that cardiac output is not matching peripheral resistance 
effects on arterial outflow (Wieling, Krediet, van Dijk, Linzer, & Tschakovsky, 2007). The 
reduction in vascular resistance has been attributed to rapid vasodilation in the working muscle 
through local intrinsic factors and possibly from an sudden rise in right atrial pressure from 
compression of intramuscular veins facilitating venous return that activates cardiopulmonary 
mechanoreceptors initiating an abrupt reflex withdrawal of sympathetic vasoconstrictor tone, 
both mechanisms leading to a subsequent transient fall in total systemic vascular resistance 
(Wieling et al., 2007). There is little consensus as to where cerebral resistance modulation 
actually takes place and how (myogenic or autonomic, or both) it is achieved (Willie et al., 
2014). 
 
1.3.2 Orthostatic Challenge Triggers Compensatory Hemodynamic Responses 
 
As already reviewed in previous Section 1.3.1., the availability of transcranial Doppler 
ultrasound to measure CBF velocity and monitor beat-to-beat changes in blood pressure have 
allowed the opportunity to measure how older adults in this thesis respond to acute 
hypotension from standing before and after spironolactone. The immediate responses to 
standing from seated position are typically an increase in heart rate, an increase in cardiac 
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output, and a decrease in systemic vascular resistance with corresponding decrease in mean 
arterial blood pressure (Sorond et al., 2009; Wieling et al., 2007).   
 
Orthostasis (maintaining upright posture) presents a serious challenge to the human 
circulation, because gravity causes redistribution of venous blood away from the heart. This is 
potentially similar to the orthostatic effects of progressively increasing lower body negative 
pressure as described in Section 1.6. Gravity increases the hydrostatic pressure component of 
transmural pressure in compliant veins, and the resulting distension increases the volume of 
blood by 500-800 mL in the lower body pulled from the thoracic vessels (Rowell, 1993). This 
reduces intrathoracic blood volume by 20% over ~15 seconds, lowering central venous pressure 
from 5 mmHg to ~0 mmHg and consequently reducing myocyte length-dependent force 
generation (through the Frank-Starling mechanism), lowering stroke volume by 30-40% prior to 
compensatory neuroendocrine responses needed to regain MAP (Levick, 2010). Consequently, 
the unloading of arterial baroreceptors (from reduced carotid pulse pressure and mean sinus 
pressure) and cardiopulmonary mechanoreceptors (from fall in central venous pressure) during 
orthostatic challenge triggers the following responses mediated through cardiac vagal 
withdrawal and increase sympathetic outflow (Breeuwsma et al., 2017; Levick, 2010; Rowell, 
1993) after the first 60 seconds of quiet standing upright: 
 Heart rate increases  
 Right atrial mean pressure decreases 




 Cardiac output decreases (due to reduced stroke volume) 
 Central blood volume decreases 
 Peripheral vascular resistance increases in skeletal muscle, splanchnic and renal vascular 
beds 
 MAP essentially unchanged (pulse pressure decreases due to a decrease in systolic pressure 
and increase in diastolic pressure) 
 
1.4 Validated Cognitive Function Assessment Tools   
 
Executive cognitive function is defined by cognitive skills that are responsible for complex 
decision making, goal-directed behaviour, initiation, sequencing, monitoring of complex 
behaviour, problem solving and delayed recall (Roman, 2003). A validated cognitive assessment 
tool such as The Montreal Cognitive Assessment (MoCA) can provide a brief measure of global 
cognitive function although originally developed to detect mild cognitive impairment (MCI) 
(Nasreddine et al., 2005). The MoCA is a single page 30-point cognitive test that takes about 15 
minutes to complete. It reliably assesses several cognitive domains with an 87% specificity to 
exclude elderly normal controls and 90% sensitivity to detect MCI described as the transitional 
intermediate clinical state between normal cognitive aging and dementia. Cognitive domains 
include visuospatial abilities using a clock-drawing task and three-dimensional cube copy. A 
short-term memory recall task that involves learning five nouns and delayed recall after 5 
minutes. Trail-Making B test assessing task switching by connecting progressively increasing 
numbers with alternating letters as quickly as possible. Attention, concentration, and working 
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memory are evaluated using a sustained attention task of tapping when a particular letter is 
called in a long sequence of random verbalized letters, serial subtraction by 7 starting at 100, 
and reciting back from memory progressively longer number sequences in forward or back 
order. Language is assessed by repetition of two syntactically complex sentences and reciting as 
many words as possible that begin with the letter “f” within 60 seconds. Finally, orientation in 
time and place are evaluated by asking the participant the day, month, year, and location the 
test is being conducted.  
 
1.5 Hypertension and Arterial Stiffness are Risk Factors for Cognitive Impairment 
 
Hypertension and central arterial stiffness are risk factors for cognitive impairment (Elias & 
Davey, 2009; Hanon et al., 2005; Paran, Anson, & Reuveni, 2003; Scuteri et al., 2005; 
Triantafyllidi et al., 2009; Waldstein et al., 2008; Waldstein et al., 2003). Arterial stiffness can 
occur with increasing age, and has been associated with worse cognitive performance (Elias & 
Davey, 2009). Of all the cognitive domains, executive function is particularly vulnerable to the 
pathological changes associated with hypertension and vascular stiffness (Kuo et al., 2004; 
Saxby, Harrington, McKeith, Wesnes, & Ford, 2003; Waldstein et al., 2008). It is estimated that 
close to 1 in 3 persons over the age of 60 may suffer from executive dysfunction based on the 
San Luis Valley Health and Aging Study (1313 individuals over 60 years old) as assessed by 
voluntary goal-oriented behaviour and self-regulation, and consequently may have significant 
difficulty following medical advice (D. A. Cahn-Weiner, P. F. Malloy, P. A. Boyle, M. Marran, & S. 
Salloway, 2000; J. Grigsby et al., 2002; D. R. Royall, D. V. Espino, M. J. Polk, R. F. Palmer, & K. S. 
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Markides, 2004; D. R. Royall, R. Palmer, L. K. Chiodo, & M. J. Polk, 2004). The incidence of more 
global cognitive impairment was observed in an epidemiological study of cognition in 1107 
older patients in the primary care setting; they found 31% scored <25 on MMSE (Ganguli et al., 
2004). Several cross-sectional studies in elderly, or patients with subjective memory complaints, 
have shown that central arterial stiffness was significantly and inversely related to executive 
function (as measured by the Cognitive Efficiency Profile) and difficulties in other cognitive 
domains (MMSE score and memory), as well as white matter hyperintensities and endothelial 
dysfunction (Elias & Davey, 2009; Hanon et al., 2005; Kearney-Schwartz et al., 2009; Scuteri et 
al., 2005; Triantafyllidi et al., 2009).  
 
The exact mechanism by which hypertension and arterial stiffness affect cognitive function is 
unclear, although it likely involves cerebral hypoperfusion and pressure pulse wave 
amplification (de la Torre, 2000; Ruitenberg et al., 2005). CBF velocity (an estimate of brain 
blood flow) was assessed using transcranial Doppler in 1730 patients with dementia in the 
Rotterdam Study, to show that greater CBF velocity (and correspondingly brain blood flow) was 
related to significantly less cognitive decline over 6.5 years (Ruitenberg et al., 2005). Several 
small studies using MRI have shown lower cerebral blood flow associated with processing 
speed, executive function, and dementia (Alosco, Gunstad, et al., 2013; Alosco, Spitznagel, et 
al., 2013; Poels et al., 2008; Rabbitt et al., 2006). Hypertension has been associated with a 
decrease in CBF and the treatment of uncontrolled hypertensive patients showed significant 
increases in CBF velocity (Ameriso, Paganini-Hill, Meiselman, & Fisher, 1990; Lipsitz et al., 2005). 
Several longitudinal trials have suggested that antihypertensive treatments may be beneficial at 
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preventing cognitive decline (Duron & Hanon, 2010). The first randomized controlled trial to 
show reduction in incidence of predefined secondary outcome of dementia (-50% over 2 years, 
p=0.05, calcium channel blocker vs placebo) was the SYST-EUR trial in isolated systolic 
hypertensive patients (Forette et al., 1998; Staessen, Birkenhager, Fagard, & Forette, 1998). 
 
1.5.1 Potentially Reversible Effects of Aldosterone Antagonism on Arterial Stiffness  
 
Drugs that inhibit the RAAS have demonstrated reductions in arterial stiffness beyond blood 
pressure reduction in hypertensive older adults, as well as in patients with diabetes and heart 
failure (Mahmud & Feely, 2004). Aldosterone antagonists in particular, have improved 
endothelial function, induced left ventricular reverse remodelling in heart failure patients, and 
reduced both sympathetic activity and arterial stiffness in patients with essential hypertension, 
independent of BP lowering effects (Davies et al., 2005; Macdonald, Kennedy, & Struthers, 
2004; Mahmud & Feely, 2005; Pitt, 2003; Pitt et al., 2003; Savoia, Touyz, Amiri, & Schiffrin, 
2008). The aldosterone antagonist spironolactone, that participants were randomized to in this 
thesis RCT, has been shown in existing evidence to decrease cfPWV and blood pressure in 
geriatric hypertensive patients, with or without diabetes, and in patients with chronic kidney 
disease (Edwards, Steeds, Stewart, Ferro, & Townend, 2009; Kithas & Supiano, 2010). Kithas et 
al (2010) evaluated 24 older hypertensive patients (mean age 70 years) taking spironolactone 
for six months to show a significant decrease in systolic, diastolic, and pulse pressure, as well as 
PWV (P<0.001). Specifically, 24-hour systolic pressure was reduced from 142 mmHg to 126 
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mmHg and cfPWV was reduced from 9.6 m/s to 8.6 m/s independent of the percent change in 
systolic blood pressure. Also in hypertensive patients, the aldosterone antagonist eplerenone 
has been shown to significantly reduce the stiffness of small resistance arteries structurally by 
decreasing the collagen/elastin ratio and decreasing circulating inflammatory mediators (Savoia 
et al., 2008). These structural changes are anticipated from the use of spironolactone in this 
thesis RCT. These data of decreasing the collagen/elastin ratio and decreasing circulating 
inflammatory mediators are supported by the observation that aldosterone levels are 
associated with hypertension and central vascular stiffness (Mahmud & Feely, 2005; Scuteri et 
al., 2005; Tzamou, Kyvelou, Karpanou, Petras, & Vyssoulis, 2015). Arterial stiffness is an 
important determinant of systolic hypertension an independent predictor of mortality in 
hypertensive patients (Laurent et al., 2001; Tzamou et al., 2015). Tzamou et al. (2015) recently 
studied 1330 untreated hypertensive patients to evaluate the relation between aldosterone 
levels and central vascular stiffness estimated as cfPWV. They found that patients with high 
aldosterone levels have higher cfPWV compared to patients with low aldosterone levels 
(P<0.001) with a significant correlation between cfPWV and aldosterone levels (Tzamou et al. 
2015).  This relationship between increased levels of aldosterone and decreased systemic 
compliance in patients with long-standing hypertension is supported by other existing evidence 
(Blacher et al., 1997). In addition, the presence of aldosterone receptors in the vasculature has 
led to the important observation that aldosterone may promote vascular stiffness induced by 
inflammation, oxidative stress, vascular remodelling, and endothelial dysfunction (Briet & 
Schiffrin, 2013; N. J. Brown, 2008; Schiffrin, 2006). Animal models have shown that vascular 
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fibrosis and hypertrophic remodeling are induced by the presence of aldosterone particularly in 
a high-salt diet (Briet & Schiffrin, 2013).  
 
Previous investigations have shown possible benefits for cognitive function from ACE inhibitors 
in heart failure patients (Zuccala et al., 2005). Furthermore, subgroup analyses of large 
prospective trials (HOPE, SCOPE, PROGRESS, HYVET-COG trials) suggest that treatment with ACE 
inhibitors or angiotensin receptor blockers may reduce the risk of cognitive impairment or 
lower the rate of cognitive decline in patients with a history of vascular disease or hypertension 
(Duron & Hanon, 2010; Skoog et al., 2005; Tzourio et al., 2003).  As a part of the HOPE trial for 
example, 9297 high risk vascular patients that were followed for 4.5 years to prospectively 
observe outcomes of stroke and cognitive function, ACE inhibitor therapy significantly reduced  
cognitive decline associated with stroke by 41% (p < 0.05) compared to placebo (Bosch et al., 
2002). In subgroup analyses of the SCOPE trial, treatment with the angiotensin receptor blocker 
candesartan was associated with less decline in attention and episodic memory (p=0.04) and 
significantly less cognitive decline was observed in patients on candesartan with a lower 
baseline cognitive function (p=0.04, MMSE 24-28, n=2070) compared to a higher baseline 
cognitive function (MMSE 29-30, n=2867) (Saxby et al., 2003; Skoog et al., 2005). In patients 
with cerebrovascular disease, treatment with perindopril with/without indapamide resulted in 
a significant reduction in the risk of cognitive decline by 19% (p=0.01), reductions in risk of 
cognitive decline with recurrent stroke by 45% (p < 0.001) and reduction in dementia associated 
with recurrent stroke by 34% (p=.03) (Tzourio et al., 2003). In the HYVET-COG trial of diuretics 
with/without an ACE inhibitor in elderly non-demented hypertensive patients showed a trend 
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for less incident dementia by 14% (95% CI 0.67-1.09), likely due to lack of power as the trial was 
terminated early because of stroke and mortality reduction with treatment compared to 
placebo (Peters et al., 2008). However, a meta-analysis of four randomized trials (PROGRESS, 
SYST-EUR, SHEP, HYVET-COG) of antihypertensive therapy did suggest that blood pressure 
lowering may reduce the risk of dementia (relative risk 0.087, p=0.045) (Peters et al., 2008). It is 
important to note that none of these trials included cognitive function as the primary outcome. 
Another potentially important consideration, and applicable to this thesis, is that blood-brain-
barrier (BBB) crossing ACE inhibitors (e.g. perindopril and ramipril are centrally-active) have 
been shown to reduce cognitive decline in hypertensive seniors with Alzheimer’s disease 
compared to non-BBB-crossing ACE inhibitors (e.g.  enalapril, p=0.0023), possibly through 
structural or functional changes in cerebral circulation associated with inhibition of angiotensin 
II (Ohrui et al., 2004). The Cognition Substudy of the Cardiovascular Health Study showed that 
in treated hypertensive patients, centrally-active ACE inhibitors were associated with 65% less 
decline in modified mini-mental state examination scores (1054 participants, over 6 years, 
p=0.01) and non-BBB-crossing ACE inhibitors were associated with 20% greater risk of dementia 
compared to non-ACE inhibitors (Sink et al., 2009). Small randomized trials with angiotensin 
receptor blockers (ARB) have shown significant improvement in memory tests (p < 0.05) among 
elderly hypertensives compared with atenolol, or improved cognitive function compared with 
hydrochlorothiazide (HCT, MMSE 22 increase to 26 after 24 months, p < 0.001) (Fogari et al., 
2003; Tedesco et al., 1999). Another small prospective ARB trial with telmisartan-HCT 
combination therapy in elderly hypertensives was shown to improve cognitive function test 
scores in word-list recall (p < 0.05) and executive function test Trails B (p <0.05) compared to 
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lisinopril-HCT after 6 months of therapy (Fogari et al., 2006). It’s fairly clear that RAAS inhibition 
plays a part in the risk of cognitive function and aging. 
 
There are currently no curative medications available for cognitive decline by increasing 
cerebral blood flow. Factors related to vascular aging, such as hypertension and arterial 
stiffness, are identifiable risk factors for reduced brain blood flow and cognition function. 
Studies with older hypertensive adults taking RAAS inhibitors have suggested reduction in 
cognitive decline with corresponding improvements in cerebral perfusion, although the ability 
of the RAAS inhibitor to cross the blood-brain barrier may have been a confounding variable. 
Aldosterone antagonists have the potential to protect cognitive function through their actions 
on improving vascular stiffness and cerebral blood flow. However, to date, very limited data are 
available investigating aldosterone antagonism effects on cognitive function (Duron & Hanon, 
2010). Recently, a small non-randomized prospective trial of 7 patients matched for age, sex, 
and cognitive function showed that 6 months of aldosterone antagonism (5 patients taking 
eplerenone, and 2 taking spironolactone) can significantly improve cognitive function (MMSE 
23.7 increased to 25.4, p < 0.05) and decrease systolic blood pressure (-14 mmHg, p < 0.05) 
without a change in mean blood pressure (Yagi et al., 2011). This preliminary study supports the 
need for further investigation, such as this thesis randomized controlled trial, as to whether 
treatment with an aldosterone antagonist has clinical benefits on cognitive function with 




The inhibition of the RAAS system has been associated with improvements in cerebral blood 
flow velocity and executive cognitive function in older hypertensive patients (Ihab Hajjar et al., 
2013; Lipsitz et al., 2005). Magnetic resonance imaging has securely shown in these older adults 
that there is a link between reduced cerebral perfusion and poorer performance on executive 
function cognitive assessments (Alosco et al., 2013). ACE inhibitors (e.g., lisinopril) and 
angiotensin receptor blockers (e.g., candesartan) have been associated with a significant 
increase in cerebral blood flow velocity (MCA velocity, P<0.03) with lowering of blood pressure, 
especially in patients with lower baseline cerebral blood flow velocity (Hajjar et al., 2013; Lipsitz 
et al., 2005). The ACE inhibitors that cross the blood-brain barrier in particular (e.g., ramipril, 
lisinopril, perindopril) have been associated with less cognitive decline versus other 
antihypertensive medications, and non-centrally active ACE inhibitors (e.g., enalapril) were 
associated with a greater risk of dementia  compared to centrally-active ACE inhibitors (Sink et 
al., 2009). Some interesting evidence has pointed to high baseline aldosterone levels as being 
associated with poorer MCA blood flow velocity, less CO2 vasoreactivity, and poorer cognitive 
function (Hajjar, Hart, Mack, & Lipsitz, 2015; Yagi et al., 2011). High baseline aldosterone may 
be a predictor of potential improvements in cognitive function and CO2 vasoreactivity following 
RAAS inhibition with an ACE inhibitor or angiotensin receptor blocker (I. Hajjar, Hart, Mack, & 
Lipsitz, 2015; Yagi et al., 2011). Yagi et al. (2011) evaluated 68 hypertensive patients (mean age 
63 years) to find an association between plasma aldosterone concentration and global cognitive 
function (using MMSE scores, coefficient - 0.51, P<0.01); to then show in 7 matched pairs of 
patients an improvement in cognitive function (MMSE score, P<0.05) after 6 months of an MR 
antagonist significantly lowered systolic blood pressure. Likely supported by the abundant 
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expression of aldosterone receptors (mineralocorticoid receptors, MRs) in the brain, and 
especially the hippocampus, which plays a role in cognitive function (Reul et al., 2000). Animal 
models have shown brain MRs also appear to play a major role in progression to hypertension 
through an MR-angiotensin II type 1 receptor pathway (H. W. Wang et al., 2016). Preclinical 
studies have also shown how spironolactone increases middle cerebral artery diameter and 
reduces wall/lumen ratio, and reduces expression of intracellular adhesion molecule (ICAM-1) 
that is a marker of inflammation (Rigsby, Ergul, Portik Dobos, Pollock, & Dorrance, 2011). 
Currently, there are no published human studies evaluating the effect of spironolactone on 
cerebrovascular hemodynamics with associated changes in executive cognitive function.   
 
1.6 Acute Changes in Blood Pressure from Progressively Increasing Lower Body 
Negative Pressure (LBNP) 
 
Spironolactone, as used in the current study with older, hypertensive individuals, is expected to 
chronically lower arterial blood pressure and to affect arterial stiffness indicators. Because of 
the potential for acute changes in blood pressure to directly affect arterial stiffness, the current 
study included a method to acutely change arterial blood pressure in younger adults to 
examine whether the results of the main study could be influenced by factors independent of 
chronic changes in stiffness indicators. Lower body negative pressure (LBNP) is a well-
established technique in research settings to study the cardiovascular effects of central 
hypovolemia, blood loss, and manipulation of baroreceptors (Butler, Yamamoto, Xing, Northey, 
& Hughson, 1992; Convertino, 2001; Convertino, Cooke, & Holcomb, 2006; Johnson et al., 2014; 
Johnston et al., 2003). The LBNP chamber is a tightly sealed rectangular box that encloses the 
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lower body of the participant. Air pressure inside the chamber is reduced by a vacuum pump, 
making pressure inside the chamber less than atmospheric pressure. Application of sub-
atmospheric pressure to the lower body redistributes fluid from the upper body to the lower 
extremities, thus reducing venous return and central venous pressure (Convertino, Ludwig, & 
Cooke, 2004; W. H. Cooke, C. A. Rickards, K. L. Ryan, T. A. Kuusela, & V. A. Convertino, 2009; 
Goswami, Grasser, Roessler, Schneditz, & Hinghofer-Szalkay, 2009). At low levels of LBNP, the 
initial fall in CVP stimulates the cardiopulmonary baroreflex causing an increase in sympathetic 
vasoconstrictor tone, and a small reduction in stroke volume with no change in heart rate 
(Convertino, 2001; C. Lydakis et al., 2008; Rowell, 1993). In addition to an arterial baroreflex 
mediated withdrawal of parasympathetic activity to increase heart rate, increases in 
sympathetic nerve activity augment the increase in heart rate, myocardial contractility and total 
peripheral vascular resistance affecting mean, systolic, and diastolic pressures (Crystal & Salem, 
2015; Fu et al., 2009; Hisdal, Toska, Flatebo, & Walloe, 2002; Kay & Rickards, 2015; Ryan, 
Rickards, Hinojosa-Laborde, Cooke, & Convertino, 2012).    
 
1.6.1 Acute Changes in Blood Pressure Can Affect Arterial Stiffness Indicators   
 
The use of LBNP allows the unique opportunity to investigate how arterial stiffness indicators 
are affected by increases in sympathetic vasomotor tone and distending arterial pressure. It is 
important to note that elastic properties of central arteries can be affected by the state of 
vascular smooth muscle tone through activation of the sympathetic nervous system induced by 
LBNP. Severe LBNP (> - 50 mmHg) elicits sympathetic nervous system activation that has been 
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shown to increase arterial stiffness (i.e., increase cfPWV) and decrease arterial compliance 
(stroke volume/pulse pressure) (A. A. Phillips, S. S. Bredin, A. T. Cote, C. T. Drury, & D. E. 
Warburton, 2013). Milder LBNP (< - 50 mmHg) however was not shown to have this effect on 
arterial stiffness.  
 
Lydakis et al. (2008) used LBNP to explore how arterial stiffness (Ti = transit time of the pressure 
pulse wave to return to the heart from peripheral sites) was dependent on blood pressure and 
sympathetic tone. LBNP increased sympathetic tone and heart rate, but reduced systolic and 
pulse blood pressure to show how arterial stiffness was essentially unchanged at moderate 
LBNP; only to increase arterial stiffness at higher LBNP (Lydakis et al., 2008). These results imply 
that the isolated sympathetic engagement during a volume-shift beyond moderate LBNP may 
affect the elastic properties and smooth muscle cell tone of the central arteries. This factor is 
important for this thesis research whereby progressively increasing LBNP to only moderate 
levels were applied to observe the effect of acute small blood pressure changes on arterial 
stiffness indicators. Importantly, this thesis will expand on existing evidence by examining the 
effect of progressively increasing LBNP on carotid stiffness, cfPWV, and PEP. 
 
In summary, aging elevates the risk of hypertension and arterial stiffness through potentially 
reversible structural and functional arterial changes likely related to the RAAS system. 
Importantly, hypertension and arterial stiffness are risk factors for major adverse cardiovascular 
events and cognitive impairment. It is possible that cognitive impairment may be from cerebral 
hypoperfusion linked to central arterial stiffness related damage to microcirculation in the 
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brain. Antagonism of the RAAS system with spironolactone has been shown in small trials, and 
supported by evidence with other RAAS inhibitors, to have the potential to reduce blood 
pressure and arterial stiffness, that may improve cerebral blood flow and cognition. 
 
1.7 Thesis Objectives 
 
1.7.1 Main Objective 
 
The main objective of this thesis was to conduct a randomized, double-blind, placebo-
controlled trial with the aldosterone antagonist spironolactone in older hypertensive adults 
stably treated by centrally acting ACE inhibitors. The purpose was to determine if 
spironolactone through its influence on blood pressure and arterial stiffness could improve 








Figure 2. Flow diagram of two thesis studies and five hypotheses 
Thesis flow diagram showing the main study (dark solid boxes) and supplementary study (light solid 
boxes) with corresponding hypotheses and chapter numbers. Boxes with dotted outline include study 
design. RCT= randomized, double-blind, placebo-controlled trial, hytv = hypertensive, ACEi = angiotensin 
converting enzyme inhibitor, +Spiro = spironolactone, -Spiro = placebo, BP = blood pressure, ↓ = 
reduction, ↑= increase, → = maintain, AS = arterial stiffness, OA = older adults, YA = younger adults. 
 
1.7.2 Secondary Objectives 
 
Important secondary objectives were to investigate cerebrovascular autoregulation changes 
with spironolactone, and to conduct a supplementary experimental study in younger adults. 
The important purpose of the experimental study in younger adults was to demonstrate 
expected blood pressure and arterial stiffness differences in older adults in the RCT, and to 
investigate the potential for acute changes in blood pressure to affect indicators of arterial 
stiffness that were applied to older adults in the RCT independent of chronic blood pressure 
changes.  The former is intended to demonstrate how even small, brief, changes in blood 
pressure can affect arterial stiffness indicators, potentially limiting interpretation of the impact 
of spironolactone on arterial stiffness.       
RCT in OA 
(hytv + ACEi) 
± Spiro in OA 
(CHAPTER 2) 
↓ central BP  
↓  central 
stiffness 
(CHAPTER 3) 




Study in YA 
(CHAPTER 2) 
Lower BP and 
stiffness vs OA 
(CHAPTER 6) 










1.8 Specific Research Questions 
 
To address these objectives, there were 5 main research questions: 
1. In older hypertensive adults stably treated by centrally acting ACE inhibitors, will 
spironolactone decrease blood pressure and arterial stiffness compared to placebo? 
(CHAPTER 3).  
 
2. In older hypertensive adults stably treated by centrally acting ACE inhibitors, does 
spironolactone improve cerebral blood flow and cognition compared to placebo? 
(CHAPTER 4).  
 
3. In older hypertensive adults stably treated by centrally acting ACE inhibitors, does 
spironolactone affect cerebrovascular autoregulation compared to placebo? (CHAPTER 
5) 
 
4. How does blood pressure and arterial stiffness in older hypertensive adults stably 
treated by centrally acting ACE inhibitors compare to healthy younger adults? (CHAPTER 
6).  
 







1. It was hypothesized that in older hypertensive adults stably treated by centrally acting 
ACE inhibitors, spironolactone will decrease blood pressure and arterial stiffness 
compared to placebo. (CHAPTER 3).  
 
2. It was hypothesized that in older hypertensive adults stably treated by centrally acting 
ACE inhibitors, spironolactone through effects on blood pressure and arterial stiffness, 
will improve cerebral blood flow and cognition compared to placebo. (CHAPTER 4).  
 
3. It was hypothesized that in older hypertensive adults stably treated by centrally acting 
ACE inhibitors, spironolactone will not affect cerebrovascular autoregulation compared 
to placebo. (CHAPTER 5) 
 
4. It was hypothesized older hypertensive adults stably treated by centrally acting ACE 
inhibitors would have higher blood pressure and greater arterial stiffness compared to 
healthy younger adults. (CHAPTER 6).  
 
5. It was hypothesized that acute changes in blood pressure would affect arterial stiffness 






CHAPTER 2 General Methods and Materials   
 
2.1 Overview of Studies 
 
This chapter outlines all the methods and materials for this thesis research. There was a main 
study and a supplementary study conducted as follows:  
1) A double-blind study in generally healthy older adults on stable centrally acting ACE 
inhibitor therapy for hypertension were randomly assigned to aldosterone antagonist 
spironolactone or placebo for 6 months. 
2) An experimental study in younger adults. 
 
2.2 Description of Participants 
2.2.1 Younger Adults 
 
Younger adult participants were recruited, using inclusion and exclusion criteria in Table 17 in 
APPENDIX 2.IE, from the University of Waterloo.  Assessments were carried out at the 
University of Waterloo in the Cardiorespiratory and Vascular Dynamics Laboratory. Written and 
informed consent was obtained from each volunteer. Based on a self-reported medical history 
(APPENDIX 3.HIF), participants were generally healthy. Participants were asked to refrain from 
alcohol, nicotine, and caffeine the day of the assessments, avoid strenuous exercise 24 hours 
before, and have only a light meal 2 hours prior to assessments. Room temperature was 
maintained from 21-23°C. Participant’s height and weight were recorded at each visit. 
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2.2.2 Older Adults  
 
Generally healthy older hypertensive participants on stable ACE inhibitor therapy were 
recruited from Family Physician offices at New Vision Family Health Team and The Centre for 
Family Medicine Family Health Team in Kitchener, Ontario, Canada. Screening for potential 
participants applied specific inclusion (APPENDIX 2.IE, Table 18) and exclusion criteria 
(APPENDIX 2.IE, Table 19) to over 20,000 electronic medical records. Medical staff at these 
physician offices contacted eligible participants and asked their permission for a student 
investigator to contact them about the study. Sixty-three candidates were interviewed for 20-
30 minutes by phone to ensure inclusion and exclusion criteria were met and to explain study 
activity if they were still eligible.  Most declined to participate due to multiple blood work 
requirements, modification of daily medication regime close to planned travel, and perception 
of risk to their current subjective healthy lifestyle. Eventually twenty-three participants were 
enrolled into the study. Participants arrived at the University of Waterloo and completed a 
comprehensive health screen, a battery of cognitive tests, and a familiarization with the study 
protocol prior to vascular assessments. The first three participants were assessed at the New 
Vision Family Health Team medical office before assessments were transitioned to University of 
Waterloo in the Cardiorespiratory and Vascular Dynamics Laboratory. Participants were 
requested to avoid exercise, caffeine, nicotine and alcohol on both days of their arterial and 
cognitive assessments. All participants provided written, informed consent to the procedures 
outlined in this study, following approval from the Office of Research Ethics at the University of 
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Waterloo (#18636). Each participant was informed about voluntary withdrawal at any time and 
was provided a wallet sized contact information card for emergency access to Investigators.  
 
 
2.3 Measurement of Blood Pressure, Heart Rate and End-Tidal Carbon Dioxide 
 
Supine brachial blood pressure was measured 3 times manually by the same investigator after 5 
minutes of resting according to American Heart Association guidelines (Pickering et al., 2005). 
Then brachial pressure was continuously collected non-invasively by finger-cuff 
photoplethysmography (Finometer Pro, Finapres Medical Systems, Amsterdam, The 
Netherlands). Brachial artery pressure data was reconstructed from finger blood pressure 
waveform filtering and calibrated using a return-to-flow technique (Guelen et al., 2003). The 
finger-cuff was placed on the right middle finger between the proximal inter-phalangeal and 
the distal inter-phalangeal joints and maintained at heart level during the entire assessment, 
including seated and standing postures. Heart rate was measured over an average of 60-90 
consecutive cardiac cycles using a 3-electrode electrocardiogram (ECG, Finapres Medical 
Systems, Amsterdam, The Netherlands) to collect electrocardiographic data (QRS complex) by 
placing the white electrode just below the clavicle of the right shoulder, red electrode at the 
left eighth intercostal space, and the black electrode just below the clavicle of the left shoulder 
forming the standard Einthoven’s triangle. Exhaled carbon dioxide (CO2) collected through a 
nasal cannula was measured with an infrared CO2 analyser (Pilot 9200, Colin Medical 
Instruments, San Antonio, TX, USA or Datex-Ohmeda 5200 CO2 Monitor, Madison, WI, USA). 
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Data were continuously recorded at 1 kHz using a data acquisition system (PowerLab, 
ADInstruments, Colorada Springs, CO, USA) and software (LabChart 5 or 7, ADInstruments). 
Analysis of hemodynamics offline involved beat-by-beat averaging gated to the ECG R-peak of 
the QRS complex. MAP was corrected to brain level while participant was seated or standing 
upright to account for orthostatic pressure gradient between the brain and heart (distance x 
0.78 mmHg/cm).  
 
Carotid pressure at the common carotid artery was measured over 15-20 cardiac cycles using 
applanation tonometry (SPT-301, Millar Instruments, TX, USA). Optimal pulse wave contour was 
determined visually by maximizing the amplitude and minimizing the diastolic pressure 
variation (Robertson, Tessmer, & Hughson, 2010). To correct for probe contact pressure, the 
mean and diastolic tonometric signals were calibrated to the mean and diastolic pressure 
measured by the Finometer Pro (Finapres Medical Systems, Amsterdam, The Netherlands). 
 
2.4 The Randomized, Double-Blinded, Placebo-Controlled Study in Older Adults 
2.4.1 The Intervention 
 
Participants were randomized in the ratio of 1:1 using specialized software in a double-blinded 
manner to receive spironolactone or placebo for 6 months as shown in the flow diagram (Figure 
3) below. This study was not registered in clinicaltrials.gov; however results will be made 
available to the public. The dispensing pharmacist (Section 2.4.2) kept a master list of study-
drug allocation and was not part of data collection or analysis. Study-drug was delivered in a 
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sealed bag directly to the medical clinic with the participant’s name for pickup by the 
participant. Study-drug was started at 25 mg daily, and then titrated up to 50 mg daily at one 
month for the remainder of study (Y. Yano et al., 2011; Zannad et al., 2011). Adherence to 
study-drug was estimated by the dispensing pharmacist counting the number of pills remaining 
on the day of their 2nd assessment---no investigators were in contact with the study-drug. This 
number was subtracted from the total number of pills dispensed to estimate how many pills 
they had taken and divided by the number of pills they should have taken between first day of 
































Figure 3. Flow diagram of RCT study activities in older adults 
Participants from New Vision FHT and The Centre for Family Medicine FHT electronic medical 
records were screened using inclusion and exclusion criteria in APPENDIX 2.IE. Eligible 
participants that were enrolled had baseline cognitive and vascular assessments then were 
randomized in a double-blinded manner, to either spironolactone (50mg once daily) or placebo. 
Estimated glomerular filtration rate (eGFR) and serum potassium (K+) were checked prior to 
start, after first week, then at weeks 5, 12 and 18 after first dose. Arterial and cognitive 
assessments were repeated after 6 months to end the study. Four participants in the Placebo 
group withdrew due to mild diarrhea, hyperkalemia prior to first dose of study-drug, brief 
symptom of rapid heart rate, and voluntarily. The one participant in the spironolactone group 
voluntarily withdrew. 
 
Screening Patient Electronic Medical Records  
23 Enrolled into Study  
4 Withdrawn  
Double-Blind Randomization 
10 Spironolactone 50 mg Once 
Daily 
13 Placebo 50 mg Once Daily 
Baseline Arterial and Cognitive Assessments 
1 Withdrawn  
9 Arterial and Cognitive 
Assessments at 6 months 
 
63 Eligible Participants 
Interviewed 
40 declined  
9 Arterial and Cognitive 




Participants had safety blood work prior to taking the study-drug, then at week-1, week-5, 
week-12, and week-18 at a local certified medical laboratory (CML Medical Lab, Greenbrook 
Drive, Kitchener, ON) to monitor serum potassium, sodium, creatinine and estimated 
glomerular filtration rate (eGFR). All participants had their blood work done at the same 
laboratory; however the timing for each sample varied 3-5 days around the predefined weeks. 
Instruction was given to each participant during the reminder call, or email, to have the blood 
sample taken by a specific date; and to eat and drink as per their normal routine.    
 
2.4.2 Randomization and Study-Drug Dispensing 
 
Randomization using software, and double-blinding, was conducted by the University of 
Waterloo School of Pharmacy, and retail, pharmacist Shanthi Sampath at The Pharma Shoppe 
(Joseph Street Site of The Centre For Family Medicine Family Health Team). The School of 
Pharmacy used The Pharma Shoppe as their dispensing and medication consultation service.  
Treatment Code allocations were kept confidential until data analysis was complete.  
 
2.4.3 Study Procedures 
 
A comprehensive Health History Form was completed with each participant at baseline 
(APPENDIX 3.HIF). Participant’s contact information, physician’s name, date of birth, sex, years 
of formal education, history of vascular disease (eg., angina, stroke, myocardial infarction), 
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medication list, smoking status, and self-reported tendency to be adherent to medication was 
included. Participants were asked to bring their medication with them to their first visit (only) 
to authenticate the type and dosing. Participants were indicated as smokers if they reported 
smoking cigars, pipes, or cigarettes during the past 60 days. Room temperature was maintained 
between 21-23°C. 
 
2.4.4 Measurement of Cerebrovascular and Cardiac Hemodynamics 
 
Cerebrovascular Hemodynamics 
Anterior cerebral blood flow (aCBF) was measured by combined brightness-mode imaging and 
Doppler ultrasound (Linear array transducer 5-10 MHz, Mindray 5, Mindray Medical Limited, 
BC, Canada) investigation of the right and left internal carotid arteries.  aCBF was calculated as 
the product of the internal carotid artery cross-sectional area (CSA=π*(diameter/2)2) and mean 
spectral blood velocity (Equation 1) and measured 1-2 cm distal to the carotid bifurcation with 
the participants chin slightly elevated and turned to the contralateral side for greater exposure 
of the artery. 
 
aCBF = (CSA x internal carotid artery blood velocity)   
Equation 1 Anterior cerebral blood flow (aCBF) 
Anterior cerebral blood flow (aCBF) calculated as the product of the internal 
carotid cross-sectional area (CSA) and mean spectral blood velocity (Newell, 




Diameters were measured in triplicate at diastole over two beats and maximum spectral 
velocities were averaged over two cycles of four beats. Only well-defined maximum frequency 
shift envelopes were used to quantify mean velocities overestimating true mean blood cell 
velocity. The true mean velocity is derived from average weighting of all the spectral signals 
from across the artery being recorded; including high-velocity blood cells in the centre and low-
velocity cells near the walls. However, mean spectral outline velocity reflects maximum 
velocities occurring at the central portion of the artery. A change in flow will produce 
proportional changes in true mean, and spectral outline, velocity profiles.  Spectral outline 
velocity profiles were chosen to minimize error introduced by small movements in sample 
volume between assessments that can affect reflected power erroneously interpreted as 
change in flow, and useful measurements could be made with a lower signal-to-noise ratio 
(Newell et al., 1994). Bilateral internal carotid artery flows were summed to quantify the 
measure of total aCBF.  
 
Cerebrovascular conductance index (CVCi) was calculated as the ratio of aCBF to MAP. 
CVCi = aCBF / MAP. 
Equation 2 Cerebrovascular conductance index (CVCi) 
Cerebrovascular conductance index (CVCi) was calculated as the anterior 
cerebral blood flow divided by MAP. 
 
Cardiac Hemodynamics 
Ultrasound brightness-mode imaging (Linear array transducer 1-5 MHz, Mindray 5, Mindray 
Medical Limited, BC, Canada) was used to assess the cross-sectional area (CSA= 
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π*(diameter/2)2) of the aortic root which was then combined with aortic velocity measured 
with Doppler ultrasound (2MHz, Multigon, New York, NY) and R-R interval to determine stroke 
volume (SV).  
SV = aortic velocity x CSA x R-R interval  
Equation 3 Stroke volume (SV) 
Stroke volume (SV) calculated as the product of aortic velocity, cross-sectional 
area (CSA) and R-R interval 
 
Aortic velocity is the blood velocity of the ascending aorta and radius is half the diameter of the 
aortic root. The area of collagenous density at the proximal aspect of the aortic root served as 
an easily visualized landmark on ultrasound. Aortic ring diameter does not change during 
orthostatic stress (Alessandri et al., 2010). Cardiac output (Q) was determined as the product of 
SV and heart rate.  
 
2.4.5 Transcranial Doppler 
 
The mean velocity of red blood cells moving through the left middle cerebral artery (MCA) was 
measured with a transcranial Doppler (TCD) with a 2MHz ultrasound probe (Multigon, New 
York, NY) only in older adults. The transducer was placed against the transtemporal acoustic 
window, with a slightly upward and forward orientation (Aaslid et al., 1989). The insonation 
depth was placed between 45 mm and 55 mm, consistent with the M1 segment of the artery 
(Gillard, Kirkham, Levin, Neville, & Gosling, 1986; Purkayastha & Sorond, 2012). Auditory pitch, 
spectral velocity trace, signal strength and TCD probe angle were consistently used to confirm 
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optimal MCA insonation (Gillard et al., 1986). Photos of the TCD probe placement, 
documentation of probe position and angle, sample volume depth and width, were used to 
ensure repeatability of sample volume between assessments for each participant. 
 
TCD ultrasonography uses the Doppler shift frequency, the difference in the frequency between 
the emitted and reflected ultrasound waves, which is directly proportional to the speed of 
moving red blood cells (blood flow velocity) as described in Equation 4.  
 
Flow Velocity (cm/s) = (Doppler Shift) x propagation speed 
          2 x Incident frequency x cos (Ө) 
 
Equation 4 Flow velocity 
Propagation speed (1541 m/s for soft tissue), Ө is angle of insonation (angle of 
the emitted wave relative to the direction of the vessel blood flow), incident 
frequency is of the emitted wave from the probe. 
 
The laminar blood flow through the MCA gives a mixture of different Doppler frequency shifts 
forming a spectral display of the distribution of the velocities of individual red blood cells 
(Purkayastha & Sorond, 2012).  
 
Cerebrovascular resistance index (CVRi) was calculated as the ratio of mean arterial pressure to 
MCA blood flow velocity (MCAv) shown here in equation 5. 
 
CVRi = MAP/MCAv. 
Equation 5 Cerebrovascular resistance index (CVRi) 
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Cerebrovascular resistance index (CVRi). 
 
It should be noted that the MCAv has been shown to be a marker of changes in cerebral blood 
flow despite the assumption that the diameter remains constant (Serrador, Picot, Rutt, 
Shoemaker, & Bondar, 2000). A slight change in arterial caliber could affect the association 
between MCA velocity and flow. Since conditions such as maximal hypercapnia may induce 
MCA diameter change, it is important to be cautious when interpreting MCA velocity measures 
from TCD (Coverdale, Gati, Opalevych, Perrotta, & Shoemaker, 2014; Coverdale, Lalande, 
Perrotta, & Shoemaker, 2015; Willie et al., 2012).  
 
2.4.6 Cerebrovascular Autoregulation 
 
The immediate responses to standing from seated position (called sit-to-stand technique) is 
typically an immediate increase in heart rate (within approximately 3 seconds), an increase in 
cardiac output (maximum about 7 seconds), and a decrease in systemic vascular resistance with 
corresponding decrease in mean arterial blood pressure (Sorond et al., 2009; Wieling et al., 
2007).  Changes in posture were used to assess dynamic cerebral autoregulation. During 
posture change from seated to standing, MCAv, MAP (calibrated to MCA level) and end-tidal 
carbon dioxide (ETCO2) were measured. The validated sit-to-stand posture change was used to 
provide immediate orthostatic hypotension without altering the spatial or gravitational relation 
between the Doppler probe and the MCA (Lipsitz et al., 2005; Serrador et al., 2005; Sorond et 
al., 2009). After 5 minutes of resting in the seated position with feet on the floor, participants 
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casually stood upright for 2 minutes. Changes in MCAv and MAP were measured after sitting 
(average 2 minutes of data) and at MAP nadir immediately after standing (average of 5 values) 














      Time 
 
Figure 4. Representative data during sit-to-stand posture change 
Representative data showing mean arterial pressure (MAP, top channel) and blood flow 
velocity through the left MCA (MCAv, bottom channel) responses before and after sit-to-stand 
posture change. The beginning of standing from seated posture is marked by upward arrow.  
 
MCAv response= (MCAv stand – MCAv sit)  
Equation 6 MCAv response from sit-to-stand posture change 
MCAv response from sit-to-stand posture change at MCAv nadir (average of 5 
values).  
 
MAP response = (MAP stand – MAP sit) 
Equation 7 MAP response from sit-to-stand posture change 






CVRi change (Equation 8) as absolute and percent values were measured as the difference 
between sitting CVRi and the CVRi from posture change. 
 
CVRi response = (CVRi stand – CVRi sit) 
Equation 8 CVRi response from sit-to-stand posture change 
CVRi response from sit-to-stand posture change. 
 
Absolute and percent changes in MAP, MCAv and CVRi after 6 months of study-drug were 
compared to establish ability to maintain cerebrovascular autoregulation.  
 
2.4.7 Cerebrovascular Reactivity 
 
Reactivity was measured as the absolute and percent change in MCAv induced by voluntary 
changes in breathing pattern while supine. ETCO2 was measured through a nasal cannula 
comfortably placed in the nostrils and fastened to the TCD headset (APPENDIX 1.M.5). Breath-
by-breath values for ETCO2 concentration were obtained and time-matched to the beat-by-beat 
data for analysis. The partial pressure of CO2 was calculated from the product of CO2 
concentration and barometric pressure. Following 5 minutes of rest, participants 
hyperventilated for 1 minute at a duty cycle of 2 seconds of maximal voluntary deep breaths, 
returned to spontaneous normal breathing for 2 minutes, then at the end of a normal breath 
voluntarily held their breath for at least 30 seconds. The mean ETCO2 of the last three breaths 
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during hyperventilation estimated hypocapnia and the ETCO2 of the first exhaled breath after 
optimal breath-hold represented hypercapnia. Participants were asked and coached to only 
breathe through their nose during assessments. The response in MCAv induced from the 
hypocapnic stimulus while hyperventilating was assessed as the difference between MCAv 
following 2 minutes of normal breathing and MCAv at nadir (10-15 beats). 
 
MCAv change hypocapnia= (MCAv hyperventilation–MCAv normal breathing) 
Equation 9 MCA velocity change to hypocapnia 
MCA velocity change to hypocapnia during hyperventilation 
 
The absolute MCAv change induced by the hypercapnic stimulus was measured as the 
difference in MCAv following 2 minutes of normal breathing and peak MCAv (10-15 beats) 
resulting from maximal voluntary breath-hold (Equation 10).  
 
MCAv change hypercapnia = (MCAv breath-hold – MCAv normal breathing)   
Equation 10 MCAv change from hypercapnia 
MCAv change from hypercapnia during maximal voluntary breath-hold 
 
Percent changes induced by ventilation modification were calculated as MCAv change divided 
by MCAv following 2 minutes of normal breathing prior to change in ventilation.  
 




Central arterial stiffness was assessed as the gold standard cfPWV, β-stiffness index and carotid 
distensibility coefficient (Lipsitz et al., 2005; Y. Zhang et al., 2014). Blood flow velocity pulse 
waves were sequentially recorded at the common femoral artery and common carotid artery.  
cfPWV (Equation 11) was estimated with Doppler ultrasound (5 MHz transducer, Multigon 
Industries, NY, USA) as transit distance (TD = surface distance from suprasternal notch to 
femoral artery site minus surface distance from suprasternal notch to carotid site using a 
calibrated wooden caliper) divided by the carotid-femoral transit time (cfTT = time from R-peak 
of QRS complex to femoral velocity waveform to reach artery site minus time from R-peak to 
carotid velocity waveform to reach artery site).  
 
cfPWV = TD/cfTT 
Equation 11 carotid-femoral pulse wave velocity (cfPWV) 
Transit distance (TD) is the surface distance from suprasternal notch to femoral 
artery site minus surface distance from suprasternal notch to carotid site. 
Carotid-femoral transit time (cfTT) represents time from R-peak of QRS 
complex to femoral artery site minus time from R-peak to carotid artery site. 
 
Analysis of transit times were done offline involving beat-by-beat averaging of 15-20 beats 
using a Savitzky-Golay smoothing 3rd order polynomial. Transit time for the carotid velocity 
waveform, or femoral velocity waveform, was defined as the time lag between the R-peak of 
the QRS complex and the foot of the pulse wave velocity spectral trace within the same cardiac 
cycle. The foot of each pulse wave velocity spectral trace was identified as the time at which 
the 2nd derivative of the smoothed velocity waveform was maximum as shown in Figure 5 (Chiu, 
Arand, Shroff, Feldman, & Carroll, 1991). To ensure optimal identification of this waveform 
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foot, the 2nd derivative window size used during analysis was specifically selected for each 









(B) Common carotid artery pulse wave velocity transit time 
 
Figure 5. Calculation of transit times for carotid-femoral pulse wave velocity (cfPWV) 
Representative data showing femoral artery pulse wave velocity transit time (A) with ECG as 
Channel 1, femoral blood flow velocity smoothed with Satvisky-Golay 3rd order polynomial 
window size 125 as Channel 2, and 2nd derivative (window size 201) pulse wave velocity 
waveform as Channel 3. Common carotid artery pulse wave velocity transit time (B) with ECG as 













polynomial window size 51 as Channel 2, and 2nd derivative (window size 175) of pulse wave 
velocity waveform as Channel 3. The arrows indicate the foot of the pulse waves at the 
maximum of the 2nd derivative waveform. T0, Tf, T0*, and Tc represent times at R-peak of QRS 
complex proximal to femoral site, at femoral site, at R-peak of QRS complex proximal to carotid 
site, and at carotid site respectively. The transit time (TT) was calculated as (Tf – T0) – (Tc – T0*) 
used to calculate cfPWV.  
 
The common carotid artery (CCA) diameter was measured from brightness-mode ultrasound 
images of the left and right CCA within 1-2 cm of the bifurcation. Three pairs of digital calipers 
were manually positioned along 1 cm segment of images captured at systole and diastole 
identified by the QRS complex over two beats to give an average of six values each.  
 
Carotid artery stiffness was assessed as carotid distensibility coefficient and β-stiffness index. 
Carotid distensibility coefficient was calculated as the change in CCA diameter (systole diameter 
(sDia) minus diastole diameter (dDia) divided by diastole diameter) divided by the carotid pulse 
pressure (cPP = systole carotid pressure (sCP) minus diastole carotid pressure (dCP)) described 
in Equation 12. 
carotid distensibility coefficient = [(sDia-dDia)/dDia]/(sCP-dCP) 
Equation 12 Carotid distensibility coefficient 
Carotid distensibility coefficient was calculated as the change in CCA diameter 
(systole diameter (sDia) minus diastole diameter (dDia) divided by diastole 
diameter) divided by the carotid pulse pressure (cPP = systole carotid pressure 
(sCP) minus diastole carotid pressure(dCP)). 
 
β-stiffness index was calculated as the natural logarithm of the ratio of systolic carotid pressure 




β-stiffness index = ln(sCP/dCP)/[(sDia-dDia)/dDia] 
Equation 13 β-stiffness index 
β-stiffness index was calculated as the natural logarithm of the systolic carotid 
pressure (sCP) to diastolic carotid pressure (dCP) ratio divided by the change in 
CCA diameter (systole diameter (sDia) minus diastole diameter (dDia) divided 
by diastole diameter). 
 
 
2.4.9 Assessment of Cognitive Function 
 
Cognitive assessments were only performed in older adults. The battery of cognitive function 
assessments were done with the participant comfortably seated and relaxed at a table prior to 
arterial assessments. The Montreal Cognitive Assessment (MoCA) was used as a brief measure 
of global cognitive function with correction for years of education (APPENDIX 4.ECF) 
(Nasreddine, Phillips, & Chertkow, 2012; Nasreddine et al., 2005). The MoCA has been 
demonstrated to be more sensitive to mild cognitive impairment associated with vascular aging 
than the Mini-Mental State Exam (Ihara, Okamoto, & Takahashi, 2013; Nasreddine et al., 2005). 
The Trail Making Test part A (APPENDIX 5.T) and B (APPENDIX 5.T) were used to calculate the 
time for Trails B-A using a stop-watch (Tombaugh, 2004). There is an association between Trails 
B-A time and executive function such as attention, visual scanning and set-shifting (Ashendorf 
et al., 2008). Digit Span Forward, followed by Digit Span Backward, used to assess short-term 
memory testing was scored as the number of rows successfully completed (Richardson, 2007) 
(APPENDIX 6.DS). Caution should be noted when extrapolating changes in cognitive function 
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measures to the general population because of bias introduced from participant’s familiarity 
with cognitive tests taken 6 months apart. 
 
2.5 Pulse Wave Transit Time Calculation 
 
Heart-digit transit time (hdTT) was calculated as the time interval between the R-peak of the 
QRS complex and foot of the smoothed middle finger artery (proper palmar digital artery) 
pressure wave form within the same cardiac cycle (Figure 6). A Savitzky-Golay smoothing 3rd 
order polynomial with sample window of 21 was applied to the finger arterial pressure 
waveform (Appendix 1.M.1). The foot was identified as the time at the peak of the 2nd 
derivative signal of the smoothed pressure wave form (Chiu et al., 1991). A particular 2nd 
derivative sample window chosen at the start of waveform beat-by-beat analysis as one of 175, 
201, 225, or 251 points to optimize reproducibility of identification of peak value corresponding 
to foot of pressure wave form (Appendix 1.M.1). Selection of sample window was visually done 
at supine posture for older adults and at the start of each level of LBNP in younger adults while 
supine as well.  Data were continuously recorded at 1 kHz using a data acquisition system 
(PowerLab, ADInstruments, Colorada Springs, CO, USA) and software (LabChart 5 or 7, 
ADInstruments). Analysis of transit times were done off-line involving beat-by-beat averaging of 







      Time 
 
Figure 6. Estimation of heart-digit transit time (hdTT) 
Sample data showing ECG, smoothed finger (digit) arterial pressure wave form, and 2nd 
derivative of finger arterial pressure waveform. The downward arrow indicates the foot of the 
finger pressure pulse waveform corresponding to the maximum of the 2nd derivative waveform. 
T0 and Tf represent times at R-peak of QRS complex and time at foot of pressure waveform 
respectively. hdTT was calculated as Tf-T0.  
 
Since hdTT is highly correlated to systolic blood pressure (Gesche, Grosskurth, Kuchler, & 
Patzak, 2012; Payne, Symeonides, Webb, & Maxwell, 2006; Zheng, Yan, Zhang, & Poon, 2015), a 
hdTTi was calculated for each participant as the mean hdTT divided by mean systolic blood 
pressure during 30-60 cardiac cycles (Equation 14). Consequently, hdTTi is transit time 
normalized to systolic blood pressure. This index was not normalized to participant’s height, or 
arm length, and there is no published data to exploring this stiffness index.  
 
hdTTi = hdTT / SBP  
Equation 14 heart-digit transit time index 















Heart-carotid pressure transit time (hcTT) was calculated as the time interval between the R-
peak of the QRS complex and foot of the smoothed carotid artery pressure wave form within 
the same cardiac cycle. A Savitzky-Golay smoothing 3rd order polynomial with sample window 
of 21 was applied to the carotid arterial pressure waveform. The foot was identified as time at 
the peak of the 2nd  derivative signal of the smoothed pressure wave form (Chiu et al., 1991). A 
particular 2nd derivative sample window was chosen for each older adult before and after 6 
months study-drug while supine, and for each younger adult while supine at each LBNP level, as 
one of 125, 151 or 175 points to optimize reproducibility of identification of peak value 
corresponding to foot of pressure wave form (APPENDIX 1.M.1). Selection of sample window 
was unique to supine posture for older adults and unique to each level of LBNP in younger 
adults while supine as well. Carotid pressure at the common carotid was measured over 15-20 
consecutive beats using applanation tonometry (SPT-301, Millar Instruments, TX, USA). Optimal 
pulse wave contour was determined visually by maximizing the amplitude and minimizing the 
diastolic pressure variation (Robertson et al., 2010). 
 
Heart-carotid velocity transit time (hcTTv) was calculated as the time interval between the R-
peak of the QRS complex and foot of the smoothed carotid artery velocity wave form within the 
same cardiac cycle (APPENDIX 1.M.1). A Savitzky-Golay smoothing 3rd order polynomial with 
sample window of 51 was applied to the carotid arterial velocity waveform. The foot was 
identified as time at the peak of the 2nd  derivative signal of the smoothed velocity wave form 
(Chiu et al., 1991). A particular 2nd derivative sample window was chosen as one of 125, 151, 
175, 201, or 225 points to optimize reproducibility of identification of peak value corresponding 
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to foot of pressure wave form. Selection of sample window was unique to supine posture for 
older adults and unique to each level of LBNP in younger adults while supine as well. Carotid 
blood velocity was measured at the carotid artery site using Doppler ultrasound probe (4 MHz, 
Multigon, New York, NY). Data were continuously recorded at 1 kHz using a data acquisition 
system (PowerLab, ADInstruments, Colorada Springs, CO, USA) and software (LabChart 5 or 7, 
ADInstruments). The correlation between hcTT and hcTTv was examined in APPENDIX M.M2. 
 
2.6 Lower Body Negative Pressure  
 
The lower body negative pressure (LBNP) chamber provides a controlled stress, similar to 
upright posture, to the cardiovascular system while participants are supine. The LBNP chamber 
is a tightly sealed rectangular box that encloses the lower body of the participant. Air pressure 
inside the chamber is reduced by a vacuum pump, making pressure inside the chamber less 
than atmospheric pressure. Consequently, blood shifts from an area of relatively high pressure 
(i.e., the upper body, outside the chamber) toward an area of relatively low pressure (i.e., the 
legs inside the chamber) decreasing central blood volume to elicit compensatory hemodynamic 
responses in an effort to maintain circulation. 
 
All assessments were performed with the younger adult participants supine and the lower body 
enclosed in a negative pressure chamber. Participants were asked to wear comfortable athletic 
t-shirts and shorts prior to putting on a neoprene “skirt” while standing. After they placed their 
lower body into the chamber, and positioned themselves comfortably on a bicycle seat (to 
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oppose the tendency to be pulled into the box) with straightened legs, an airtight seal between 
the skirt and the chamber was created. A belt is placed at the level of the participant’s iliac 
crest to maintain this airtight seal while not mechanically compressing the intestinal region 
minimizing effect on splanchnic blood flow (Goswami et al., 2009). The air pressure inside the 
chamber was lowered by turning on a vacuum pump with adjustable suction capacity 
(Beaumark 99056). The vacuum was plugged into a commercially-available variable voltage 
transformer (Staco Inc, Dayton, Ohio) to allow for variable applied voltage that created a range 
of LBNP (0 mmHg to -30 mmHg) monitored in real-time by a hand-held manometer (VWR, 
Traceable®, Radnor, Pennsylvania).  
 
The data collection was started after at least 5 minutes of baseline resting. Assessments were 
made after 3 minutes at each LBNP level. The LBNP was adjusted to -10 mmHg for 3 minutes, -
20 mmHg for 3 minutes, and finally at -30 mmHg applied suction for 3 minutes before data 
collection. After data collection, the negative pressure was stopped and equipment was 
disconnected and removed from the participant. This equipment included a finger-cuff 
photoplethysmography (Finometer Pro, Finapres Medical Systems, Amsterdam, The 
Netherlands) and a 3-electrode electrocardiogram (ECG, Finapres Medical Systems, 
Amsterdam, The Netherlands). 
 




Pre-ejection period (PEP) was only assessed in younger adults. PEP was calculated as the time 
interval between the time at the R-peak of the QRS complex and the foot of the smoothed 
aortic velocity wave form within the same cardiac cycle (Figure 7). Aortic blood velocity was 
measured at the suprasternal notch with a cardiac Doppler ultrasound probe (2MHz) with 
sample volume placed at the aortic arch (Multigon, New York, NY). A Savitzky-Golay smoothing 
3rd order polynomial with a sample window of 75 was applied to the aortic velocity waveform. 
The foot of each pulse wave was identified as the time at which the 2nd derivative of pulse wave 
was maximum using a 151, 175 or 201 point sample window selected to optimize 
reproducibility of identification of peak value corresponding to foot of velocity waveform 






Figure 7. Calculation of pre-ejection period (PEP) 
Sample data showing ECG, aortic blood velocity waveform, and 2nd derivative of aortic velocity 
waveform. The arrow indicates the foot of the aortic velocity waveform at the maximum of the 
2nd derivative. T0 and Tf represent time at R-peak of QRX complex and time at the foot of the 











The proportion that PEP represented within hdTT was calculated as PEP divided by hdTT 
(Equation 16). Aorta-digit transit time (adTT) was calculated as the difference between hdTT 
and PEP as shown in Equation 17. 
PEP %= PEP/hdTT x 100 
Equation 15 Pre-ejection period (PEP) proportion of hdTT 
Pre-ejection period (PEP) calculated as PEP divided by pulse wave transit time 
(hdTT) multiplied by 100.  
 
adTT = hdTT - PEP  
Equation 16 Aorta-digit transit time (adTT) 
Aorta-digit transit time (adTT) calculated as heart-digit transit time (hdTT) 
minus pre-ejection period (PEP).  
 
The aorta-carotid transit time (acTT) was calculated as the interval between the time at the R-
peak of the QRS complex and foot of the carotid pressure wave form (hcTT) within the same 
cardiac cycle minus PEP (Equation 17). Analysis of PEP times were done off-line involving beat-
by-beat averaging of 30 cardiac cycles. 
 
acTT = hcTT - PEP  
Equation 17 Aorta-carotid transit time (acTT) 
Aorta-carotid transit time (acTT) calculated as the hcTT minus PEP. This is a 




2.7 Data preparation for analysis 
 
Beat-by-beat data including blood pressure, heart rate, middle cerebral artery blood flow 
velocity, exhaled carbon dioxide, carotid artery blood flow velocity, femoral artery blood flow 
velocity, aortic artery blood flow velocity, finger arterial pressure, and carotid artery pressure, 
were saved as Microsoft Excel files. Each measured variable was examined per cardiac cycle.  
Signals from the Finometer when automatic calibrations for changes in finger artery contraction 
and dilatation took place using a built-in Physiocal algorithm were not included in the analysis. 
One mean value was derived for each variable per stage of LBNP (baseline, -10 mmHg, -20 
mmHg, -30 mmHg), posture (supine and standing), and before or after study-drug in RCT. Table 














Table 1 Summary of measures 
 
Measure Older Adults Younger Adults 
Age X X 
Aorta-carotid transit time  X 
Aorta-digit transit time  X 
Brachial Diastolic Pressure X X 
Brachial Mean Arterial Pressure X X 
Brachial Pulse Pressure X X 
Brachial Systolic Pressure X X 
Cardiac output  X 
Carotid Diastolic Pressure X X 
Carotid distensibility coefficient X X 
Carotid Mean Arterial Pressure X X 
Carotid Pulse Pressure X X 
Carotid Systolic Pressure X X 
Cerebral blood flow X  
Cerebrovascular Conductance index X  
Cerebrovascular Resistance Index X  
cfPWV X X 
cfPWV Index  X 
Heart Rate X X 
Heart-carotid transit time X X 
Heart-digit transit time  X 
Heart-digit transit time index X X 
Middle cerebral artery velocity  X 
Pre-ejection phase  X 
Stroke volume  X 
Total peripheral resistance  X 
β-stiffness index X X 
   
 
2.8 Statistical Analyses 
 
The RCT design required 32 participants to be randomized 1:1 to detect a significant difference 
between the groups based on pilot data (Professor Richard Hughson) that estimated a desired 
Cohen’s d effect size of 1.0.  Targeted recruitment was 40 participants to account for some 
study discontinuation. Sample size was calculated for this trial using an unpaired t-test 
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comparing two groups with a desired power of 80% and α of 0.05.   The anticipated  effect size 
of main study outcome anterior cerebral blood flow on cognitive function was based on mean 
poorest quartile of lowest cerebral blood flow (479 mL/min) and slowest speeds on Trails B-A 
(for cognitive function measure) compared to mean cerebral blood flow (592 mL/min) of all 
other quartiles of speeds on Trails B-A. The corresponding mean difference and pooled 
standard deviation of cerebral blood flow were 113 mL/min and 110 mL/min respectively. 
Notably, there is no published data on effect size of spironolactone on cerebral blood flow and 
cognition from which to calculate sample size.  
 
Testing for association was by Pearson product-moment correlation. To test for treatment 
effect after 6 months of spironolactone or placebo, a 2-way repeated measures ANOVA was 
used to test main effects (treatment group or time) and interactions (treatment group and 
time). A 2-way repeated measures ANCOVA was used to test treatment effects on carotid 
distensibility with age as a covariate. A 1-way repeated measures ANOVA was used to 
determine main effect for level of LBNP on dependent variables in younger adults. The post hoc 
Holm-Sidak Test was used to determine significance between groups. Treatment effect for all 
other comparisons between group differences was with an unpaired 2-tailed t-test. When 
assumption of normality, or equal variance failed, a Mann-Whitney Sum Rank Test was used. A 
Wilcoxon Signed Rank Test was used when normality test failed for paired t-testing. Data are 
expressed as mean ± standard deviation. Significance was set at P<0.05. All statistical analyses 




CHAPTER 3 Effect of Spironolactone on Blood Pressure and Arterial Stiffness in 




The objective of this chapter was to assess the effect of the aldosterone antagonist 
spironolactone administered for 6 months on blood pressure and arterial stiffness in older 
hypertensive adults stably treated by centrally acting ACE inhibitors compared to placebo in a 
RCT. Carotid blood pressure was assessed and arterial stiffness was estimated by cfPWV, 
carotid distensibility coefficient and β-stiffness index. Independent of the effects of angiotensin 
II, aldosterone induces reversible functional and structural vascular changes that increase 
systemic vascular resistance and arterial stiffness (Davies et al., 2005; Farquharson & Struthers, 
2000, 2002; Kithas & Supiano, 2010; Mahmud & Feely, 2005). Therefore it was hypothesized 
that in older hypertensive adults stably treated by centrally acting ACE inhibitors, 








Pooled baseline participant’s age, mean arterial pressure (MAP), systolic blood pressure (SBP), 
diastolic blood pressure (DBP) and pulse pressure (PP) were 65±3 years, 97±9 mmHg, 142±16 
mmHg, 75±8 mmHg, and 66±13 mmHg respectively. Arterial stiffness indicators cfPWV, carotid 
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distensibility coefficient and β-stiffness index were 7.22±1.09 m/s, 0.0014±0.0006 -1mmHg and 
8.78±3.53 au respectively. There was a significant negative linear correlation between age and 
carotid distensibility coefficient (Figure 8, r= - 0.51, P<0.05).   
 
All baseline measures of carotid pressures and arterial stiffness indicators were similar between 
the two groups (Table 2). The Spironolactone (Spiro) group carotid systolic blood pressure 
(cSBP) and pulse pressure (cPP) were numerically greater than Placebo before 6 months of 
study-drug. The carotid MAP (cMAP), diastolic blood pressure (cDBP), cfPWV, carotid 
distensibility coefficient, and β-stiffness index were similar between groups at baseline. 
Randomization appeared to be effective. 
 
The change in cMAP after 6 months of study-drug for the Spiro group was not significantly 
different than Placebo (Figure 9). However, the change in cSBP (P<0.05) and cPP (P<0.05) after 
6 months of study-drug for Spiro was significantly different than Placebo (Figure 9). Figure 10 
shows a non-significant difference in cfPWV for Spiro compared to Placebo after 6 months of 
study-drug. 
 
The change in carotid distensibility coefficient (Table 3) and β-stiffness index (Table 3) was 









Figure 8. Scatterplot of carotid distensibility coefficient versus age 
A scatterplot (black dots) of carotid distensibility coefficient (mmHg-1) versus age (years) for 
pooled data (n=18). There was a significant linear negative correlation between carotid 








































































 mean ±SD 
 
   
Carotid Pressure (mmHg)   
   cMAP 96±16 91±7 
   cSBP 144±24 131±17 
   cDBP 73±13 71±5 
   cPP 71±14 60±17 
   
Arterial Stiffness    
   cfPWV (m/s) 7.42±1.37 6.99±0.68€ 
   Carotid Distensibility Coefficient (mmHg-1) 0.0013±0.0005 0.0015±0.0007 
   β-stiffness index, arbitrary units 8.46±2.22 9.15±4.75 
   
   
Spiro=spironolactone group, Placebo=placebo group, cMAP=carotid mean arterial pressure, 
cSBP=carotid systolic blood pressure, cDBP=carotid diastolic blood pressure, cPP=carotid pulse 
























Figure 9. Changes in carotid pressures after 6 months of study-drug 
 
Carotid MAP (cMAP, mmHg, left pair of bars), systolic blood pressure (cSBP, mmHg, second 
from left pair of bars), diastolic blood pressure (cDBP, mmHg, second from right pair of bars), 
and pulse pressure (cPP= cSBP – cDBP, mmHg, right pair of bars) differences are shown for 
placebo (dark bars) and spironolactone (Spiro, light bars) after 6 months. Two-way repeated 
measures ANOVA were performed to establish significant interactions between Spiro and 
Placebo after 6 months of study-drug for cSBP (P<0.05) and cPP (P<0.05). There were no 
significant interactions for cMAP (P=0.13) and cDBP (P=0.40) between Spiro and Placebo. Data 























































Figure 10. Change in carotid-femoral pulse wave velocity (cfPWV) after 6 months of study 
drug 
cfPWV (m/s) differences after 6 months of study-drug are shown for placebo (Placebo, dark 
bar) and spironolactone (Spiro, light bar). A 2-way repeated measures ANOVA was performed 
to establish no significant interaction between Placebo and Spiro groups after 6 months of 





























































    
   Carotid Distensibility Coefficient (-mmHg-1) 0.0002±0.0005 -0.0000±0.0006 0.47b  
    
   β-stiffness index (a.u.) -0.54±2.86 -1.24±3.43 0.65 
    
    
    
a2-way repeated measures ANOVA for treatment and time interaction, b2-way ANCOVA with 































The objective of this chapter was to test the hypothesis that spironolactone administered for 6 
months would decrease blood pressure and arterial stiffness in older hypertensive adults stably 
treated by centrally acting ACE inhibitors compared to placebo. Important findings from this 
RCT were a significant reduction in cSBP and cPP; but cfPWV, carotid distensibility coefficient, 
and β-stiffness index, remained unchanged after 6 months of study-drug. 
 
The first notable finding from the pooled baseline data was a significant association between 
carotid distensibility coefficient and age at baseline (r= - 0.51, P<0.05); which is consistent with 
current studies (Mattace-Raso et al., 2006; Mitchell, 2008).  These participants were then 
effectively randomized as supported by the similar central arterial measures and blood 
pressure at baseline. Six months of mineralocorticoid receptor (MR) antagonism with 
spironolactone significantly reduced both carotid systolic and pulse pressure; only numerically 
improving cfPWV and carotid distensibility coefficient. In agreement with these results, Hwang 
et al. (2013) found in response to MR antagonism that arterial stiffness numerically improved 
despite significant decrease in systolic and pulse pressure. This randomized, double-blind, 
crossover study using eplerenone (an MR antagonist) in 23 generally healthy older adults (mean 
age 64 years) for one month showed a numeric decrease in PWV (9.17±1.19 Placebo vs. 
8.92±1.19 m/sec MR antagonist, P=0.5) or increase in carotid distensibility (23.1±1.8 Placebo vs. 
23.3±1.7 10−3/kPa MR antagonist, P=0.8). Although one month is notably less than the six 
months of treatment used in the current study, there was sufficient time in their study to 
significantly decrease systolic pressure by 7 mmHg and pulse pressure by 5 mmHg. It is possible 
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that the significant reduction in pulse pressure shown in this thesis RCT may have reduced the 
deleterious hemodynamic pulsatility experienced in the high flow, low impedance, cerebral circulation. 
This could correspondingly reduce the potential damage to deep microcirculation manifesting as white 
matter hyperintensities and cognitive dysfunction (Mitchell, 2008; Mitchell, 2011). In contrast, 
MacKenzie et al. (2009) observed a slight increase in PWV with a corresponding reduction in 
systolic and pulse pressures. These results should be compared to the current study with 
caution, because the MacKenzie et al. (2009) study involved ACE inhibition (perindopril) for 10 
weeks, not MR antagonism (spironolactone) for 6 months, and only measured blood pressure in 
duplicate using a mercury sphygmomanometer instead of continuous beat-by-beat blood 
pressure monitoring.  De Souza et al. (2010) investigated the effects of spironolactone (median 
dose 50 mg daily) in 173 hypertensive patients already taking antihypertensives (94% ACE 
inhibitors/AR blockers) finding that cfPWV numerically improved after 2-4 months of therapy 
from baseline 10.4 m/s to 10.0 m/s; consistent with this thesis RCT. Their study was not 
prospectively designed to evaluate cfPWV, therefore no statistical analysis was done to 
compare baseline to post-therapy values. The lack of a significant increase in carotid 
distensibility in the current study is consistent with Lipsitz et al. (2005) that showed carotid 
distensibility in controlled-hypertension and normotensive study arms remained unchanged 
with 6 months of RAAS inhibition. Only the aggressively managed uncontrolled-hypertensive 
arm (> 160 mmHg at entry into study) in their study showed an increase in carotid distensibility. 
 
A potential mechanism to explain how arterial stiffness remained essentially unchanged (i.e., 
only numeric improvements in cfPWV and carotid distensibility coefficient) after MR 
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antagonism could be explained by recent evidence that acute inhibition (single dose) of MRs 
with eplerenone impairs vascular dilation by specifically impairing vascular endothelial function  
independent of blood pressure change or vascular smooth muscle responsiveness to exogenous 
vasodilator nitric oxide (Hwang et al., 2016). This is supported by evidence in older adults free 
from cardiovascular disease that one month of MR antagonism did not lead to reduced 
oxidative stress, or improved arterial stiffness, despite significant blood pressure reduction 
(Hwang et al., 2013).  Hwang et al., 2016 noted that in 22 healthy older adults (mean 61 years) 
endothelium-dependent vasodilation following acute inhibition of MR activation with 
eplerenone was significantly reduced by 19% (P ≤ 0.03). Endothelial nitric oxide synthase 
activity, that represents capacity to produce vasodilator nitric oxide in normal healthy aging, 
was correspondingly reduced (P=0.02) with the MR antagonism compared to placebo 
supporting that MR activation plays a role in regulating endothelial nitric oxide activity to 
promote endothelium-dependent dilation in healthy aging (Hwang et al., 2016). Aldosterone 
activation of MR on endothelial cells leads to production of nitric oxide that diffuses to vascular 
smooth muscle cells and counteracts the MR-dependent vasoconstriction (Galmiche et al., 
2014; Skott et al., 2006). There is a dynamic balancing of affects from aldosterone MR 
activation between endothelial-dependent vasodilation and smooth muscle-dependent 
vasoconstriction. The effects of MR activation on vascular reactivity in healthy humans remains 
controversial however, because of conflicting results on improvement of endothelial-




Since it is well established that ACE inhibitors have consistently shown to improve endothelial 
function in animals and coronary artery disease patients through up-regulation of endothelial 
nitric oxide expression, it is possible that stable ACE inhibition in the current study prior to 
baseline vascular assessments had already improved endothelial function enough to minimize 
further improvements (Ceconi et al., 2007; Su, 2015). If indeed, MR antagonism could provide 
improvement in endothelial function as addressed above. Perhaps data from a randomized, 
double-blind, placebo-controlled study of 115 patients, without the detrimental effects of 
hypertension or coronary artery disease, supports this explanation: the significant decrease in 
systolic blood pressure was independent of cfPWV after 3 months of spironolactone (Hare et 
al., 2013). Enrolling patients without the bias introduced from stable ACE inhibitor therapy 
could allow for a better estimate of the effects of spironolactone on central vascular stiffness. 
The study by Kithas et al. (2010) supports possible explanation since the beneficial effects of 
reduced cfPWV and blood pressure with 6 months of spironolactone in a geriatric hypertensive 
population was after antihypertensive medication withdrawal prior to baseline measures of 
cfPWV and blood pressure. Mahmud & Feely (2005) assessed 24 hypertensive older adults 
naïve to antihypertensive therapy in order to show a significant (1.54 m/s) reduction in cfPWV 
and blood pressure after one month of spironolactone.  
 
Mean cfPWV from the current study (7.4 m/s spironolactone and 7.0 m/s placebo) was lower 
than suggested normative data for mean age 64-65 with hypertension of 10.2 m/s (Alecu et al., 
2008). Alecu et al. (2008) proposed, using a multivariate analysis, that age, BMI, diabetes, heart 
rate, MAP and antihypertensive treatment were all determinants of cfPWV in hypertensive 
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patients that collectively affect cfPWV explaining 19.8% of the variance. Although, the current 
study baseline cfPWV is consistent with central PWV measured by Kroner et al (2014) that 
directly measured aortic PWV using MRI to be 7.4±1.4 m/s with velocity-encoded MRI in 
generally healthy older adults (mean age 56 years). cfPWV in this thesis RCT was also consistent 
with the large Framingham Heart Study Third Generation cohort that measured cfPWV in 3,205 




This thesis RCT has several limitations. First, study findings are only generalizable to 
hypertensive patients stably treated with centrally acting ACE inhibitors willing to take 
spironolactone for 6 months. The few participants that enrolled, then went on to complete the 
study, tended to be motivated male patients. Participants were not self-selected to participate 
in research studies ongoing at their physician’s office. This could have minimized sample bias 
that may be introduced by participants actively seek opportunity to enrol in research studies 
that may be more sensitive to maintaining a healthy lifestyle. However, it is always important to 
be cautious if generalizing study results to a population other than the sample studied.  
 
 
Stiffness of central elastic arteries like the aorta predicts cardiovascular risk and cfPWV is the 
accepted gold standard for central arterial stiffness assessment (Mitchell et al., 2010; Van 
Bortel et al., 2012; Vlachopoulos, Aznaouridis, & Stefanadis, 2010). However different 
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measurement techniques to generate cfPWV show a lack of standardization, reinforcing the 
need for caution when interpreting results across trials it is difficult to compare across studies 
due to the variability in methodologies (Townsend et al., 2015; Van Bortel et al., 2012). Notable 
different techniques include the use of transcutaneous infrared plethysmography or pulse 
tonometry to estimate pulse arrival time (Phillips et al., 2013). This thesis RCT used Doppler 
ultrasound to estimate pulse wave transit times based on blood velocity instead of a common 
mechanotransducer method (Complior®, ALAM Medical, Vincennes, France) or applanation 
tonometry method (SphygmoCor, AtCor Medical, West Ryde, Australia) to measure transit 
time, making the assumption that transduction of arterial pressure pulse wave velocity 
corresponds to the flow PWV of the spectral Doppler ultrasound.  These common systems use 
mechanotransducers applied to the skin and measure real-time pressure pulse waves at the 
carotid and femoral sites. Notably, it has been demonstrated that there is a strong association 
between Complior method (i.e., pressure pulse wave propagation) and Doppler ultrasound (i.e., 
blood cell velocity pulse wave) with an intra-class correlation coefficient of 0.91 (Calabia et al., 
2011). This thesis also demonstrated a strong correlation between pressure pulse wave velocity 
and blood cell pulse wave velocity at the carotid artery site (r = 0.92, P<0.00001, Figure 29, 
APPENDIX 1.M.2). Lastly, there is potential for acute changes in blood pressure to affect 
indicators of arterial stiffness; as explored in CHAPTER 7. 
 
In conclusion, spironolactone significantly reduced blood pressure but had no effect on central 
arterial stiffness in older hypertensive adults stably treated by centrally acting ACE inhibitors 
compared to placebo in an RCT. These data do not support the hypothesis that spironolactone 
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will decrease blood pressure and decrease arterial stiffness in older adults on stable ACE 





















CHAPTER 4  Effect of Spironolactone on Cerebral Blood Flow and Cognition in Older 




The objective of this chapter was to assess the effect of spironolactone administered for 6 
months on cerebral blood flow and cognitive function in older hypertensive patients who were 
receiving stable treatment with centrally acting ACE inhibitors. Cerebral blood flow was 
estimated as anterior cerebral blood flow (aCBF) and cognitive function assessed using the 
Montreal Cognitive Assessment (MoCA), Trails B-A, and Digit Span Forward and Digit Span 
Backward tests. It was hypothesized that in older hypertensive adults stably treated by centrally 
acting ACE inhibitors that spironolactone will improve cerebral blood flow and cognition 
compared to placebo based on existing studies that have collectively shown that RAAS 
inhibition improves arterial stiffness, cerebral blood flow velocity,  and cognition (Lipsitz et al., 








There were eighteen participants (mean age 65±3 years) that completed the RCT (Table 4).  All 
participants were taking a centrally acting ACE inhibitor; most of which were taking ramipril. 
Approximately half were taking a statin for lowering lipids, and half were taking a combination 
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ACE inhibitor with hydrochlorothiazide diuretic. Serum sodium and potassium were similar 
between Spiro and Placebo. Renal function, represented as serum creatinine or estimated 
glomerular filtration rate (eGFR), was also similar between the groups during the study. There 
were 3 participants in the Spiro group and 1 participant in the Placebo group that a self- 
proclaimed history of chest pain or heart attack; otherwise clinical characteristics were similar. 
The mean adherence to study-drug was excellent; 95% or greater for both groups. 
 
There were no significant differences in any of the baseline measures of age, sex, BMI, brachial 
pressure, or cognitive function measures between the groups suggesting successful 
randomization (Table 5). The Spiro group had higher systolic blood pressure (SBP,) and pulse 
pressure (PP,) compared to the Placebo group. However, the Placebo group had a higher BMI 
and heart rate than Spiro group. It is unclear if these were relevant differences given the 
sample size. MAP and diastolic pressures (DBP) were similar between the two groups.  MAP and 
DBP changes after 6 months of study-drug were not significantly different between Spiro and 
Placebo (Figure 11). In contrast, SBP (P<0.05) and PP (P<0.05) changes after 6 months of study-
drug were significantly different between the groups (Figure 11). There was a trend toward an 
increase in heart rate for Spiro group (P=0.06, Table 6). 
 
Baseline anterior cerebral blood flow (aCBF) was similar between the two groups and remained 
similar after 6 months of study-drug (Figure 12). Baseline CVCi (cerebrovascular conductance 
index=aCBF/MAP) was similar between the two groups and remained similar after 6 months of 
study-drug (Figure 13). Changes in Montreal Cognitive Assessment Test (MoCA) scores and 
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Trails B-A times after 6 months of study-drug for Spiro were similar to Placebo (Table 6); as 
were Digit Span Forward and Digit Span Backward changes after 6 months of study-drug (Table 
5).  













   Statin 44 56 
   ASA 33 33 
   Ramipril (ACE inhibitor)   67 78 
   Lisinopril (ACE inhibitor) 0 11 
   Perindopril (ACE inhibitor) 33 11 
   Anticoagulant 0 11 
   HCTZ 44 56 
   Calcium Channel Blocker 11 11 
   Beta-Blocker 33 22 
   




   Serum Sodium  138±2  139±1 




   Serum Creatinine (µmol/L) 89±14  82±16 
   eGFR  (mL/min/1.73m2 ) 77±14  76±9 
 
   
Spiro=spironolactone group, Placebo=placebo group, Statin= HMG-CoA reductase inhibitor, 
ASA= acetylsalicylic Acid, HCTZ=hydrochlorothiazide, eGFR= Estimated Glomerular Filtration 





















   
Age (years) 66±3 64±4 
Male (%) 100 67 




   MoCA (score) 25±2 25±2 
   Trails B-A (seconds) 34.5±16.6 44.9±25.1 
   Digit Span Forward (row number) 5±1 4±1 
   Digit Span Backward (row number) 4±1 4±1 
   
Heart Rate (beats/min) 64±9 72±14 
 
Brachial Pressure (mmHg) 
  
   MAP 98±12 93±7 
   SBP 145±17 132±14 
   DBP 75±12 73±5 




   aCBF (mL/min) 828.9±256.6 874.6±193.7 
   CVCi (mL/min/mmHg) 9.5±2.2 8.6±2.8 
   
   
Spiro=spironolactone group, Placebo=placebo group, BMI = Body Mass Index, MoCA=Montreal 
Cognitive Assessment, MAP=Mean Arterial Pressure, SBP=systolic blood pressure, DBP=diastolic 
blood pressure, PP=pulse pressure, aCBF =  anterior cerebral blood flow, CVCi= cerebrovascular 










Table 6. Changes in cognitive function, blood pressure, and cerebral blood flow after 6 
















    
Cognitive Function    
   MoCA (score) 2±2 1±2 0.55 
   Trails B-A (seconds) -4.0±13.5 -7.4±16.0 0.63 
   Digit Span Forward (row) 0±1 0±1 0.84 
   Digit Span Backward (row) 0±1 0±1 0.46 
    
Heart Rate (beats/min) 4±9 -5±9 0.06 
 
Brachial Blood Pressure (mmHg) 
   
   MAP -7±11 1±8 0.14  
   SBP -14±14 0±11 <0.05  
   DBP -3±12 -0±7 0.52  
   PP -12±11 0±8 <0.05  
 
Cerebral Blood Flow  
   
   aCBF (mL/min) 4.0±136.6 -38.6±140.3 0.52  
   aCBF (%) 0.5±17.1 -6.2±18.0 0.55b   
    
    
aTwo-way repeated measures ANOVA for treatment and time interaction, bunpaired t-test, 
Spiro=spironolactone group, Placebo=placebo group, MoCA=Montreal Cognitive Assessment, 
MAP= Mean Arterial Pressure, SBP=systolic blood pressure, DBP=diastolic blood pressure, 





Figure 11. Change in brachial pressures after 6 months of study-drug 
MAP (mmHg, left pair of bars), systolic blood pressure (SBP, mmHg, second from left pair of 
bars), diastolic blood pressure (DBP, mmHg, second from right pair of bars), and pulse 
pressure (PP=SBP – DBP, mmHg, right pair of bars) changes are shown for placebo (Placebo, 
dark) and spironolactone (Spiro, light) after 6 months of study-drug. *Two-way repeated 
measures ANOVA were performed to establish significant interactions between Spiro and 
Placebo after 6 months study-drug for SBP (P<0.05) and PP (P<0.05). There were no 
significant interactions between Spiro and Placebo after 6 months study-drug for MAP 




















































Figure 12. Anterior cerebral blood flow (aCBF) at baseline and after 6 months of study-
drug 
aCBF (mL/min) at baseline (dark bars) and after 6 months of study-drug (grey bars) are 
shown for spironolactone (Spiro, right pair of bars) and placebo (Placebo, left pair of bars) 
groups. Two-way repeated measure ANOVA was performed to establish no significant 
interaction between or within groups after 6 months of therapy (P=0.52). Data are means 
















































Figure 13. Change in cerebrovascular conductance index (CVCindex) after 6 months of study-
drug 
CVCi (aCBF/MAP=cerebrovascular conductance index, ((mL/min)/mmHg) changes are shown for 
placebo (Placebo) and spironolactone (Spiro) after 6 months of study-drug. Two-way repeated 
measure ANOVA was performed to establish no significant interaction between or within 





















































There were no adverse events that led to discontinuation in the Spiro group. Table 7 shows that 
three participants randomized to Placebo withdrew due mild diarrhea or hyperkalemia prior to 
first dose of study-drug. One participant had a single brief episode of symptomatic rapid heart 
rate. One participant in each group voluntarily withdrew due to concerns of compromising 













   
Mild diarrhea   1 
Hyperkalemia prior to study drug initiation  1 
Voluntarily withdrew  1 1 
Brief symptom of rapid heart rate  1 
   
   





















The objective of this chapter was to assess the effect of spironolactone on cerebral blood flow 
and cognitive function in older hypertensive patients who were receiving stable treatment with 
centrally acting ACE inhibitors. It was hypothesized that spironolactone would improve cerebral 
blood flow and cognition from existing studies that have shown a significant negative 
correlation between cerebral blood flow (total cerebral blood flow measured using MRI) and 
cfPWV; and based on evidence of higher cfPWV being independently associated with 
manifestations of brain small-vessel disease (i.e., greater volume of white matter 
hyperintensities) in hypertensive patients (Henskens et al., 2008; Tarumi et al., 2014; Xing et al., 
2017). In this thesis RCT, aCBF and cognitive function remained unchanged after 6 months of 
spironolactone. It is possible that aCBF was maintained by the slight non-significant 
improvement in cerebrovascular conductance to compensate for the reduction in MAP.   
 
This thesis RCT results are consistent with Hajjar et al.  (2013) that showed 12 months of RAAS 
inhibition with an ACE inhibitor (or angiotensin receptor blocker, ARB) preserved cerebral blood 
flow in older hypertensive adults of similar age and blood pressure. Although, their study used 
MCA velocity (MCAv) using transcranial Doppler ultrasound as a different marker of cerebral 
blood flow, and therapy was preceded by a washout period allowing for antihypertensive 
medication withdrawal. The current thesis RCT showed that absolute or percent change in aCBF 
(measured as the sum of internal carotid artery blood flow) after 6 months of spironolactone 
remained unchanged; despite very good adherence to study-drug in both groups (95±2% vs 
97±4%, P=0.35). Hajjar et al. (2013) showed that maintenance of cerebral blood flow velocity 
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was despite significant reductions in blood pressure with ACE inhibitor lisinopril (systolic BP 153 
mmHg reduced to 126 mmHg and diastolic BP 85 to 70 mmHg, P<0.001), which is similar to this 
RCT.  In contrast, Lipsitz et al. (2005) showed that RAAS inhibition (6 months of ACE inhibitor or 
ARB) significantly improved cerebral blood flow estimated by MCA velocity. However, this was 
only in participants that initially had uncontrolled hypertension (systolic pressure >160 mmHg 
at study entry) and given RAAS inhibition to achieve the target systolic pressure of <140 mmHg 
for six months unlike participants in the current study that already had well controlled systolic 
blood pressure at baseline cerebrovascular and cognitive assessments. The findings in the 
current RCT are consistent with the controlled-hypertension group (treated hypertensive 
patients with systolic pressure <140 mmHg at study entry) in Lipsitz et al. (2005) that also 
showed maintenance of cerebral blood flow after 6 months of RAAS inhibition. Collectively this 
evidence suggests that cerebral blood flow is preserved despite significant reductions blood 
pressure. The similar cerebrovascular conductance between the groups in the current RCT is 
supported by similar cerebral blood flow and MAP changes after 6 months of study-drug.  
Although one may expect MR antagonism to increase cerebrovascular conductance as 
predicted from evidence showing a significant negative association between lower cerebral 
blood flow velocity and high baseline aldosterone (Hajjar et al., 2015). This thesis RCT did not 
measure serum aldosterone. 
 
The mean MoCA score of 25±2 for each group at baseline validated effective randomization of 
executive cognitive function between the groups and was above the normative data mean 
MoCA score of 22±5 for 228 subjects of the age group 65 – 75 years  as part of the longitudinal, 
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population-based, Dallas Heart Study (Rossetti, Lacritz, Cullum, & Weiner, 2011). Unlike Yagi et 
al. (2011) that found MR antagonism for 6 months added to ongoing hypertension treatment 
significantly improved cognitive function in 7 matched patients, the current RCT finding was 
that cognitive function remained similar between the two groups after 6 months of MR 
antagonism. This finding was unexpected based on the Yagi et al. (2011) results yielded from 
participants of similar age, MAP, SBP and DBP as this thesis RCT using a less sensitive executive 
function assessment tool Mini-Mental State Examination (MMSE; unlike the MoCA used in 
current study) that were only matched by age, sex and MMSE score instead of double-blind 
randomization as in the current study (Dong et al., 2012). A recent post hoc analysis of the large 
HOPE 3 study supports this thesis RCT finding: 1626 intermediate cardiovascular risk patients 
(at least 70 years, no blood pressure medication) over 6 years taking a RAAS inhibitor that 
lowered blood pressure (systolic mean decline 6 mmHg) did not prevent cognitive decline 
estimated as Digit Symbol Substitution Test, modified MoCA, and Trails B results being 
comparable to placebo (Bosch, 2016). Cerebral blood flow was not measured in HOPE-3. 
 
The current RCT finding that maintaining cerebral blood flow preserves cognitive function is 
consistent with a study in which patients who were unable to maintain cerebral blood flow as a 
result of a transient ischemic attack (L. Wang, Jia, & Wu, 2013).  Wang et al. (2013) showed that 
temporarily reduced cerebral blood flow was associated with declined executive cognitive 
function (assessed using the MoCA) and lower MCA peak systolic velocities (P < 0.001). This 
could even be generalized to maintaining Trails B-A times and Digit Span Backward levels as 
they are simply expanded components of the MoCA assessing various cognitive domains.  
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Perhaps if participants in this thesis RCT had executive dysfunction at baseline, there could have 
been a significant improvement in Trails B-A times as demonstrated by Hajjar et al (2015) with 
RAAS inhibition in patients with executive dysfunction.  If the hypothesis of this thesis is still 
potentially true that the beneficial effects of spironolactone on blood pressure and arterial 
stiffness will improve cerebral blood flow and cognition, future research is still needed given 




The main limitation is that the small sample size did not provide statistical power to detect 
significant differences in the primary outcome marker of aCBF.  The sample size required to 
detect a significant difference in mean spironolactone aCBF (832.9 mL/min) and placebo (836.0 
mL/min) is estimated from this current study as 330 participants (165 in each group) with a 
significance level (α) of 0.05 and desired power of 0.8 (Sigmaplot 12.5, Systat Software Inc, San 
Jose, California, USA).  The calculated Cohen’s d effect size for spironolactone was 0.3 from this 
thesis RCT data; much smaller than the desired Cohen’s d effect size of 1.0 that was used to 
calculate sample size during the trial design. This larger desired effect size was based on 
observational, non-interventional, pilot data as described in the methods Chapter 2 (2.8). Since 
it is also possible that the small sample size of 9 participants in each treatment group resulted 
in a Type II error of a “false negative”, due to a low statistical power to detect a true difference 
in baseline measures between the treatment groups, with SBP and PP in particular, 2-way 
repeated measures ANOVA tests were conducted. These showed a significant interaction 
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between treatment group (spironolactone or placebo) and time (pre- or post-treatment) on 
dependent variable SBP. This was also true for PP. The correlation between the covariate of 
baseline SBP and post treatment SBP was not similar between the groups, not surprisingly, 
since spironolactone was expected to reduce blood pressure more effectively than placebo.  
 
Another limitation is that study findings are really only generalizable to older hypertensive 
patients on stable centrally-active ACE inhibition willing to take spironolactone for 6 months. 
The third is that the few participants that enrolled and completed the study tended to be 
motivated male patients. These motivated participants may have introduced bias of an 
uncommonly health-aware sample of older adults not representative of the general 
hypertensive population. Although, it should be noted, that these participants were not 
previously identified as being interested in participating in clinical trials by their Family 
Physicians which would have been noted in their electronic medical records. The fifth is that 
internal carotid artery blood flow is only a marker of brain blood flow and does not represent 
total brain blood flow that includes blood flow from vertebral arteries. Blood viscosity and 
hematocrit, which are inversely related to brain blood flow velocity, were not measured in the 
current study (Ameriso et al., 1990; Fiermonte, Aloe Spiriti, Latagliata, Petti, & Giacomini, 
1993). Blood flow velocities could increase approximately 20% with a drop in hematocrit from 
40% to 30% (Purkayastha & Sorond, 2012). All assessments were done on the background of 
centrally acting ACE inhibition that may have already optimized marginal benefits of additional 
RAAS inhibition with an MR antagonist. Since the MoCA is primarily a screening test for MCI, 
other more sensitive measures of cognitive function could have been applied in this thesis. 
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Stroop, Eriksen Flanker Task, Wisconsin Card Sorting, or N-back may have provided a greater 
power to detect changes in cognitive domains. 
 
In conclusion, cerebral blood flow and cognitive function was unchanged from spironolactone 
administered for 6 months in older hypertensive adults who were receiving stable treatment 
with centrally acting ACE inhibitors. These data do not support the hypothesis that 


















CHAPTER 5  Effect of Spironolactone on Cerebrovascular Autoregulation in Older 




The objective of this chapter was to assess the effect of spironolactone administered for 6 
months on cerebrovascular autoregulation in older hypertensive patients who were receiving 
stable treatment with centrally acting ACE inhibitors. The changes in mean arterial pressure 
(MAP), MCA velocity, and cerebrovascular resistance index (CVRi) responses to posture change 
from seated to standing upright were estimates of cerebrovascular autoregulation. The 
secondary objective was to assess the effect of spironolactone on changes in cerebrovascular 
reactivity to carbon dioxide (CO2). Since existing evidence that RAAS inhibition in older 
hypertensive adults significantly reduces blood pressure without compromising orthostatic 
changes in cerebral blood flow (Lipsitz et al., 2005), it was hypothesized that spironolactone 









There were no significant differences between the spironolactone (Spiro) and placebo (Placebo) 
groups in hemodynamic responses before, or after 6 months, of study-drug. Specifically, the 
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posture (from seated to standing) change in MAP, MCA velocity, and cerebrovascular resistance 
index (CVRi=MAP divided by MCA velocity) was similar during baseline assessments (Table 8). 
The percent change in CVRi (Spiro 1±9 % vs Placebo -3±9 %, P=0.34) was also similar.  
 
Posture change (absolute and percent) in MCA velocity at baseline was similar between Spiro 
and Placebo groups (Figure 14). Posture change (absolute and percent) in MAP at baseline was 
statistically different between Spiro and Placebo groups (Figure 15).  
 
The differences in MAP and MCA velocity responses to posture change were reassessed after 6 
months of study-drug. Absolute and percent differences in change of MAP for Spiro were 
similar to Placebo (Table 9). Absolute and percent differences in change of MCA velocity for 
Spiro were also similar to Placebo (Table 9). Correspondingly, absolute and percent differences 
























    
  Posture change in MAP (mmHg) -9±8 -12±4 0.41 
  Posture change in MCA velocity (cm/s) -5.0±2 -4.5±3 0.66 
  Posture change in CVRi (mmHg/(cm/s)) 0.03±0.19 -0.04±0.22 0.50 
    
    
aFrom unpaired t-test, Spiro=spironolactone group, Placebo=placebo group, MAP=mean arterial 
pressure, MCA = middle cerebral artery,  CVRi= cerebrovascular resistance index (MAP/MCA 





















Figure 14. Baseline responses of middle cerebral artery (MCA) velocity to posture change 
Baseline posture change in MCA velocity for spironolactone (Spiro, light bars)  and placebo 
(Placebo, dark bars) in absolute (cm/s, left pair of bars) and percent (%, right pair of bars) 
immediately upon standing upright from resting seated posture. Unpaired t-tests were 
performed to establish no significant differences between Spiro and Placebo groups for 
absolute MCA velocity (cm/s, P=0.66) and percent MCA velocity (%, P=0.97) responses. Data are 



























Figure 15. Baseline responses of MAP to sit-to-stand posture change 
Baseline posture change in MAP for spironolactone (Spiro, light bars) and placebo (Placebo, 
dark bars) in absolute (mmHg, left pair of bars) and percent (%, right pair of bars) immediately 
upon standing upright from resting seated posture. Unpaired t-tests were performed to 
establish no significant differences between Spiro and Placebo groups for absolute MAP 

















































mean ±SD  
 
P-valuea 
    
  Posture change in MAP (mmHg) -2±8 1±11 0.48  
  Posture change in MAP (%) -3±7 1±12 0.43  
  Posture change in MCA velocity (cm/s) 1±3 1±5 0.88  
  Posture change in MCA velocity (%) 2±7 2±12 0.98  
  Posture change in CVRi (mmHg/(cm/s)) -0.1±0.2 -1.2±3.2 0.77 
  Posture change in CVRi (%) -7.3±10.4 -0.7±24.1 0.68 
    
    
aFrom unpaired t-test, Spiro=spironolactone group, Placebo=placebo group, MCA=middle 
cerebral artery, MAP=mean arterial pressure, CVRi=cerebrovascular resistance index 
(MAP/MCA velocity). Difference=posture change in measure after 6 months of study-drug 























Cerebrovascular reactivity to CO2  
 
The change in MCA velocity during hypercapnia and hypocapnia for the Spiro group was similar 
to Placebo during baseline assessments (Table 10).  APPENDIX 1.M, section M.5, includes end-
tidal CO2 values measured during assessments. The difference in change in MCA velocity during 
hypercapnia and hypocapnia for the Spiro group after 6 months of study-drug remained similar 























 (n=9)  
mean ±SD 
Placebo 





    
Baseline     
   Hypercapnia change in MCA velocity (cm/s) 27±8 26±20 0.18 
   Hypercapnia change in MCA velocity (%) 66±25 56±25 0.48 
   Hypocapnia change in MCA velocity (cm/s) -13±5 -13±6 0.87 
   Hypocapnia change in MCA velocity (%) -27±9 -27±11 1.00 
    
Difference in change after 6 months of study-drug    
   Hypercapnia change in MCA velocity (cm/s) -7±14 -4±17 0.77 
   Hypercapnia change in MCA velocity (%) -18±33 -2±22 0.34 
   Hypocapnia change in MCA velocity (cm/s) -1±6 -3±4 0.42 
   Hypocapnia change in MCA velocity (%) -5±11 -8±12 0.58 
    
    
aFrom unpaired t-test, Spiro=spironolactone group, Placebo=placebo group, hypercapnia 
induced by breath-hold, hypocapnia induced by increased respiratory rate, see APPENDIX 1.M.5 
for CO2 values. Hypercapnia change in MCA velocity=MCA velocity during hypercapnia minus 
MCA velocity during resting respiratory rate (i.e., normocapnia). Hypocapnia change in MCA 






















The objective of this chapter was to test the hypothesis that spironolactone would maintain 
cerebrovascular autoregulation in older hypertensive patients who were receiving stable 
treatment with centrally acting ACE inhibitors.  The secondary objective was to assess the effect 
of spironolactone on cerebrovascular reactivity to CO2. 
 
The significant reductions in SBP and PP after 6 months of spironolactone, as reviewed in 
CHAPTER 4, did not appear to compromise dynamic cerebrovascular autoregulation estimated 
as differences in the immediate change in MCA velocity, MAP, and CVRi to standing upright. 
After 6 months of study-drug, posture change in MCA velocity as a marker of cerebral blood 
flow, and posture change in MAP, remained similar between Spiro and Placebo. It is possible 
that the postural change in MAP for the Spiro group was not as large as the Placebo group due 
to improved arterial function. Posture change in CVRi for the Spiro group was correspondingly 
similar to Placebo after 6 months of study-drug. These findings that changes to MCA velocity, 
MAP and CVRi remain uncompromised despite a significant reduction in blood pressure is 
consistent with existing evidence that RAAS inhibition (spironolactone is a RAAS inhibitor) in 
older hypertensive patients significantly reduced blood pressure without compromising 
orthostatic changes in brain blood flow (Lipsitz et al., 2005). Lipsitz et al. (2005) also conducted 
a prospective study to observe how significantly lowering systolic blood pressure (delta MAP 17 
mmHg) with a RAAS inhibitor in uncontrolled hypertensive older adults did not compromise 
their cerebrovascular autoregulatory response to posture change; MAP, MCA velocity and CVRi 
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remained unchanged similar to this thesis RCT. To support these findings, Hajjar et al. (2013) 
showed that posture changes from (seated to standing) in MCA velocity and CVRi were 
unaffected after 12 months of an angiotensin receptor blocker in 60 plus year old hypertensive 
patients. This same study did however show a significant reduction in CVRi after 12 months of 
an ACE inhibitor in these patients. There does not appear to be published evidence with an MR 
antagonist (like spironolactone) that supports this thesis RCT finding that cerebral 
autoregulation remains stable despite a significant blood pressure reduction after 6 months of 
spironolactone.  
 
Cerebrovascular reactivity to CO2 was unaffected after 6 months of spironolactone. Observed 
differences in change in MCA velocity during hypercapnia and hypocapnia for the Spiro group 
was similar to Placebo after 6 months of study-drug. Cerebrovascular reactivity to CO2 would 
have been shown to improve if, for example, there was a greater difference in change in MCA 
velocity during hypercapnia observed for the Spiro group compared to the Placebo group after 




The first limitation is the use of MCA blood flow velocity as a marker of cerebral blood flow; 
despite the common use of changes in MCA blood flow velocity in response to an active sit-to-
stand procedure used to induce hemodynamic changes to assess cerebrovascular 
autoregulation (Hajjar et al., 2013; Lipsitz et al., 2005; Lipsitz et al., 2000). The second limitation 
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is variability in the angle of the transmitted ultrasound wave from the transcranial Doppler 
(TCD) probe. To ensure MCA blood flow velocity during TCD ultrasound accurately represents 
the velocity of moving red blood cells, the angle Ө of the transmitted ultrasound wave to the 
direction of moving red blood cells must be zero. If the angle is zero, or the emitted wave is 
parallel to the direction of flow, the cosine of zero is 1, to achieve the most accurate measure of 
flow velocity (flow velocity = (Doppler shift frequency x speed of sound in blood)/(2x ultrasound 
transmission frequency x cosine Ө)). The larger Ө is, the larger cosine Ө is, and the greater the 
error in the velocity measure. Importantly, Ө less than 30 degrees keeps the error below 15% 
(Purkayastha & Sorond, 2012). The third limitation is the assumption that MCA diameter, based 
on a study that used a 1.5T MRI to measure MCA diameter (providing 0.5 mm resolution), 
remains constant (Serrador et al., 2000). Especially during changes in ETCO2 that could acutely 
alter the caliber of the MCA and impact resistance to blood flow.  This is supported by more 
recent studies using a higher resolution MRI (3T and 7T with 0.4 mm and 0.2 mm resolution 
respectively) to measure MCA diameter may change with ETCO2 levels and this change in 
diameter may be diminish with aging (Coverdale, Badrov, & Shoemaker, 2017; Coverdale et al., 
2014; Verbree et al., 2014). The fourth limitation was the strict eligibility criteria of this thesis 
RCT limits generalizability of findings to generally healthy older adults on stable centrally acting 
ACE inhibitor therapy; participants with significant comorbidities may have responded 
differently to 6 months of spironolactone therapy.  
 
The current study findings support the hypothesis that spironolactone would maintain 
cerebrovascular autoregulation in older hypertensive patients who were receiving stable 
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treatment with centrally acting ACE inhibitors. Better blood pressure control was not associated 


























The primary objective of this chapter was to compare blood pressure and arterial stiffness of 
younger adults to the older adults in the RCT. Arterial stiffness was estimated by cfPWV, carotid 
distensibility coefficient and β-stiffness index. Aging is an important risk factor for developing 
hypertension likely due to changes in artery wall structure, up-regulation of RAAS activity, 
hypertension, a reduction in compliance and an increase in arterial stiffness (Fukutomi & Kario, 
2010; Nilsson, 2008). It is possible that normal arterial aging involves structural and functional 
changes as an initial mechanism for elevating risk of hypertension. It was hypothesized that 
older hypertensive adults stably treated by centrally acting ACE inhibitors would have higher 
blood pressure and greater arterial stiffness, measured by all computed indices, compared to 








Blood pressure and arterial stiffness were assessed in 17 older adults (OA, mean age 65±3 
years) and 14 younger adults (YA, mean age 26±5 years) as shown in Table 11.  The OA group 
had significantly greater mean arterial pressure (MAP), systolic blood pressure (SBP), diastolic 
102 
 
blood pressure (DBP) and pulse pressure (PP) compared to YA (Table 11). Heart rate however 
was similar between the groups. Regional stiffness indicator cfPWV in OA showed significantly 
greater arterial stiffness compared to YA with a percent difference of 24.8% (Table 11). Local 
stiffness indicators carotid distensibility coefficient (Figure 16) and β-stiffness index (Figures 17) 
in OA also showed significantly greater arterial stiffness compared to YA. The percent 
differences were 56.2% and 57.4% respectively. 
 
Transit time estimates hdTTi (heart-digit transit time from R-peak of QRS complex for pressure 
pulse wave to reach digit artery divided by SBP) and hcTT (heart-carotid transit time is from R-
peak to time for pressure pulse wave to reach carotid artery) were significantly less for OA 
compared to YA; indicating greater arterial stiffness in OA (Table 11). The percent differences 
were 15.4% and 23.5% respectively. hdTTi per unit height for YA (9.3 ms/mmHg/m) was 
significantly greater than OA (7.5 ms/mmHg/m, P<0.01), representing less arterial stiffness in 











Table 11. Comparison of heart rate, blood pressure, arterial stiffness and transit times of 













    
Age (years) 65±3 26±5 P<0.05 
    
Heart Rate (beats/min) 68±13 64±7 0.32 
 
Brachial Pressure (mmHg) 
   
   MAP 97±9 86±9 P<0.01 
   SBP 142±16 124±12 P<0.05 
   DBP 75±8 67±9 P<0.05 
   PP 66±13 57±7 P<0.05 
 
Arterial Stiffness 
   
   cfPWV (m/s) 7.22±1.09 5.43±1.13 P<0.001 
    
Transit Times    
   hdTTi (ms/mmHg) 1.3±0.2 1.5±0.2 P<0.05 
   hcTT (ms) 68±17 84±15 P<0.05 
    
    
aFrom unpaired t-test, OA = older adults, YA = younger adults, MAP= Mean Arterial Pressure, 
SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, PP=Pulse Pressure, cfPWV=carotid-
femoral pulse wave velocity, hdTTi=heart-digit transit time from R-peak of QRS complex for 
pressure pulse wave to reach digit artery divided by SBP, hcTT= heart-carotid transit time is 
from R-peak to time for pressure pulse wave to reach carotid. cfPWV was n=13. All measures 














Figure 16. Carotid distensibility coefficient for older adults and younger adults 
 
Carotid distensibility coefficient (mmHg-1) for older adults compared to younger adults. 
Unpaired t-test was performed to establish that carotid distensibility for older adults was 
























































Figure 17. β-stiffness index for older adults and younger adults  
 
β-stiffness index (a.u.) for older adults compared to younger adults. Unpaired t-test was 
performed to establish that β-stiffness index for older adults was significantly greater than 






















































The objective of this chapter was to compare blood pressure and arterial stiffness of younger 
adults to the older adults in the RCT. Measures of blood pressure and arterial stiffness 
supported the hypothesis of higher blood pressure and greater arterial stiffness in older adults 
in the RCT compared to younger adults. The percent differences in the regional stiffness 
indicator cfPWV, and transit times, were generally smaller than the percent differences for the 
local stiffness indicators carotid distensibility coefficient and β-stiffness index. 
 
It is accepted that older adults with hypertension have greater arterial stiffness, which results in 
increasingly faster pulse transmission to the periphery, than younger adults. The older adults in 
this thesis RCT showed greater arterial stiffness than younger adults represented as faster 
cfPWV, smaller carotid distensibility coefficient and greater β-stiffness index. These younger 
adults had comparable blood pressure to other generally healthy younger adults of similar age 
(Cooke et al,. 2009). These results of increasing PWV with age are supported by existing 
evidence with similar markers of central arterial stiffness. Choi et al. (2010) showed an increase 
in central PWV of 1.26 m/s for every 11-year increase in age. As well, Mitchell et al. (2004) 
showed an estimate cfPWV of 1.04 m/s for every 8.5-year increase in age. Both indicators of 
central arterial stiffness increase with age to support the current thesis study findings. The very 
largeobservational study of 11,092 participants by Boutouyrie et al. (2010) was consistent with 
this thesis data of increasing arterial stiffness with age; amplified by increasing blood pressure. 
For example, there is a spectrum of increasing cfPWV (9m/s to 13m/s) with increasing blood 
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pressure (<120/80 to ≥ 160/100) within the same 60-69 year age category (Boutouyrie et al., 
2010).  
 
Transit times hdTTi and hcTT, were significantly shorter in older adults of the RCT compared to 
younger adults, reflecting greater arterial stiffness. This is consistent with the study that 
demonstrated increasing age as a significant contributor to decreasing hdTT, also measured 
from R-peak of QRS complex to the finger artery, in 116 adults of mean age 41±13 years of -6 
ms per 10-year increase in age (P<0.0001) (J. Allen & A. Murray, 2002).  Similarly, a study in 266 
healthy adults age 18-78 years showed that hdTT was inversely related to age (β = -0.754, 
P<0.001) (Zhang, Zheng, Ma, & Sun, 2011). 
 
These younger adults in this thesis experimental study were compared to controlled 
hypertensive older adults, which may be unlike normotensive older adults. The presence of 
hypertension may have accelerated normal central arterial aging limiting generalizability of 
findings to healthy adults with hypertension. The cross-sectional population-based study by 
Amar et al. (2001) of 993 participants (35-64 years) supports this; it showed that patients 
treated for hypertension exhibit greater central arterial stiffness than normotensive subjects 
even after adjusting for age (Amar, Ruidavets, Chamontin, Drouet, & Ferrieres, 2001). 
Hasegawa et al (1997) also reported acceleration of arterial stiffness indicators hdTT and PWV 




The percent differences in the regional vascular transit indicators were generally smaller than 
the percent differences for the local carotid artery indicators possibly due to non-uniform 
stiffness along the arterial tree from differences in properties between elastic and muscular 
arteries that may be affected by sympathetic vasoconstriction and regional differences in 
transmural pressures (Tsuchikura et al., 2010).  This is supported by the study findings by Paini 
et al. (2006) that age and blood pressure had a stronger independent influence on local carotid 
stiffness than regional vascular transit indicator cfPWV; that was amplified by the presence of 
hypertension. The study by Jurasic et al. (2009) supports the 56% difference in β-stiffness index 
in this thesis by showing a similar (53%) difference between 25-35 year age group and 65-75 
year age group. However, inconsistent with this thesis, findings from large studies show that 
age had a similar impact on cfPWV as carotid stiffness; although still amplified by hypertension 
(Boutouyrie et al., 2010; Bruno et al., 2017; Huang, Hu, Huang, Sun, & Zhu, 2008). When 
considering possible reasons why percent differences in regional transit times, hdTT and hcTT, 
were generally smaller than the percent differences for the local carotid artery indicators, 
carotid distensibility coefficient and β-stiffness index, there may be variability introduced by the 




There are several important limitations to consider. The first limitation is that hdTTi has no 
comparative data, or existing evidence from other studies, to validate the current findings. It is 
important to note, however, that hdTT is a popular non-invasive pulse transit time estimate 
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being widely pursued for cuff-less blood pressure monitoring because of the observed 
association with systolic blood pressure (Gao, Olivier, & Mukkamala, 2016; Mukkamala et al., 
2015). The second would be variability introduced from participant’s height when calculating 
hdTTi since a study by Allen et al. (2002) showed a 0.7 ms increase in transit time per 
centimeter of height. However, this source of bias would have existed randomly across the age 
spectrum of adults in the current thesis research as supported by the observation that 
calculated hdTTi per unit height for YA was still significantly greater than OA, representing less 
arterial stiffness in YA. The same was true for central transit time hcTT per unit height for YA vs 
OA. The same study by Allen et al. (2002) showed that central transit times (similar to hcTT) 
were not associated with subject’s height; possibly due to the contribution of a variable pre-
ejection period (PEP is the time from the R-peak of the QRS complex to the onset of aortic 
blood flow) being a substantially larger proportion of hcTT compared to hdTT because of the 
shorter path length to the carotid site compared to the finger. As will be reviewed in Section 
7.3, PEP represents 26 % to 33% of the total hdTT, and 58% to 64% of the total hcTT, which is 
consistent with existing evidence showing that PEP represents a nontrivial fraction of pulse 
wave transit time and source of variability (Payne, 2006). 
 
In conclusion, all measures of blood pressure and indicators of arterial stiffness supported the 
hypothesis of higher blood pressure and greater arterial stiffness in older adults in the RCT 










The primary objective of this chapter was to demonstrate the potential for an acute decrease in 
systolic and pulse pressure to affect indicators of arterial stiffness that were applied to older 
adults in the RCT, and to determine if any change in stiffness might simply be a consequence of 
the reduction in arterial blood pressure anticipated with addition of spironolactone to stable 
ACE inhibitor therapy. Changes in cardiac dynamics and arterial blood pressure were induced in 
younger adults by application of mild to moderate levels of lower body negative pressure 
(mLNBP). The arterial stiffness indicators in this study included cfPWV, a carotid distensibility 
coefficient, and β-stiffness index. Secondary objectives included the assessment of the impact 
of acute changes in blood pressure on transit times hdTT (heart-digit transit time from R-peak 
of QRS complex for pressure pulse wave to reach digit artery) and hcTT (heart-carotid transit 
time from R-peak for pressure pulse wave to reach carotid artery). The PEP was also assessed 
(i.e., PEP is the heart-aorta time from the R-peak to the onset of aortic blood flow). Brachial 
blood pressure measurements included mean arterial pressure (MAP), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and pulse pressure (PP). Stroke volume (SV), cardiac 
output (CO) and total peripheral resistance (TPR) were also assessed. This chapter also includes 
the post hoc analysis of the impact that the orthostatic stress on blood pressure changes from 
quiet standing in older adults (OA) to mLBNP in younger adults (YA).  Since acute changes in 
blood pressure can shift the operational point of the arterial compliance curve versus 
mechanically stiffer arteries that operate on a different compliance curve (Chirinos, 2012; 
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McEniery, Wilkinson, & Avolio, 2007; Shibata & Levine, 2011), it was hypothesized that acute 








There were significant interactions between SBP (P<0.05), DBP (P<0.001) and PP (P<0.001) with 
level of LBNP as shown in Table 12. Specifically, SBP and PP decreased with progressively 
increasing LBNP; while DBP and TPR (P<0.05) increased. MAP essentially remained stable 
(P=0.09).  Heart rate at LBNP -30 mmHg was significantly faster than heart rate at all other LBNP 
levels (P<0.01, Table 12). Importantly, stroke volume (SV, P<0.001) and cardiac output (CO, 
P<0.001) were significantly decreased by 31.7% and 22.0% respectively with progressively 
increasing LBNP to -30 mmHg as shown in Table 12. 
 
Regional arterial stiffness indicator cfPWV (Figure 20) numerically increased by 3.3% to show a 
non-significant increase in arterial stiffness. Local stiffness indicators carotid distensibility 
coefficient (Figure 21) and β-stiffness index (Figure 22) numerically decreased by 9.7% and 
increased 14.7% respectively to also show a non-significant increase in arterial stiffness. Figure 
23 shows a strong negative linear correlation between percent change carotid distensibility 
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coefficient and percent change in β-stiffness index. There was a significant linear correlation 
between cfPWV and cfPWV index (cfPWV divided by SBP) for each level of LBNP (Figure 24). 
 
There was a significant increase in PEP (heart-aorta time from the R-peak to the onset of aortic 
blood flow) with progressively increasing LBNP (P<0.001, Table 13). Correspondingly, there was 
a significant increase in regional transit times hdTT (P<0.001, Table 13, transit time from R-peak 
of QRS complex for pressure pulse wave to reach digit artery) and hcTT (P<0.001, Table 13, 
transit time from R-peak of QRS complex for pressure pulse wave to reach carotid artery). 
Aorta-digit transit time (adTT = hdTT - PEP) significantly decreased by 5.0% (P<0.05) and aorta-
carotid (acTT = hcTT - PEP) remained unchanged (Table 13).  There was a significant increase in 
PEP/hdTT (%) with progressively increasing LBNP (P<0.001, Figure 23). PEP/hdTT (%) at LBNP 0 
mmHg was significantly less than PEP/hdTT (%) at -20 mmHg and -30 mmHg. As well, PEP/hdTT 
(%) at LBNP -10 mmHg was significantly less than at -30 mmHg. There was no interaction of 











Table 12. Hemodynamics of younger adults at four levels of progressively increasing lower 
body negative pressure (LBNP) 
aFrom 1-way repeated measures ANOVA, b Significantly different than all levels using Holm-
Sidak Test, c Significantly different than LBNP 0 and -10 mmHg, d significantly different than 
LBNP -10 mmHg, using Tukey Test, MAP= Mean Arterial Pressure, SBP=Systolic Blood Pressure, 
DBP=Diastolic Blood Pressure, PP=Pulse Pressure, TPR = total peripheral resistance 



























      
Heart Rate 
(beats/min) 























   
   MAP 86±9 88±9 87±9 88±10 0.09 
   SBP 124±12 126±11 123±12 121±13d <0.05 
   DBP 67±9b 69±9 69±9 71±9d <0.001 
   PP 57±7 57±8 53±9 50±10b <0.001 
      
TPR (mmHg∙min∙ L-1)     18±4b  21±6  22±5     24±6d       <0.001 
       




Figure 18. carotid-femoral PWV (cfPWV) at four levels of lower body negative pressure (LBNP) 
 
cfPWV (m/s) at 0 mmHg, -10 mmHg LBNP, -20 mmHg LBNP, and -30 mmHg LBNP.  One-way 
repeated measures ANOVA was used to determine no effect of LBNP on cfPWV (P=0.65). Data 

































Figure 19. Carotid distensibility coefficient at four levels of lower body negative pressure 
(LBNP) 
Carotid distensibility coefficient (mmHg-1) at 0 mmHg LBNP, -10 mmHg LBNP, -20 mmHg LBNP, 
and -30 mmHg LBNP.  One-way repeated measures ANOVA was used to determine no effect of 




















































Figure 20. β-stiffness index at four levels of lower body negative pressure (LBNP) 
β-stiffness index (arbitrary units=a.u.) at 0 mmHg LBNP, -10 mmHg LBNP, -20 mmHg LBNP, and -
30 mmHg LBNP.  One-way repeated measures ANOVA was used to determine no effect of LBNP 


































Figure 21 % Change Distensibility Coefficient vs % Change β-stiffness index 
 
A scatterplot of change (from 0 mmHg to -30 mmHg LBNP) in carotid distensibility coefficient 














































% change β-stiffness index  





Table 13. Pre-ejection period (PEP) and transit times in younger adults at four levels of 






















      
 PEP (ms)  49±15b 56±13c 61±12 65±16 <0.001 
      
 hdTT (ms) 189±19b 196±19 195±20 198±21 <0.001 
      
 adTT (ms) 139±18c 140±15 134±13 132±13 <0.05 
      
 hcTT (ms)    84±15b 89±15 94±17         102±19 <0.001 
      
 acTT (ms)           35±11    33±9 34±12        36±10 0.22 
      
      
aFrom 1-way repeated measures ANOVA, b Significantly different than all levels, c Significantly 
different than LBNP -30 mmHg, using Holm-Sidak Test, PEP=Pre-Ejection Period (time from the 
R-peak to the onset of aortic blood flow), hdTT=heart-digit transit time (from R-peak of QRS 
complex for pressure pulse wave to reach digit artery), adTT=aorta-digit (hdTT – PEP), hcTT= 
heart-carotid transit time (from R-peak for pressure pulse wave to reach carotid), acTT=aorta-

























Figure 22. cfPWV vs cfPWVi at four levels of lower body negative pressure (LBNP) 
Scatterplots of cfPWV (carotid-femoral PWV) vs cfPWVi (cfPWVi = cfPWV divided by SBP) four 
levels of LBNP: A. -30 mmHg LBNP, B. -20 mmHg LBNP, C. -10 mmHg LBNP and D. 0 mmHg LBNP 
all demonstrating significant linear correlations between cfPWV and cfPWVi represented by the 
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Figure 23. Percent pre-ejection period (PEP) of heart-digit transit time (hdTT) at four levels of 
graded lower body negative pressure (LBNP) 
Percent PEP of hdTT (PEP/hdTT, %) at 0 mmHg LBNP, -10 mmHg LBNP, -20 mmHg LBNP and -30 
mmHg LBNP.  PEP=Pre-ejection period (heart-aorta time from the R-peak to the onset of aortic 
blood flow), hdTT=heart-digit transit time from R-peak of QRS complex for pressure pulse wave 
to reach digit artery. One-way repeated measures ANOVA was used to determine an effect of 
LBNP on PEP/hdTT (P<0.001). a significantly different than LBNP -20 mmHg and -30 mmHg, b 





































Figure 24. Percent pre-ejection period (PEP) of heart-carotid transit time (hcTT) at four levels 
of graded lower body negative pressure (LBNP) 
Percent PEP of hcTT (PEP/hcTT, %) at 0 mmHg, -10 mmHg LBNP, -20 mmHg LBNP and -30 mmHg 
LBNP.  PEP=Pre-ejection period (heart-aorta time from the R-peak to the onset of aortic blood 
flow), hcTT=heart-carotid transit time from R-peak of QRS complex for pressure pulse wave to 
reach carotid artery. One-way repeated measures ANOVA was used to determine no effect of 




































Impact of orthostatic challenge on hemodynamics 
 
In this post hoc analysis, the mean age of the OA was 65±3 years and 26±5 years (P<0.001) for 
YA. The impact of standing in OA and mLBNP in YA, and comparison, on blood pressure changes 
are shown in Table 14. Measurements in OA were at 60-90s of standing and at steady-state -
30mmHg LBNP for YA.  In OA, it was found that MAP, SBP, DBP, PP and heart rate all 
significantly increased (Table 14).  In YA, MAP remained unchanged, both SBP and PP 
significantly decreased, and DBP significantly increased. If comparing pressure changes in YA to 
















Table 14. Change in heart rate and blood pressure for older adults (OA) during standing to 
younger adults (YA) during moderate LBNP 
 
a From paired t-test; b from unpaired t-test, change in OA from standing 60-90 seconds, change 
in YA from steady-state moderate LBNP at -30 mmHg, b/m=beats per minute, MAP= Mean 





























OA vs YA 
% Change 
      
Change in Heart rate (b/m)   9±6 P<0.001 6±10 P<0.05  
Change in Heart rate (%) 14±11  11±19  0.55 
Change in MAP (mmHg) 16±7 P<0.001 2±4          0.09  
Change in MAP (%) 17±8  2±5  <0.001 
      
Change in SBP (mmHg) 21±12 P<0.001 -3±7 P<0.05  
Change in SBP (%) 15±8  -2±6  <0.001 
      
Change in DBP (mmHg) 14±6 P<0.001 4±4 P<0.01  
Change in DBP (%) 18±8  7±6  <0.001 
      
Change in PP (mmHg) 8±8 P<0.01 -7±7 P<0.001  
Change in PP (%) 12±13  -13±11  <0.001 
      





The objective of this chapter was to demonstrate in young healthy adults the potential for an 
acute decrease in SBP and PP to affect indicators of arterial stiffness that were applied to older 
adults in the RCT; spironolactone in the RCT was shown to decrease cfPWV by 9.9%, decrease 
SBP by 9.7% and decrease PP by 17.1%.   Findings from this experimental study were that small 
acute reductions in SBP by 2.4% and PP by 14.0% were concurrent with a non-significant 
increase in arterial stiffness (i.e., increase in cfPWV, decrease in carotid distensibility coefficient 
and increase in β-stiffness index by 3.3%, 9.7% and 14.7% respectively).  PEP, and 
correspondingly regional transit times hdTT and hcTT, increased with these acute reductions in 
systolic and pulse pressure. These data support the hypothesis that acute changes in blood 
pressure would affect arterial stiffness indicators as measured on the older adults in the RCT. 
 
This thesis used mLBNP (down to -30 mmHg) that modified cardiac and arterial hemodynamics 
to show a 31.7% (P<0.001) decrease in stroke volume, 22.0% (P<0.001) decrease cardiac 
output, a reduction in both SBP (P<0.05) and PP (P<0.001), while DBP increased (P<0.001) and 
MAP remained essentially unchanged; which is consistent with existing evidence (William H. 
Cooke, Caroline A. Rickards, Kathy L. Ryan, Tom A. Kuusela, & Victor A. Convertino, 2009; Fu et 
al., 2009). The significant increase in heart rate (P<0.01) was expected and consistent with 
other studies using similar LBNP (Bronzwaer et al., 2016; Charalampos Lydakis et al., 2008; 
Pannier, Bouckaert, & Lefebvre, 1995). It should be noted that there is variability in 
cardiovascular responses to LBNP as suggested in the study by Phillips et al. (2013) where 
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systolic blood pressure did not significantly decrease at a similar LBNP applied in this thesis for 
younger adults. 
 
Regional central arterial stiffness indicator cfPWV numerically increased with acute reductions 
in SBP and PP, demonstrating slightly faster pressure pulse wave propagation, and 
correspondingly a non-significant increase in central arterial stiffness. This is consistent with the 
observed directional changes with local arterial stiffness indicators carotid distensibility 
coefficient and β-stiffness index; which are strongly correlated. Importantly, previous studies 
have also shown a numeric increase in central arterial stiffness at a similar LBNP (-30 mmHg) 
despite an increase in sympathetic nervous system engagement reflex to a decrease in central 
blood volume and central venous pressure (Lydakis et al., 2008; Phillips, Bredin, Cote, Drury, & 
Warburton, 2013). Very relevant to this thesis finding that cfPWV numerically increased at -30 
mmHg LBNP, Lydakis et al (2008) demonstrated a numeric shortening in transit time of the 
pulse wave from the heart to the peripheral reflecting sites back to the heart during -30 mmHg 
down to -50 mmHg LBNP, considered as an increase in PWV, that was independent of the effect 
of sympathetic activation on the elastic properties and smooth muscle cell tone of the central 
arteries. Further support to this thesis finding is evidence that cfPWV could significantly 
increase at maximal levels beyond -50 mmHg LBNP in response to a similar acute decrease in 
SBP, stroke volume, and cardiac output, and increase in total peripheral resistance (Phillips et 
al., 2013). Phillips et al. (2013) showed at maximal tolerated LBNP in 8 subjects that cfPWV 




Transit time consists of two distinct components: the PEP, which corresponds to the time from 
the start of ventricular depolarization to the onset of ventricular ejection, and the time it takes 
the arterial pulse wave to travel from the aortic valve to a point in the peripheral arteries; such 
as the finger [digit], carotid or femoral artery in this thesis. Essentially, transit time is composed 
of a delay component during isovolumetric contraction, PEP, and a peripheral component 
during pressure wave propagation along the artery, aorta to peripheral site. This central 
component PEP has been shown to be prolonged when either stroke volume, or ventricular 
filling, is reduced (Newlin & Levenson, 1979; Weissler, Peeler, & Roehll, 1961). PEP got longer 
with hemodynamic changes associated with progressively increasing LBNP from 49±15 ms to 
65±16 ms (P<0.001) in the current study. This represents 26 % to 33% of the total hdTT, and 
58% to 64% of the total hcTT, which is consistent with existing evidence showing that PEP 
represents a nontrivial fraction of pulse wave transit time and source of variability (Payne, 
Symeonides, Webb, & Maxwell, 2006). Notably, diastolic blood pressure significantly increased 
in the current study, contributing to a corresponding increase in ventricular afterload. The 
observed lengthening of PEP may be explained by a widening of the pressure gradient leading 
to a slower rise of left ventricular pressure during isovolumetric contraction secondary to 
shortened myocardial fiber length from the hypovolemic-reduction in left ventricular end-
diastolic volume (Reeves et al., 1960; Wallace, Skinner, & Mitchell, 1963). When PEP 
contribution to the hcTT is removed, expressed as aorta-carotid TT, central arterial stiffness was 
estimated to remain unchanged (P = 0.22), which is consistent with existing work, and this 




As an estimate of regional peripheral arterial stiffness in this thesis, aorta-digit TT (heart-digit 
TT minus PEP) decreased by 5% (P<0.05), to demonstrate a slightly shorter time for the 
pressure pulse wave to arrive at the finger, and possibly increased peripheral arterial stiffness.  
This increase in stiffness is consistent with an increase in sympathetic nervous system 
engagement elevating smooth muscle cell tone contributing to the observed significant 
increase in TPR in this thesis. This increase in peripheral arterial stiffness may have been due to 
a direct influence of increased baroreceptor-mediated sympathetic vasomotor tone increasing 
TPR to maintain MAP given the decrease in cardiac output resulting from a decrease in central 
blood volume. This finding is consistent with the study by Fu et al (2009) also at LBNP of -30 
mmHg where they measured a decrease in right atrial pressure and cardiac output with the 
corresponding increase in TPR; combined with the evidence from Cooke et al (2009) that 
sympathetic nervous system activity linearly increases with progressively decreasing LBNP to 
support this point of sympathetic nervous system engagement. The decrease in transit time can 
likely be explained by the analytical framework by the Moens-Korteweg formula already 
discussed (Ahlstrom, Johansson, Uhlin, Länne, & Ask, 2005; W. Chen, Kobayashi, Ichikawa, 
Takeuchi, & Togawa, 2000).  PWV depends on the dimension of the vessel and the distensibility 
of the vessel wall expressed by the Moens-Korteweg formula: PWV2 = Eh/2Rρ. Where PWV 
reflects aorta-digit TT between two arterial sites, and is directly related to the elastic modulus 
E, wall thickness h, and inversely related to interior diameter 2R and density of blood ρ. An 
increase in elastic modulus E by increasing smooth muscle cell tone, reflected as increasing 
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arterial stiffness, would directly increase PWV given less influential changes in the ratio of wall 
thickness to diameter (Chen et al., 2000; Ahlstrom et al., 2005).   
 
The continuous measurements of heart rate, autonomic nervous system engagement, and 
blood pressure during quiet standing or LBNP have shown similar changes during head-up tilt 
(HUT) (Bloomfield et al., 1997; Butler, Yamamoto, Xing, Northey, & Hughson, 1993; Kirbis, Grad, 
Meglic, & Bajrovic, 2013). Butler et al. (1993) showed that LBNP and HUT in younger adults 
increased heart rate, MAP, and DBP; and decreased SBP and PP. Their findings are consistent 
with this thesis finding of increases in heart rate, MAP and DBP, with concurrent decrease in 
SBP and PP. The recent study by Tymko et al. (2016) also reported LBNP and HUT tilt would 
increase heart rate and MAP. This thesis compared the impact on heart rate and blood pressure 
from the orthostatic stress of 60-90s of quiet standing in OA to simulated orthostasis induced 
from mLBNP in YA. The impact of orthostasis in OA was significantly greater than YA.  The 
current study showed that MAP, SBP, DBP, PP and heart rate all significantly increased during 
orthostasis in OA; with SBP, DBP, PP and heart rate to a significantly greater extent than YA.  
This increase in blood pressure in OA is inconsistent with previous studies, using the same 
technique to monitor beat-by-beat blood pressure while standing, which showed more modest 
changes in blood pressure and heart rate during orthostasis (Imholz, Dambrink, Karemaker, & 
Wieling, 1990; van Wijnen et al., 2017). It is possible that mLBNP was insufficient to induce the 
same hemodynamic effects as true gravity. It may also be possible that less arterial stiffness 
demonstrated in YA (CHAPTER 6) may be linked to these observed modest changes in blood 






Several limitations exist in this study that require consideration. First, the actual fluid shift 
leading to a reduction in central blood volume from sub-atmospheric pressure on the lower 
extremities from progressively increasing LBNP that reduced SV, cardiac output, and blood 
pressure, was not measured (Bronzwaer et al., 2016; Bronzwaer, Ouweneel, Stok, Westerhof, & 
van Lieshout, 2015). Consequently, the differences in central hypovolemia between participants 
could be a confounding factor related to the differential cardiovascular reflex responses 
between individuals (Bronzwaer et al., 2016). Since orthostatic stress has been shown to shift 
300 to 800 mL of blood from the chest to the lower body, the magnitude of central 
hypovolemia during LBNP may be considered as to affect cardiovascular responses (Sjostrand, 
1953). Differences in fluid shift volume between subjects during the same sub-atmospheric box 
pressure are an intrinsic limitation of LBNP and few studies have addressed how to enable 
individualization of LBNP-induced central blood volume shifts. In addition to the shift of blood 
volume to the veins and interstitial spaces of the leg, it is possible that the shift of blood to the 
small vessels in the leg provide a source of inter-participant variability by influencing the sub-
atmospheric pressure feedback loop on baroreceptors (Cirovic, Walsh, Fraser, & Gulino, 2006; 




Progressively increasing LBNP increases sympathetic nervous system activity (William H. Cooke 
et al., 2009; Khan, Sinoway, & MacLean, 2002). The second limitation to consider is that 
sympathetic nervous system engagement was not measured in the current study and may have 
affected central arterial stiffness (Swierblewska et al., 2010). It is possible that the baroreflex 
mediated increase in sympathetic nervous system activity is unique to the individual 
participants as suggested from a recent study investigating inter-participant cardiovascular 
responses to LBNP compared with consistent and reproducible responses for the individual 
participant. The study by Bronzwaer et al. (2016) found that distinct and reproducible 
cardiovascular response patterns of 10 healthy younger adults from LBNP induced sympathetic 
activity were related to the participant’s resting heart rate (P<0.05) and gain of the 
baroreceptors (P<0.05) over time.  If Bronzwaer et al. (2016) had however measured 
sympathetic nervous system activity, they may have made the different conclusion that 
Hinojosa-Laborde et al. (2014) did; that cardiovascular response patterns to central 
hypovolemia are not actually related to either resting sympathetic nervous system activity 
(heart rate) or sympathetic baroreflex gain.  Measuring sympathetic nervous system activity 
may have helped clarify how unloading of arterial baroreceptors from reduced central volume 
affects blood pressure and arterial stiffness indicators.    
 
The third limitation is that LBNP was only to -30 mmHg. Reflex responses to a greater fluid shift 
from greater sub-atmospheric pressures reductions on the lower extremities may induce 
cardiovascular responses that are not generalizable to this LBNP level. For example, Philips et 
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al. (2013) showed a significant increase in markers of central arterial stiffness and sympathetic 
activity at maximal tolerated LBNP levels.  
 
In conclusion, the acute slight decreases in systolic and pulse blood pressure were associated 
with a non-significant increase in central stiffness (cfPWV decrease, carotid distensibility 
coefficient decrease and β-stiffness index increase), slightly elevated peripheral stiffness (aorta-
digit TT decrease) and elevated TPR. Despite given limitations, this supports the hypothesis that 
acute blood pressure changes would affect arterial stiffness indicators representing a 
confounding variable affecting main study results independent of the expected greater chronic 
blood pressure changes from spironolactone in the RCT. Therefore this supplementary 
experimental study showed that it is important to consider how acute variability in blood 
pressure may affect some indicators of arterial stiffness beyond greater chronic blood pressure 












CHAPTER 8  General Discussion 
8.1 Overview 
 
Hypertension and central arterial stiffness are demonstrated risk factors for cognitive 
impairment, likely involving reduced cerebral blood flow during aging (Elias et al., 2009; Hanon 
et al., 2005; Paran et al., 2003; Ruitenberg et al., 2005; Scuteri et al., 2005; Waldstein et al., 
2008). Aldosterone antagonists such as spironolactone in this thesis RCT have been shown to 
reduce blood pressure and arterial stiffness in older hypertensive adults through arterial 
structural and functional changes that may explain some evidence of improvements in cognitive 
function after 6 months of therapy (Edwards et al., 2009; Farquharson & Struthers, 2000; Kithas 
& Supiano, 2010; Macdonald et al., 2004; Mahmud & Feely, 2005; Savoia et al., 2008). 
However, there are currently no curative medications available for cognitive decline by 
increasing cerebral blood flow; and to date, very limited data are available investigating 
aldosterone antagonism effects on cognitive function (Duron & Hanon, 2010). The main 
objective of the of this thesis was to conduct a small randomized, double-blind, placebo-
controlled trial with Spiro in older hypertensive adults stably treated by centrally acting ACE 
inhibitors to test the hypothesis that spironolactone, through its influence on blood pressure 
and arterial stiffness, could improve cerebral blood flow and cognition. Secondary objectives 
were to examine cerebrovascular autoregulation changes with spironolactone, and to conduct 
a supplementary experimental study with younger adults. The purpose of the experimental 
study in younger adults was to test the hypotheses that blood pressure and arterial stiffness are 
different than older adults in RCT and to demonstrate the potential for acute changes in blood 
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pressure to impact interpretation of indicators of arterial stiffness that were applied to older 
adults in the RCT. This final chapter provides a summary of important thesis findings and 
considers main limitations of the RCT and experimental study. Finally, each of the posed 




















8.2 Spironolactone Improves Blood Pressure but Arterial Stiffness, Cerebral Blood Flow 
and Cognitive Function Remain Unchanged. 
 
The results of chapters 3, 4 and 5 showed that six months of aldosterone antagonism with 
spironolactone significantly reduced systolic blood pressure and pulse blood pressure while 
arterial stiffness, cerebral blood flow, cognition, and cerebrovascular autoregulation remained 
unchanged. This is inconsistent with some evidence that aldosterone antagonism could 
decrease blood pressure and improve cognition (Yagi et al., 2011; Hajjar et al., 2013), or 
decrease arterial stiffness while improving cerebral blood flow (Tarumi et al., 2014; Lipsitz et al, 
2005). This thesis findings of reduced systolic blood pressure and unchanged cfPWV were 
consistent with the recent subset of 648 SPRINT trial participants showing that RAAS inhibition 
(76% ACE inhibitor or angiotensin receptor blocker) leading to a similar SBP reduction as the 
RCT of this thesis (average delta of 14.8 mmHg) did not significantly reduce cfPWV over the 3 
years of follow up (Group et al., 2015; Supiano, 2017). Lower pulse pressure shown in this thesis 
reflects less arterial stiffness, and although both pulse pressure and cfPWV are independent 
predictors of cardiovascular outcomes, cfPWV is considered a more direct measure of arterial 
stiffness (Chirinos, 2012). A potential mechanism to explain how arterial stiffness remained 
essentially unchanged after aldosterone antagonism (mineralocorticoid receptor specifically, 
MR) is from recent evidence that acute inhibition of MRs with eplerenone impairs vascular 
dilation by specifically impairing vascular endothelial function  independent of blood pressure 
change or vascular smooth muscle responsiveness to exogenous vasodilator nitric oxide (Hwang 
et al., 2016). Hwang et al. (2016) found that vascular endothelial nitric oxide synthase activity, 
that represents capacity to produce vasodilator nitric oxide in normal healthy aging, was 
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correspondingly reduced with the MR antagonism compared to placebo. In contrast, 
aldosterone activation of MR on endothelial cells leads to production of nitric oxide that 
diffuses to vascular smooth muscle cells and counteracts the MR-dependent vasoconstriction. 
There is a dynamic balancing of affects from aldosterone MR activation between endothelial-
dependent vasodilation and smooth muscle-dependent vasoconstriction (Skott et al., 2006; 
Galmiche et al., 2014).   
 
The main limitation is that the small sample size did not provide statistical power to detect 
significant differences in the primary outcome marker of anterior cerebral blood flow (aCBF).  
The sample size required to detect a significant difference in mean aCBF (832.9 mL/min) after 6 
months of spironolactone compared to placebo (836.0 mL/min) is estimated from this current 
study as 330 participants (165 in each group) with a significance level (α) of 0.05 and desired 
power of 0.8 (Sigmaplot 12.5, Systat Software Inc, San Jose, California, USA).  The calculated 
Cohen’s d effect size for spironolactone was 0.3 from this thesis data; much smaller than the 
desired Cohen’s d effect size of 1.0 that was used to calculate sample size during the trial 
design. There is the possibility that stable ACE inhibition in the older adults in this thesis RCT 
already had improved arterial structure and function enough to minimize further potential 
changes with spironolactone  (Ceconi et al., 2007; Dudenbostel & Glasser, 2012; Hare et al., 
2013; Kithas & Supiano, 2010; Mahmud & Feely, 2005). The larger desired effect size used to 
calculate sample size needed was based on experimental, non-interventional, pilot data as 




Another limitation is the variability in measurement techniques to generate carotid-femoral 
pulse wave velocity (cfPWV) may make cross-trial comparisons challenging. Notable different 
techniques include the use of transcutaneous infrared plethysmography or pulse tonometry 
combined with volumetric changes in a cuff to estimate pulse arrival time (Butlin & Qasem, 
2017; A. A. Phillips, S. S. D. Bredin, A. T. Cote, C. T. Drury, & D. E. R. Warburton, 2013). This 
thesis used Doppler ultrasound to estimate pulse wave transit times based on blood velocity 
instead of the common mechanotransducer method that estimates pressure pulse wave transit 
time. However cfPWV generated from Doppler ultrasound method is in strong association with 
the pressure pulse wave propagation method represented by an intra-class correlation 
coefficient of 0.91 (Calabia et al., 2011) and, as demonstrated in this thesis, a strong correlation 
between pressure pulse wave velocity and blood cell pulse wave velocity at the carotid artery 
site (r = 0.74, P<0.01, Figure 30, APPENDIX 1.M.2). Even techniques for measuring transit 
distances between arterial sites can vary across studies making it difficult to compare across 
studies due to the variability in methodologies (Townsend et al., 2015; Van Bortel et al., 2012).  
These thesis findings, possibly due to mechanisms and limitations described, do not support the 
hypothesis that through the effects on blood pressure and arterial stiffness, spironolactone 








8.3 Arterial Stiffness Indicators Affected by Age and Acute Blood Pressure Changes  
 
The main objectives of the supplementary experimental study in younger adults reviewed in 
chapters 6 and 7 were to test the hypotheses that older hypertensive adults stably treated by 
centrally acting ACE inhibitors in the RCT would have higher blood pressure and greater arterial 
stiffness; and acute reductions in blood pressure would affect indicators of arterial stiffness 
that were applied to these older adults in the RCT. The post hoc analysis was done of 
hemodynamic changes during central hypovolemia from moderate lower body negative 
pressure (mLBNP) in younger adults were compared to hemodynamic changes from the 
orthostatic challenge of quiet standing in older adults.   
 
Aging is an important risk factor for developing hypertension due to changes in artery wall 
structure, up-regulation of RAAS activity, rise in pulse blood pressure, and correspondingly an 
increase in vascular stiffness (Fukutomi & Kario, 2010; Nilsson, 2008).  The findings from 
CHAPTER 6 were that measures of blood pressure and indicators of arterial stiffness supported 
the hypothesis of higher blood pressure and greater arterial stiffness in older adults in the RCT 
compared to younger adults. This finding was true for each arterial stiffness indicator computed 
in the study and supports the accepted observation that older adults with hypertension have 
greater arterial stiffness, which results in increasingly faster pulse transmission to the 
periphery, than younger adults (J Allen & A Murray, 2002; Amar et al., 2001; Boutouyrie et al., 
2010; Choi et al., 2010; Hasegawa et al., 1997; Mitchell et al., 2004; Y.-L. Zhang, Zheng, Ma, & 
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Sun, 2011). Observing expected, and interesting, pressure and arterial stiffness differences with 
age was important to validate measures as being consistent with existing evidence.  
 
The findings in CHAPTER 7 during acute manipulations of cardiovascular function in young 
adults with application of mLBNP were important to support the thesis hypothesis that acute 
changes in blood pressure affected some indicators of arterial stiffness. The acute reductions in 
systolic blood pressure (SBP) and pulse pressure (PP) were associated with a non-significant 
increase in central stiffness (cfPWV increase, carotid distensibility coefficient decrease and β-
stiffness index increase), slightly elevated peripheral stiffness (aorta-digit TT decrease) and 
elevated TPR. Consequently, it is important to consider the potential impact acute changes in 
BP may have on the interpretation of arterial stiffness indicators applied in the RCT. 
 
There are several important limitations to the supplementary experimental study. The first 
limitation is that hdTTi (time from R-peak to digit artery divided by SBP) is not a standard 
method for estimating arterial stiffness in current publications. As well, this thesis showed that 
PEP represents a nontrivial fraction of heart-digit TT and non-trivial source of variability (Payne, 
Symeonides, Webb, & Maxwell, 2006). It is however important to note that heart-digit TT is a 
popular non-invasive pulse transit time estimate being widely pursued for cuff-less blood 
pressure monitoring because of the observed association with blood pressure (Mukkamala et 
al., 2015; Gao, Olivier, & Mukkamala, 2016). The actual fluid shift leading to a reduction in 
central blood volume from progressively increasing LBNP on the lower extremities that reduced 
stroke volume, cardiac output, and blood pressure, was not measured to account for inter-
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participant variability in central hypovolemia that affect cardiovascular responses (Bronzwaer, 
Ouweneel, Stok, Westerhof, & van Lieshout, 2015; Bronzwaer et al., 2016; William H. Cooke et 
al., 2009; Khan et al., 2002; Sjostrand, 1953; Swierblewska et al., 2010).   The differences in fluid 
shift volume and sympathetic nervous system engagement between subjects is an intrinsic 
limitation of LBNP. The shift of blood volume to the small vessels and interstitial spaces of the 
leg provide a source of inter-participant variability by influencing the LNBP feedback loop on 
baroreceptors (Truijen et al., 2012; Stewart, 2003; Cirovic, Walsh, Fraser, & Gulino, 2006). 
Continuous measurement of the sympathetic nervous system activity during assessments may 
have helped clarify how unloading of arterial baroreceptors from reduced central volume 












8.4 Summary of Findings that Address Thesis Research Questions 
 
The objectives of this thesis were to address posed research questions about the effect 
spironolactone on blood pressure, arterial stiffness, cerebral blood flow, and cognition when 
safely added to existing stable ACE inhibitor therapy in older hypertensive adults. Each of the 5 
thesis questions are restated here and addressed individually based on research findings:  
 
1. In older hypertensive adults stably treated by centrally acting ACE inhibitors, will 
spironolactone decrease blood pressure and arterial stiffness compared to placebo? 
No, spironolactone significantly reduced blood pressure but had no effect on arterial 
stiffness in older hypertensive adults stably treated by centrally acting ACE inhibitors 
compared to placebo in this RCT. These data do not support the hypothesis that 
spironolactone will decrease blood pressure and improve arterial stiffness in older 
adults on stable ACE inhibitor treatment for hypertension; likely due to mechanisms 
and limitations described in CHAPTER 3.  
 
2. In older hypertensive adults stably treated by centrally acting ACE inhibitors, does 
spironolactone improve cerebral blood flow and cognition compared to placebo? No, 
cerebral blood flow and cognitive function were unchanged from spironolactone 
administered for 6 months in older hypertensive patients who were receiving stable 
treatment with centrally acting ACE inhibitors. These data do not support the 
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hypothesis that spironolactone improves cerebral blood flow and cognitive function; 
likely due to identifiable study limitations as described in CHAPTER 4.  
 
3. In older hypertensive adults stably treated by centrally acting ACE inhibitors, does 
spironolactone affect cerebrovascular autoregulation compared to placebo? No, 
spironolactone maintained cerebrovascular autoregulation in older hypertensive 
patients who were receiving stable treatment with centrally acting ACE inhibitors. 
Better blood pressure control was not associated with orthostatic declines in 
cerebral blood flow as examined in CHAPTER 5. 
 
4. How does blood pressure and arterial stiffness in older hypertensive adults stably 
treated by centrally acting ACE inhibitors compare to healthy younger adults? All 
measures of blood pressure and indicators of arterial stiffness supported the 
hypothesis of higher blood pressure and greater arterial stiffness in older adults in 
the RCT compared to younger adults as examined in CHAPTER 6.  
 
5. Are indicators of arterial stiffness unaffected by acute changes in blood pressure? 
No, acute changes in blood pressure did affect indicators of arterial stiffness. There 
was an increase in cfPWV, decrease in carotid distensibility coefficient and increase 
in β-stiffness index to collectively show a non-significant decrease in central arterial 
stiffness with acute reductions in SBP and PP. There was also a slight increase 
peripheral arterial stiffness (aorta-digit TT significantly decreased) and increase in 
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total peripheral resistance (TPR). This supports the hypothesis that acute blood 
pressure changes would affect arterial stiffness indicators representing a 
confounding variable affecting main study results independent of chronic blood 
pressure changes. Therefore it is important to consider how variability in blood 
pressure, and TPR, may affect indicators of arterial stiffness; and caution is 
necessary when making conclusions about the underlying mechanism of improved 
arterial stiffness as described in CHAPTER 7. 
 
The collective findings from this thesis demonstrate that spironolactone, an inexpensive 
antihypertensive drug, can safely be added to stable centrally acting ACE inhibitor therapy in 
older hypertensive adults to effectively reduce blood pressure; while arterial stiffness, cerebral 
blood flow and cognition remain unchanged. These novel RCT data provide necessary input to 
estimate the sample size necessary to address the research question of the effect of 
spironolactone, through reduction of blood pressure and arterial stiffness, on CBF and 
cognition. The thesis findings are limited by the effect of acute blood pressure changes on 
arterial stiffness indicators, small RCT sample size, and a proposed mechanism how aldosterone 
antagonism in hypertensive patients may not improve arterial stiffness in contrast to findings 
from small studies by Kithas et al. (2010) or Yagi et al. (2011) that showed improved arterial 
stiffness and blood pressure. These limited findings reinforce the need for future studies to 





8.5 Future Research 
 
There is a need for research exploring the effect of an aldosterone antagonist on arterial 
stiffness, cerebral blood flow and cognitive function could involve a clinical trial with a larger 
sample size of hypertensive participants than this thesis RCT (with a washout period to RAAS 
inhibitors) at least 60 years of age and with mild cognitive impairment (MoCA < 22). In a 
double-blind fashion, participants could be randomly given spironolactone (200mg daily based 
on patient tolerability) or a calcium channel blocker for 60 months treated to a SBP target of 
less than 120 mmHg with a non-RAAS inhibitor (Group et al., 2015).  It is also possible to use 
finerenone 20mg once daily (given suitable Health Canada approval); the higher MR selectivity 
than spironolactone may improve effect size to allow for a smaller sample size. Calcium channel 
blockers have been shown to reduce blood pressure with less effect on arterial stiffness than 
RAAS inhibitors (Andreadis et al., 2010; Y. Chen, Shen, Liu, & Yang, 2017).  A third observational 
study arm of generally healthy normotensive participants at least 60 years of age with mild 
cognitive impairment is also recommended. These participant’s outcomes on arterial stiffness 
and cerebral blood flow would represent normal variability independent of blood pressure 
changes. A smaller randomized, double-blinded, trial with shorter follow-up could involve 
participants with compromised cerebral circulation such as vascular type dementia, or prior 
stroke, that are naïve to RAAS inhibition. Arterial stiffness could be estimated by the gold 
standard cfPWV and total cerebral blood flow assessed as the sum of bilateral internal carotid 
and vertebral arteries (mean velocity multiplied by cross-sectional area) using a 3T MRI or 
duplex ultrasound, then normalized to the participant’s grey matter volume. Executive 
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cognitive function should be assessed by trained clinician using the MoCA, Stroop, Flanker Task 
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These six appendices cover important methodological considerations that include how and why 
window sample sizes were selected during waveform analysis (1.M.1). Tailored waveform 
analysis is important to estimating mean transit times from R-peak of QRS complex to foot of a 
waveform. Appendices include the comparison of heart to carotid pressure transit time to heart 
to carotid velocity transit time of waveforms (1.M.2); as well as safety considerations (1.M.3) 
and generalizability of the outcomes in the RCT (1.M.4). The RCT involved a pharmaceutical. 
Consequently, careful consideration was made to ensure participant safety, while still 
maintaining optimal potential for study-drug efficacy. Since most pharmaceutical trials have 
limited generalizability to the general population due to exclusion criteria, effort was made to 
clarify how results of this RCT would apply to the general population.  
 
The last section on end-tidal CO2 (1.M.5) includes important data during hyper- and hypocapnic 
breathing patterns. This data is included here to supplement Results 5.3 so as to not distract 
the reader from the main objectives of CHAPTER 5 that did not focus on end tidal CO2. 
 
 
Appendices 2.IE, 3.HIF, 4.ECF, 5.T and 6.DS cover inclusion/exclusion criteria, health history 
forms, and executive cognitive function tests MoCA, Trails and Digit Span respectively. Criteria 
in APPENDIX 2.IE were used to screen potential subjects in both the RCT and experimental 
studies; especially important in the RCT. Health History Forms in APPENDIX 3.HIF were an 
important part of documenting potential drug interactions and baseline criteria during RCT, or 
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potential health issues that may prevent completion of the thesis studies. Cognitive function 
tests in the last 3 appendices are validated tests to assess executive function and were used 






















APPENDIX 1.M  Methodological Considerations 
 
1.M.1  Selection of Sample Window Size for Arterial Waveform Digital Filter Smoothing 
and 2nd Derivative 
 
A Savitzky-Golay smoothing 3rd order polynomial digital filter was used to increase the signal-to-
noise ratio of both arterial velocity and pressure waveforms while preserving the shape of the 
original signal. Applying this digital filter required selection of a sliding sample window size for 
each waveform that maintained peak and width of the original waveform. Finger arterial 
pressure waveform sliding sample windows are shown below in Figure 25 as 11, 21, 51, or 75 
points and the 21 point window size was selected for data analysis based on smoothness of the 


















Figure 25. Application of digital filter for smoothing finger arterial pressure (finAP) using a 
Satvitsky-Golay 3rd order polynomial vs time (seconds) 
Channel 1 is ECG, Channel 2 is original finger arterial pressure signal, Channel 3 is finger arterial 
pressure signal smoothed with a Satvitski-Golay 3rd order polynomial digital filter with sample 
window 11, Channel 4 is sample window 21, Channel 5 is sample window 51 and Channel 6 is 


























Figure 26 shows the Savitzky-Golay smoothing 3rd order polynomial smoothed finger arterial 
waveform (finAP) with a 21 point window size with the 2nd derivative of that waveform using 5 
different sample window sizes: 151, 175, 201, 225, and 251. The optimal window size of 151 
was selected, after checking larger sizes, for this particular participant based on alignment of 
foot of pressure waveform (i.e., minimum) with peak of 2nd derivative waveform. Notably, this 
peak of the 2nd derivative with window sample size 151 occurs after the peak of the 2nd 
derivative with the larger window samples to better identify the foot of the finAP.  Once the 
optimal 2nd derivative sample window size was set, the foot was identified as the time at the 
peak of the 2nd derivative signal of the smoothed velocity wave form in the same cardiac cycle 
(Chiu, Arand, Shroff, Feldman, & Carroll, 1991). Selection of each 2nd derivative sample window 
size was done at the start of each level of lower body negative pressure; and for the RCT at the 











Figure 26. Selection of optimal window sample size for 2nd derivative of smoothed finger 
arterial pressure (finAP) waveform vs time (seconds) 
Channel 1 is ECG, Channel 2 is smoothed finger arterial pressure (finAP) using a Satvitsky-Golay 
3rd order polynomial digital filter,  Channel 3 is 2nd derivative sample window 151, Channel 4 is 
sample window 175, Channel 5 is sample window 201 and Channel 6 is sample window 225, 































Figure 27 shows the Savitzky-Golay smoothing 3rd order polynomial smoothed carotid pressure 
arterial waveform with a 51 point window size with the 2nd derivative of that waveform using 5 
different sample window sizes: 125, 151, 175, 201 and 225. The optimal window size of 125 was 
selected, after checking larger sizes,  for this particular participant based on alignment of foot 
of pressure waveform (i.e., minimum) with peak of 2nd derivative. The peak of the 2nd derivative 
with window sample size 125 occurs after the peak of the 2nd derivative with window larger 
sample sizes.  Selection of each 2nd derivative sample window size was done at the start of each 















Figure 27. Selection of optimal window sample size for 2nd derivative of smoothed carotid 
arterial pressure (cAP) waveform vs time (seconds) 
Channel 1 is ECG, Channel 2 is smoothed carotid arterial pressure (cAP) using a Satvitsky-Golay 
3rd order polynomial window size 51,  Channel 3 is 2nd derivative sample window 125, Channel 4 
is sample window 151, Channel 5 is sample window 175 and Channel 6 is sample window 201, 


































Similarly, Figure 28 shows the Savitzky-Golay smoothing 3rd order polynomial smoothed aortic 
velocity waveform with a 75 point window size with the 2nd derivative of that waveform using 3 
different sample window sizes: 151, 175, and 201. The optimal window size of 151 was selected 
for this particular participant, after checking larger sizes, based on alignment of foot of pressure 
waveform with peak of 2nd derivative. The peak of the 2nd derivative with window sample size 
151 occurs after the peak of the 2nd derivative with window sample sizes 175 and 201.  
Selection of each 2nd derivative sample window size was done at the start of each level of lower 













Figure 28. Selection of optimal window sample size for 2nd derivative of smoothed aortic 
velocity (aV) waveform vs time (seconds) 
Channel 1 is ECG, Channel 2 is smoothed aortic velocity waveform (aV) using a Satvitsky-Golay 
3rd order polynomial, Channel 3 is 2nd derivative sample window 151, Channel 4 is sample 






























Table 15 provides a summary of sample window sizes for Satvitsky-Golay 3rd order polynomial 
digital filter and 2nd derivative waveform for all arterial velocity and pressure waveforms in this 
thesis. Selection of the foot of each waveform as the maximum of the second derivative was 
done using automatic point selection within LabChart 7 (i.e., macro routine) for all velocity and 
pressure waveforms except femoral velocity. Selection of the foot of the femoral velocity 
waveform was done manually using digital markers for transit time measurement set from R-
peak of QRS complex to the first peak of second derivative of that waveform during same 
cardiac cycle---the automatic point selection within LabChart 7 (i.e., macro routine) was unable 
to consistently identify the first peak unless the amplitude exceeded the second peak of 















Table 15. Summary of Satvitsky-Golay 3rd order polynomial digital filter and 2nd derivative 






Satvitsky-Golay 3rd order 
polynomial window  






   
Finger pressure 21  151,175,201,225,251 
   
Carotid pressure 21  125,151,175,201,225 
 

















   
   
   
*one sample window size was selected from these options based on alignment between foot of 
smoothed waveform with peak of 2nd derivative waveform at the start of series of cardiac 




















1.M.2  Comparison of Carotid Velocity Pulse Wave Transit Time to Carotid Pressure Pulse 
Wave Transit Time 
 
The heart to carotid velocity transit time (hcTTv) was compared to heart to carotid pressure 
transit time (hcTT) to investigate similarity between transit times of these two types (velocity 
versus pressure) of waveforms. Identical to hcTT, hcTTv was calculated as the time interval 
between the R-peak of the QRS complex and foot of the smoothed carotid artery velocity 
waveform within the same cardiac cycle. A Savitzky-Golay smoothing 3rd order polynomial was 
applied and optimal 2nd derivative samples window size selected as outlined in Table 14 
(Section 1.M.1).  
 
Age, heart rate, blood pressure, and transit times of older and younger adults are shown in 
Table 16. In older adults, hcTT was similar to hcTTv; and significantly shorter than younger 
adults. There was a strong significant linear correlation between hcTT and hcTTv for both 
younger adults (YA, Figure 29) and older adults (OA, Figure 30) respectively. Figure 31 shows 
the Bland-Altman plot of hcTTv and hcTT in OA to show that hcTTv slightly underestimates 
transit times compared to hcTT. The variability around the mean is fairly constant; except that 
possibly, hcTTv may overestimate of transit time difference beyond 70 ms. The distance 
between upper and lower margins is wider than upper and lower margins for hcTTv and hcTT in 
YA shown in Figure 32. In these YA, hcTTv appears to also slightly underestimate transit time 






Table 16. Heart rate, blood pressure and carotid arterial transit times of older adults (OA) and 












P-value a   
OA vs YA 
    
Age (years) 65±3 26±5 P<0.05 
    
Heart Rate (beats/min) 68±13 64±7 0.32 
 
Brachial Pressure (mmHg) 
   
   MAP 97±9 86±9 P<0.01 
   SBP 142±16 124±12 P<0.05 
   DBP 75±8 67±9 P<0.05 
   PP 66±13 57±7 P<0.05 
 
Transit times (ms) 
   
    
   hcTT  68±17 84±15 P<0.05 
   hcTTv  67±21 81±15 P<0.05 
    
    
aFrom unpaired t-test, MAP= Mean Arterial Pressure, SBP=Systolic Blood Pressure, 
DBP=Diastolic Blood Pressure, PP=Pulse Pressure, hcTT=heart to carotid pressure transit time is 
time from R-peak to foot of pressure wave at carotid artery, hcTTv=heart to carotid velocity 
transit time is time from R-peak to foot of velocity wave at carotid artery. All measures while 






Figure 29. Scatterplot of hcTTv versus hcTT in younger adults (YA) 
A scatterplot (black dots) of hcTTv (hcTTv=heart to carotid velocity transit time is time from R-
peak to foot of velocity wave at carotid artery, ms) and hcTT (hcTT=heart to carotid pressure 
transit time is time from R-peak to foot of pressure wave at carotid artery, ms) for younger 
adults. There was a significant linear correlation between hcTTv and hcTT as represented by the 
































Figure 30. Scatterplot of hcTTv versus hcTT in older adults (OA) 
A scatterplot (black dots) of hcTTv (hcTTv=heart to carotid velocity transit time is time from R-
peak to foot of velocity wave at carotid artery, ms) and hcTT (hcTT=heart to carotid pressure 
transit time is time from R-peak to foot of pressure wave at carotid artery, ms) for older adults. 
There was a significant linear correlation between hcTTv and hcTT as represented by the trend 













































Figure 31. Bland-Altman plots of hcTTv and hcTT for OA 
The Bland-Altman plot of heart-carotid TT (hcTTv=heart to carotid velocity transit time is time from R-
peak to foot of velocity wave at carotid artery, ms) velocity compared to heart-carotid TT (hcTT=heart to 
carotid pressure transit time is time from R-peak to foot of pressure wave at carotid artery, ms) pressure 








































Figure 32. Bland-Altman plots of hcTTv and hcTT for YA 
The Bland-Altman plot of heart-carotid TT (hcTTv=heart to carotid velocity transit time is time from R-
peak to foot of velocity wave at carotid artery, ms) velocity compared to heart-carotid TT (hcTT=heart to 
carotid pressure transit time is time from R-peak to foot of pressure wave at carotid artery, ms) pressure 




































Average hcTTv and hcTT (ms) 
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1.M.3  Safety Considerations during Randomized, Double-Blind, Placebo-Controlled Trial  
 
Spironolactone is indicated in Canada for essential hypertension (50-100mg/day); usually in 
combination with other drugs (Pfizer, 2012). The two most common adverse events are 
elevation of serum potassium (hyperkalemia) and gynecomastia (breast discomfort), although 
spironolactone is generally well tolerated in non-diabetic hypertensive patients. Prospective 
trials have shown 0%-4% risk of hyperkalemia (serum potassium >5.0 mmol per liter) and 0%-
5% risk of gynecomastia in older patients with or without diabetes, and hypertension (Davies et 
al., 2005; Engbaek, Hjerrild, Hallas, & Jacobsen, 2010; Kithas & Supiano, 2010). Hyperkalemia 
and gynecomastia were not observed in small trials that excluded patients with diabetes or 
poor renal function, and not observed in this thesis RCT (Kithas & Supiano, 2010; Wray & 
Supiano, 2010). The open-label trial by Engbaek showed that of the 344 older hypertensive 
patients (10.5% were diabetic), those with compromised renal function (eGFR 43.3 
ml/min/1.73m2) were at significantly elevated risk of hyperkalemia compared to those with 
better renal function (P < 0.05) (Engbaek et al., 2010). Therefore, blood work for serum 
potassium levels and renal function were routinely monitored in the current RCT: before initial 
dose, one week after initial dose or titration, then 12 and 18 weeks from initial dose (Zannad et 
al., 2011).  In the current RCT, serum potassium (K+) was closely monitored before taking the 
study-drug, after first dose, and after dose adjustments. The protocol involved: Withholding 
study-drug if K+ was ≥ 5 mmol/L after initial 25 mg once daily dose or ≥ 6 mmol/L at any time; 
there was a decrease from the 50 mg study-drug to 25 mg if the K+ level was 5.0 to 5.9 mmol/L 
(Y. Yano et al., 2011; Zannad et al., 2011). Participants were asked to tell their Family Physician 
if they experience dizziness, diarrhea, vomiting, rapid or irregular heartbeat, lower extremity 
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swelling, or difficulty breathing. If systolic blood pressure dropped below 100 mmHg or there 
were symptomatic problems (e.g. dizziness, general fatigue) during the RCT, the protocol was to 
reduce the dose of study-drug (Yuichiro Yano et al., 2011).  
 
Renal function was monitored during the RCT. If renal function declined to less than eGFR 
(estimated glomerular filtration rate) of 60 mL/min per 1.73 m2 participants were withdrawn 
from the RCT since moderate renal insufficiency (eGFR ≤ 60 mL/min per 1.73 m2) is not 
common in generally healthy older adults with hypertension. A systematic review of clinical 
trials for the prevalence of renal dysfunction in older adults showed that only up to 35% with, 
or without, hypertension have moderate renal impairment measured as eGFR ≤ 60 mL/min per 
1.73 m2 for three or more months (Q.-L. Zhang & Rothenbacher, 2008). A prospective trial of 
1856 older hypertensive patients, free from diabetes like the current study criteria, however 
showed the prevalence of overt renal insufficiency (eGFR ≤ 60 mL/min per 1.73 m2) of only 10% 
(Cerasola, Mule, Cottone, Nardi, & Cusimano, 2008). Concomitant medications were recorded 
in this thesis RCT to identify potential drug-drug interactions, especially combining study-drug 
with strong inhibitors of CYP3A4 and potassium supplements (Pfizer, 2012). 
 
Other measurement modalities were of little risk to patient health. Cognitive testing offered 
very low risk to participant’s health. If patients found cognitive testing upsetting, they were free 
to withdraw themselves from the trial. The equipment used to measure vascular parameters 
was non-invasive with minimal risk to participants: electrodes for electrocardiogram could have 
provided risk of skin rash from adhesive, and Doppler ultrasound could have had a risk of skin 
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burn if transmission power is set excessively high. Minimal power settings were used to obtain 























1.M.4  Generalizability of Study Results to Generally Healthy Older Adults  
 
Eligibility criteria in this trial were not intended to be so rigorous as to impair generalizability to 
the participant population for whom the intervention may be applied. Specifically, generally 
healthy older adults diagnosed with hypertension, taking stable centrally-active ACE inhibition, 
in a primary care setting. A systematic review of 283 randomized controlled trials showed that 
drug intervention trials apply 35% more exclusion criteria versus non-drug intervention trials 
(p=0.003), and more often exclude based on medication and comorbidity that may be poorly 
justified (Van Spall, Toren, Kiss, & Fowler, 2007).  
 
Inclusion criteria in this thesis RCT capture a sample of older hypertensive patients that could 
represent 43% of the Canadian population ages 60-85 years (Robitaille et al., 2012).  Older 
adults, from 60 years of age, are at 9% risk of dementia (if <75 years, and 15-20% if 75-79 years) 
and it is estimated that close to 1 in 3 older adults may suffer with executive dysfunction based 
on the San Luis Valley Health and Aging Study of 1313 individuals over 60 years old (Fitzpatrick 
et al., 2004; Jim Grigsby et al., 2002). Executive dysfunction was assessed in study by Fitzpatrick 
et al. (2004) as voluntary goal-oriented behaviour and self-regulation, and consequently may 
have significant impairment following medical advice and are more likely to develop disability 
(Deborah A. Cahn-Weiner, Paul F. Malloy, Patricia A. Boyle, Mary Marran, & Stephen Salloway, 
2000; Jim Grigsby et al., 2002; Donald R. Royall, Raymond Palmer, Laura K. Chiodo, & Marsha J. 
Polk, 2004).  Adults over 65 years of age have been shown to experience similar 31% executive 
function impairment (Donald R. Royall, David V. Espino, Marsha J. Polk, Raymond F. Palmer, & 
Kyriakos S. Markides, 2004). Two large randomized controlled trials investigating cognitive 
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impairment and high blood pressure, SYST-EUR and PROGRESS, also preferentially selected 
adults at least 60 years (Forette et al., 1998; Tzourio et al., 2003). Sixty years of age may also be 
a hemodynamic transition point, where pulse pressure (systolic blood pressure – diastolic blood 
pressure) and central pulse wave velocity typically begin to increase, potentially elevating risk 
of cognitive decline (Hanon et al., 2005; Kearney-Schwartz et al., 2009; Waldstein et al., 2008).   
 
Diagnosed hypertensives with controlled blood pressure (systolic pressure ≤ 140 mmHg and/or 
diastolic pressure ≤ 90 mmHg) taking standard-care antihypertensive medications is 
representative of the small matched group prospective study suggesting aldosterone 
antagonism improved cognition in elderly hypertensives (MMSE 23.7 increased to 25.4, P < 
0.05) (Yagi et al., 2011). A large longitudinal trial by the ARIC Investigators showed an elevated 
risk of cognitive decline (attention and memory) over 6 years in 4,800 patients diagnosed with 
hypertension and over 57 years old (Knopman et al., 2001). Another longitudinal trial of 1373 
elderly (59-71 years) over 4 years showed an elevated risk of severe cognitive decline (4 or 
more points on MMSE) irrespective of antihypertensive medication use in those with high 
blood pressure (SBP >160 mmHg or DBP >95 mmHg) (Tzourio, Dufouil, Ducimetiere, & 
Alperovitch, 1999). In summary, diagnosis of hypertension elevates risk of cognitive decline. 
 
Exclusion criteria in this thesis RCT mainly reflect therapeutic contraindications and warnings. 
Strategies for reducing bias from confounding variables such as age and cardiovascular disease 




1.M.5  End-Tidal Carbon Dioxide during Cerebrovascular Assessments in Older Adults 
 
This part of APPENDIX 1.M provides supportive data on end-tidal carbon dioxide (ETCO2) not 
included in Results section 5.3 so as to not distract the reader from objectives of CHAPTER 5. In 
these older adults of the RCT, ETCO2 during the assessment of anterior cerebral blood flow 
(aCBF, Table 17) at baseline and after six months of study-drug were similar between the 
groups. Baseline ETCO2 during hypocapnia (reduced CO2 in the blood reflected in expired partial 
pressure of gas) and during hypercapnia (elevated CO2 in the blood reflected in expired partial 
pressure of gas) were similar between the two groups (Table 17) and remained similar after six 
months of study-drug. At baseline, the hypocapnic stimulus (i.e., controlled mild 
hyperventilation) lead to a 61±13% decrease in ETCO2 for the Spironolactone group and a 
57±13% decrease in ETCO2 for the Placebo group (P=0.67, Figure 33). There was a 30±13% 
increase in ETCO2 for the Spironolactone group and a 23±14% increase in ETCO2 for Placebo 
group with the hypercapnic (i.e., maximal voluntary breath-hold) stimulus (P=0.38, Figure 33).  
 
The Spironolactone group normocapnia-R ETCO2 at 41±2 mmHg (Table 17) before 
hyperventilation (hypocapnic stimulus) was significantly greater than ETCO2 normocapnia-H 
before breath-hold (hypercapnic stimulus) at 34±7 mmHg (P<0.05). The Placebo group ETCO2 at 
37±4 mmHg during normocapnia-R before hyperventilation (hypocapnic stimulus) was 







Table 17. End-tidal carbon dioxide (ETCO2) during measurement of cerebral hemodynamics at 














    
ETCO2 Baseline     
     During assessment of aCBF supine (mmHg) 42±3 40±4 0.20 
     Normocapnia-R before hyperventilation (mmHg) 41±2 37±4 <0.05 
     Hypocapnia (mmHg) 16±5 16±5 0.93 
     Change from normocapnia-R (%) -61±13 -57±13 0.67 
     Normocapnia-H before breath-hold (mmHg) 34±7* 35±4* 0.84 
     Hypercapnia (mmHg) 44±8 43±5 0.76 
     Change from normocapnia-H (%) 30±13 23±14 0.38 
    
ETCO2 change from Baseline     
     During assessment of aCBF supine (mmHg) 1±1 3±1 0.30 
     Normocapnia-R before hyperventilation (mmHg) 1±3 5±2 <0.05 
     Hypocapnia (mmHg) -2±3 -1±5 0.44 
     Change from normocapnia-R (%) -5±7 -6±6 0.85 
     Normocapnia-H before breath-hold (mmHg) 3±0 5±2 0.53 
     Hypercapnia (mmHg) 3±1 6±1 0.28 
     Change from normocapnia-H (%) -4±6 3±3 0.44 
    
    
aFrom unpaired t-test, *P<0.05 Normocapnia-H before breath-hold vs Normocapnia-R before 
hyperventilation supine, Spiro=spironolactone group, Placebo=placebo group, aCBF=anterior 














Figure 33. Baseline changes in end-tidal carbon dioxide (ETCO2) during hypocapnia and 
hypercapnia for placebo (Placebo) and spironolactone (Spiro) groups in the RCT 
End-tidal carbon dioxide (ETCO2) during hypocapnia (%, dark bars) and hypercapnia (%, light 
bars) are shown for placebo (Placebo, left pair of bars) and spironolactone (Spiro, right pair of 
bars) at baseline. Unpaired t-tests were performed to establish no significant differences in % 
change ETCO2 between placebo and spironolactone during either hypocapnia (P=0.67) or 









































APPENDIX 2.IE  Inclusion and Exclusion Criteria for Studies 
 




18-35 years of age  
 








Resting heart rate >110 beats/minute 
 
Confirmed essential hypertension diagnosis according to Hypertension Canada 



















Table. 19 Inclusion criteria for older adults in RCT 
 
 
 60 years of age (maximum 75 years) 
 
Confirmed essential hypertension diagnosis according to Hypertension Canada 
guidelines (≥ 140mmHg/≥ 90mmHg) 
 
On stable maintenance therapy of a centrally acting ACE inhibitor for at least 6 months 
(including perindopril, ramipril, captopril, fosinopril, lisinopril, and trandolapril) 
 



















Table 20. Exclusion criteria for older adults 
 
 
Serum potassium ≥ 5.0 mmol/L 
 
Taking potassium or salt supplements 
 
History of hyperkalemia 
 
Hepatic impairment (contraindicated in Child-Pugh Class C) 
 
Diagnosis of congestive heart failure 
 
Renal dysfunction (contraindicated in moderate to severe renal impairment): 
eGFR < 60 mL/min/1.73m2 using MDRD equation  
(eGFR = 186 x (serum Creatinine, mg/dL)-1.154 x (age)-0.203 [x 0.742 female] x [1.21 Black])  
 
Use of aldosterone antagonist in last 6 months 
 
Diagnosis of diabetes with microalbuminuria 
 
Taking insulin and/or oral hypoglycemic agents, angiotensin receptor blockers, direct 
renin inhibitors 
 
Taking strong CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, 
telithromycin, clarithromycin, ritonavir, and nelfinavir), lithium, or St John’s Wort 
 
Systolic blood pressure ≤ 100 mmHg and diastolic blood pressure ≤ 60 mmHg 
 













APPENDIX 3.HIF  Health History Forms 
 
HEALTH HISTORY FORM (RCT) 
 
The Effect of Spironolactone on Vascular Dynamics and Cognitive Function 
 
Researchers and Contact Information: 
Richard Hughson, PhD phone: 519-888-4567 ext 32516      email: hughson@uwaterloo.ca  
Jason Xeni, MSc phone: 519-591-1113 email: jxeni@uwaterloo.ca  
Katelyn Fraser, MSc phone: 519-571-4981                     email: k4fraser@uwaterloo.ca 
Danielle Greaves, MSc phone: 519-888-4567 ext 32127 email: dgreaves@uwaterloo.ca  
 
      Name :______________________________________________          [Code:      ] 
 Phone Number:_________________________________________________ 
 Email:_________________________________________________________ 
 Family Doctor:__________________________________________________ 
 
1. Date of Birth (day/ month/year):____________________________ 
 
2. Sex (male or female):____ _________________________________ 
 
3. Reason(s) why the participant can’t follow instructions and complete 
this study:  
(Yes or No) _____ . If yes, explain why. 
 
4. Years of formal education (from grade 1 to now):  
________ years of formal education. 
5. Diplomas, certificates or degrees:  
 (check all that apply, twice if two of the same level) 
 
  □ None            □ High School             
 □ Trade certificate/diploma   □ Community College diploma  
□ University undergraduate degree  □ University Graduate degree 
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6. Check all the boxes apply (mark every box participant diagnosed with):  
 
□ Chest Pain (Heart Attack or Angina)  □ Hypertension             
  □ Atrial Fibrillation     □ Stroke or TIA 
   □ Mild Cognitive Impairment   □ Depression 
7.  Medications (including supplements) taken within the last 6 months: 
Medication Name Dose 
(mg or g) 
Route 
(mouth, on skin, 
inhaled, or injected) 
Frequency 
(1,2, or 3 times 
daily) 
   
 
 
                  
   
 
 
                 
 
 
                  
 
 a. Frequency participant forgets to take these above medications:  
 Never   Rarely        Sometimes       Often        Always 
 
 b. Reason(s) why the participant may not take a medication:   
  
□ No    □ Yes           If yes, explain. 
8. Current smoking status (cigarettes, a pipe, or cigars):  





Health History Form Experimental Study 
 
Changes in Arterial Stiffness Indicators 
 
Researchers and Contact Information:      Date: 
Richard Hughson, PhD phone: 519-888-4567 ext 32516     email: hughson@uwaterloo.ca  
Jason Xeni, MSc phone: 519-591-1113 email: jxeni@uwaterloo.ca  
Katelyn Fraser, MSc phone: 519-571-4981                     email: k4fraser@uwaterloo.ca 
Danielle Greaves, MSc phone: 519-888-4567 ext 32127 email: dgreaves@uwaterloo.ca  
Kinesiology, Applied Health Sciences, University of Waterloo, Waterloo ON N2L 3G1 
  
 
SELF-REPORT CHECK LIST                           Participant ID: _______________ 
 
Exclusion Criteria: If any of the following apply, you should not participate in this study 
- Diabetes       -Respiratory illness 
- Resting heart rate > 110bpm                              -Raynaud’s syndrome 
- High blood pressure (≥ 140/90)    -History of fainting  
- Peripheral vascular disease     -Pregnancy 
One or more of these applies:     Yes   or    No 
 
Do you have any allergies or sensitivities to water based gels or adhesives? Yes   or   No 
  
Current Health (within the past 3 months) 
 






List current medications (including supplements and vitamins): 
1. 5.  
2. 6.  
3. 7.  













































APPENDIX 6.DS  Digit Span Tests Forwards and Backwards 
 
 
 
 
 
 
 
 
